tag:blogger.com,1999:blog-9174374625162190022024-03-15T12:11:11.712-07:00Biotech/Medical Tech Stock News from Investorideas.comBiotech, Pharma and Medical Technology Stock News : OTC stocks, TSX Stocks, NASDAQ and NYSE Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.comBlogger914125tag:blogger.com,1999:blog-917437462516219002.post-17353623397019894772024-03-15T12:10:00.000-07:002024-03-15T12:10:13.765-07:00Biopharma Stock News Bite - Geron Corporation (Nasdaq: GERN) Makes NASDAQ Top Gainers List on FDA News<a href="https://www.investorideas.com/news/2024/biotech/03151StockBites-GERN.asp">Biopharma Stock News Bite - Geron Corporation (Nasdaq: GERN) Makes NASDAQ Top Gainers List on FDA News</a>: Biopharma Stock News Bite - Geron Corporation (Nasdaq: GERN) Makes NASDAQ Top Gainers List on FDA NewsInvestor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-51030212773912936662024-03-13T12:24:00.000-07:002024-03-13T12:24:07.730-07:00Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results<a href="https://www.investorideas.com/news/2024/biotech/03131StockBites-HRTX.asp">Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results</a>: Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial ResultsInvestor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-1792895642436805392024-03-12T11:37:00.000-07:002024-03-12T11:37:52.330-07:00Biotech Stock News Bite - Regulus Therapeutics Inc. (Nasdaq: RGLS) Makes NASDAQ Top Ten Gainers List<a href="https://www.investorideas.com/news/2024/biotech/03121StockBites-RGLS.asp">Biotech Stock News Bite - Regulus Therapeutics Inc. (Nasdaq: RGLS) Makes NASDAQ Top Ten Gainers List</a>: Biotech Stock News Bite - Regulus Therapeutics Inc. (Nasdaq: RGLS) Makes NASDAQ Top Ten Gainers ListInvestor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-17593061108421242232024-03-11T07:42:00.000-07:002024-03-11T07:42:13.908-07:00 Watching Biotech & Life Science Stocks: (Nasdaq: $IXHL) (Nasdaq: $ATRA) (ASX: $CHM.AX)(Nasdaq: $IMRX) <p> <b style="text-align: center;"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Watching Biotech & Life Science Stocks: (Nasdaq: $IXHL) (Nasdaq: $ATRA) (ASX: $CHM.AX)(Nasdaq: $IMRX)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Transportation Stocks on the Move: (Nasdaq: $DUOT) (Nasdaq: $RVSN) (NYSE: $ASC)</span></i></b><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"><o:p></o:p></span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-gfUJwLVyGmLgiYfe26qCLGx80dt6lS5DbNwFliYI6cyAgzAI-BezSITRL0Mvza8O2nnPPvmaI2NsZ2ydSU1E5kSV7pBh98jEteLfp2FixT7vA89OmKxRMlXUmTEXV3ELOZiertiE3Y6SM7iYc9ayaZtyddlbRbykpY-_fxvIrm4jGA0928LwbhSW8X4/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj-gfUJwLVyGmLgiYfe26qCLGx80dt6lS5DbNwFliYI6cyAgzAI-BezSITRL0Mvza8O2nnPPvmaI2NsZ2ydSU1E5kSV7pBh98jEteLfp2FixT7vA89OmKxRMlXUmTEXV3ELOZiertiE3Y6SM7iYc9ayaZtyddlbRbykpY-_fxvIrm4jGA0928LwbhSW8X4/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">March 11, 2024 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech and Transportation sectors.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at </span></b><a href="https://www.investorideas.com/news/2024/main/03111Stocks.asp">https://www.investorideas.com/news/2024/main/03111Stocks.asp</a><o:p></o:p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest biotech companies focus on cancer treatments and medical cannabis and psychedelic medicine uses.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The latest transportation companies provide transportation include a tanker company and rail safety companies using AI (artificial intelligence) technology.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.incannex.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Incannex Healthcare Inc.</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/IXHL?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq: IXHL</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://www.atarabio.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Atara Biotherapeutics</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/ATRA?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq: ATRA</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://chimerictherapeutics.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Chimeric Therapeutics</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/CHM.AX?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">ASX: CHM</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://immuneering.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Immuneering Corporation</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/IMRX?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq: IMRX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is an oral, once-daily deep cyclic inhibitor currently in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily deep cyclic inhibitor and will be evaluated in a Phase 1/2a study in patients with advanced solid tumors harboring RAS or RAF mutations. The company’s development pipeline also includes several early-stage programs.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/AUTO/Stock_List.asp#other"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Transportation Directories</span></b></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://ardmoreshipping.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Ardmore Shipping</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/ASC?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE:ASC</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) owns and operates a fleet of MR product and chemical tankers ranging from 25,000 to 50,000 deadweight tonnes. Ardmore provides, through its modern, fuel-efficient fleet of mid-size tankers, seaborne transportation of petroleum products and chemicals worldwide to oil majors, national oil companies, oil and chemical traders, and chemical companies. Ardmore's core strategy is to continue to develop a modern, high-quality fleet of product and chemical tankers, build key long-term commercial relationships and maintain its cost advantage in assets, operations and overhead, while creating synergies and economies of scale as the company grows. Ardmore provides its services to customers through voyage charters and time charters, and enjoys close working relationships with key commercial and technical management partners. Ardmore's Energy Transition Plan ("ETP") focusses on three key areas: transition technologies, transition projects, and sustainable (non-fossil fuel) cargos. The ETP is an extension of Ardmore's strategy, building on its core strengths of tanker chartering, shipping operations, technical and operational fuel efficiency improvements, technical management, construction supervision, project management, investment analysis, and ship finance.<o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><a href="https://www.duostechnologies.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Duos Technologies Group</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/DUOT?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:DUOT</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) based in Jacksonville, Florida, through its wholly owned subsidiary, Duos Technologies, Inc., designs, develops, deploys and operates intelligent vision-based technology solutions using Machine Vision and Artificial Intelligence (“AI”) to analyze fast moving freight, passenger and transit trains and trucks streamlining operations, improving safety and reducing costs. The Company provides cutting edge solutions that automate the mechanical and security inspection of fast-moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://railvision.io/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Rail Vision Ltd</span></a><span style="color: #201d20; font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/RVSN?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq: RVSN</span></a><span style="color: #201d20; font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a technology company that is seeking to revolutionize railway safety and the data-related market. The Company has developed cutting-edge, artificial intelligence-based, industry-leading technology specifically designed for railways. The Company has developed its railway detection and systems to save lives, increase efficiency, and dramatically reduce expenses for the railway operators. Rail Vision believes that its technology will significantly increase railway safety around the world, while creating significant benefits and adding value to everyone who relies on the train ecosystem: from passengers using trains for transportation to companies that use railways to deliver goods and services. In addition, the company believes that its technology has the potential to advance the revolutionary concept of autonomous trains into a practical reality.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read the recent AI Transportation article at:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/news/2024/technology/03041AI-Stocks.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/news/2024/technology/03041AI-Stocks.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read the recent Biotech/Oncology Article at:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/news/2024/biotech/03061Pancreatic-Cancer-Market-Stocks.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/news/2024/biotech/03061Pancreatic-Cancer-Market-Stocks.asp</span></a><o:p></o:p></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/"><span style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span lang="EN-US" style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;"> is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.<o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span> </p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgFakpLaUeoehRSdZmFsf-x82wUktmYvjnoA6_3wTbuGsu7fDTboYSuuRc_UyjaN0e4jcbAwSa3UukTpVl4WqvOrGbJwuBDivVUIV9EuMazREP1Tc2reLfa026M6Qea-CbdqMUK8MF-Yl01miEqlaPlQgmXftR7PO1uoMBqKQZ5qV-YCbYqzYWSugfccUU/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgFakpLaUeoehRSdZmFsf-x82wUktmYvjnoA6_3wTbuGsu7fDTboYSuuRc_UyjaN0e4jcbAwSa3UukTpVl4WqvOrGbJwuBDivVUIV9EuMazREP1Tc2reLfa026M6Qea-CbdqMUK8MF-Yl01miEqlaPlQgmXftR7PO1uoMBqKQZ5qV-YCbYqzYWSugfccUU/s320/social-media%20ICONS.png" width="320" /></a></div><div><br /></div>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-92050115566304892952024-03-06T08:34:00.000-08:002024-03-06T08:34:52.509-08:00 Cancer/Oncology Stocks to Watch; (Nasdaq: $GLSI) (NYSE American: $CLDI) (Nasdaq: $FUSN) (NASDAQ: $ACHL) <p> <b style="text-align: center;"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Cancer/Oncology Stocks to Watch; (Nasdaq: $GLSI) (NYSE American: $CLDI) (Nasdaq: $FUSN) (NASDAQ: $ACHL)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Focus on Biotech Stocks: (Nasdaq: $GUTS) (NYSE: $ANRO) (Nasdaq: $KYTX) (Nasdaq: $BYSI)</span></i></b><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"><o:p></o:p></span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhGRPb86K8zEGoGsM-1TFf05JTFLFrOFadL38HHU7Af4UCl9Cli-ImtRlt9H0xBM4f3Z5FRoFySmwE0g7mpn0XcLBgnYZ1niEmJL2WWC3o6sEoUhJgFTV_C_L1o9xbV8UOrkeMyTuEvaYjFHWAQfmlF3ycUJ6R7DsKfvimvIiZaJoNHuje1BRrmWDQtb3w/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhGRPb86K8zEGoGsM-1TFf05JTFLFrOFadL38HHU7Af4UCl9Cli-ImtRlt9H0xBM4f3Z5FRoFySmwE0g7mpn0XcLBgnYZ1niEmJL2WWC3o6sEoUhJgFTV_C_L1o9xbV8UOrkeMyTuEvaYjFHWAQfmlF3ycUJ6R7DsKfvimvIiZaJoNHuje1BRrmWDQtb3w/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">March 6, 2024 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at </span></b><a href="https://www.investorideas.com/news/2024/main/03061Stocks.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/news/2024/main/03061Stocks.asp</span></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest biotech companies are focused on cancer treatment, oncology, metabolic therapeutics, autoimmune diseases and neurobiology.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNoSpacing"><a href="https://www.fractyl.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Fractyl Health, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/GUTS?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:GUTS</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including T2D and obesity. Despite advances in treatment over the last 50 years, T2D and obesity continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Lexington, MA.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNoSpacing"><a href="https://www.altoneuroscience.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Alto Neuroscience, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/ANRO?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE: ANRO</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, PTSD, schizophrenia, and other mental health conditions.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNoSpacing"><a href="https://kyvernatx.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Kyverna Therapeutics, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/KYTX?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:KYTX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead product candidate, KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1 trials in the United States and Germany for patients with lupus nephritis.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNormal"><a href="https://greenwichlifesciences.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Greenwich LifeSciences, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/GLSI?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:GLSI</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. Greenwich LifeSciences has commenced a Phase III clinical trial, Flamingo-01.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNormal"><a href="https://www.calidibio.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Calidi Biotherapeutics, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/CLDI?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE American: CLDI</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNormal"><a href="https://fusionpharma.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Fusion Pharmaceuticals Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/FUSN?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq: FUSN</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 clinical trial; and FPI-2059, a small molecule targeting neurotensin receptor 1, currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors and immuno-oncology agents. The Company received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion has a Good Manufacturing Practice compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs. The Company has signed strategic actinium supply agreements with Niowave, Inc. and BWXT Medical.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNormal"><a href="https://www.achillestx.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Achilles Therapeutics Plc ADR</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/ACHL?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ:ACHL</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biopharmaceutical company developing AI-Powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US"> </span></p><p class="MsoNormal"><a href="https://beyondspringpharma.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">BeyondSpring Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/BYSI?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:BYSI</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a global clinical-stage biopharmaceutical company focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company is advancing its first-in-class lead asset, Plinabulin, as a direct anti-cancer agent in various cancer indications and to prevent chemotherapy-induced neutropenia. Its pipeline also includes three preclinical immuno-oncology assets. Additionally, BeyondSpring’s subsidiary, SEED Therapeutics, leverages a proprietary targeted protein degradation (TPD) drug discovery platform and has an initial R&D collaboration with Eli Lilly.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNoSpacing"><img align="left" height="100" hspace="12" src="file:///C:/Users/Home/AppData/Local/Temp/msohtmlclip1/01/clip_image003.gif" v:shapes="Picture_x0020_3" width="100" /><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Research more biotech stocks with Investorideas Biotech stock directory<o:p></o:p></span></p><p class="MsoNoSpacing"><a href="https://www.investorideas.com/BIS/Stock_List.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/BIS/Stock_List.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/"><span style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span lang="EN-US" style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;"> is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.<o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIbKxlYTAlP7fo9AIO8vbgXUzDOh1UBqiK_ervvjrrCS92llSOICdMf5c_bVKXNlaw9v3Ocouz2HpgaK2SJnG_VufW1VBFuO41a5j1-GW-f4vvxFHJYSAgA9BppiHbhUNAdU3oP9rcAW-TVHifhakMAqjVDKZ0pBUMYQ4hUN6t_8gZc5oYELI4yyGTV6c/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhIbKxlYTAlP7fo9AIO8vbgXUzDOh1UBqiK_ervvjrrCS92llSOICdMf5c_bVKXNlaw9v3Ocouz2HpgaK2SJnG_VufW1VBFuO41a5j1-GW-f4vvxFHJYSAgA9BppiHbhUNAdU3oP9rcAW-TVHifhakMAqjVDKZ0pBUMYQ4hUN6t_8gZc5oYELI4yyGTV6c/s320/social-media%20ICONS.png" width="320" /></a></div><br /><p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><br /><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-35371789868672369372024-03-06T08:13:00.000-08:002024-03-06T08:13:33.263-08:00Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market (NASDAQ: $ONCY) (TSX: $ONC.TO) (NASDAQ: $BLRX) (NASDAQ: $IMRX) (NASDAQ: $CADL) @Oncolytics @BioLineRx_Ltd @Immuneering @CandelTx<p> </p><p align="center" class="MsoNormal" style="text-align: center;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Biotech/Oncology Stocks
Targeting the Pancreatic Cancer Market (NASDAQ: $ONCY) (TSX: $ONC.TO) (NASDAQ: $BLRX)
(NASDAQ: $IMRX) (NASDAQ: $CADL) @Oncolytics @BioLineRx_Ltd @Immuneering
@CandelTx<o:p></o:p></span></b></p>
<p align="center" class="MsoNormal" style="text-align: center;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></b></p>
<p align="center" class="MsoNormal" style="text-align: center;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">A Race worth Winning<o:p></o:p></span></b></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjOQ8eJDq_u-kIz2-i_7IV0tmvEzG8Mu5EvHEk7ZkcLAix8xGmKtPnA6zmNSVJkkVW1tpozviH9mM4b1nfbwiEMhYMGmPY5HO9mk0DthowuRcPFMKG9m6V8rzijiqECCMMsvJYabNEqPDTNAEI_lxbyWnwWmG4ra9EnGlEeHFvxHpQMf45mhI5L9d6Jkaxs/s400/ONCY%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="174" data-original-width="400" height="139" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjOQ8eJDq_u-kIz2-i_7IV0tmvEzG8Mu5EvHEk7ZkcLAix8xGmKtPnA6zmNSVJkkVW1tpozviH9mM4b1nfbwiEMhYMGmPY5HO9mk0DthowuRcPFMKG9m6V8rzijiqECCMMsvJYabNEqPDTNAEI_lxbyWnwWmG4ra9EnGlEeHFvxHpQMf45mhI5L9d6Jkaxs/s320/ONCY%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">March 6,
2024 - </span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"><span style="mso-spacerun: yes;"> </span></span></a><a href="https://www.investorideas.com/"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">, a global investor news source covering
biotech and pharma stocks issues a sector snapshot on developments for
pancreatic cancer treatments, featuring </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Oncolytics
Biotech<sup>®</sup> Inc. (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/ONCY?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">NASDAQ:
ONCY</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">) </span><span lang="EN-US"><a href="https://ca.finance.yahoo.com/quote/ONC.TO?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(TSX:
ONC</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">), a clinical-stage immunotherapeutics
company focused on oncology.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Read this article,
featuring ONCY in full at:</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <a href="https://www.investorideas.com/news/2024/biotech/03061Pancreatic-Cancer-Market-Stocks.asp">https://www.investorideas.com/news/2024/biotech/03061Pancreatic-Cancer-Market-Stocks.asp</a><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"><a href="https://www.researchnester.com/sample-request-5299?utm_source=globenewswire.com&utm_medium=referral&utm_campaign=Paid_globenewswire"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Research
Nester says</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">, “The global pancreatic
cancer market size is slated to expand at ~18% CAGR between 2024 and 2036. The
market is poised to garner a revenue of USD 36 billion by the end of 2036, up
from a revenue of ~USD 6 billion in the year 2023. The incidence of pancreatic
cancer is increasing globally, which is driving the growth of the market.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal;"><span lang="EN-US" style="color: #1a1a1a; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";">The American Cancer
Society’s </span><span lang="EN-US"><a href="https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";">estimates</span></a></span><span lang="EN-US" style="color: #1a1a1a; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";"> for pancreatic cancer in the United States
for 2024 are: “About 66,440 people (34,530 men and 31,910 women) will be
diagnosed with pancreatic cancer. About 51,750 people (27,270 men and 24,480
women) will die of pancreatic cancer. Pancreatic cancer accounts for about 3%
of all cancers in the US and about 7% of all cancer deaths.”<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal;"><span lang="EN-US" style="color: #1a1a1a; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Biotech/oncology stocks targeting the
growing global pancreatic cancer market have made headlines with recent
developments and breakthroughs in treatments.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Oncolytics Biotech<sup>®</sup> Inc. (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/ONCY?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">NASDAQ:
ONCY</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">) </span><span lang="EN-US"><a href="https://ca.finance.yahoo.com/quote/ONC.TO?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(TSX:
ONC</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">), a clinical-stage immunotherapeutics
company focused on oncology </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/oncolytics-biotech-files-amendment-initiate-120000058.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">just
announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"> it has submitted an amendment to
GOBLET to initiate a new Phase 1/2 cohort evaluating pelareorep in combination
with modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab (Tecentriq<sup>®</sup>)
in patients with newly diagnosed metastatic pancreatic ductal adenocarcinoma
(PDAC). This amendment will be reviewed by the Paul Ehrlich Institute (PEI;
Germany’s regulatory body) for approval before patient enrollment can begin.
The cohort, the fifth of the GOBLET gastrointestinal cancer study, is being
supported by the US$5 million Therapeutic Accelerator Award from the Pancreatic
Cancer Action Network (PanCAN), an innovative program established to accelerate
the development of new treatments for pancreatic cancer.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“We are enthusiastic to have the support of
PanCAN to expand the evaluation of pelareorep in pancreatic cancer and explore
mFOLFIRINOX as another combination that could improve outcomes for patients.
Notably, this patient population is newly diagnosed patients who are receiving
first-line treatment. Chemotherapies, including either mFOLFIRINOX or
gemcitabine and nab-paclitaxel, are the backbone treatment regimens of
pancreatic cancer therapy<sup>1</sup>. Evaluating pelareorep in combination
with these widely used regimens is an important step in our broad clinical
development program,” said Dr. Matt Coffey, President and Chief Executive
Officer of Oncolytics. “Last fall, we reported a 62% objective response rate
for the GOBLET PDAC cohort studying pelareorep in combination with the
checkpoint inhibitor atezolizumab in addition to gemcitabine and nab-paclitaxel
(</span><span lang="EN-US"><a href="https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">link
to the PR</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">, </span><span lang="EN-US"><a href="https://oncolyticsbiotech.com/wp-content/uploads/2023/10/ESMO_2023_PDAC_poster-FINAL1a.pdf"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">link
to the poster</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">). This response is about
three times that of historical controls and forms the basis of the
registrational program, expected to begin this year. Therefore, we are
enthusiastic about this new mFOLFIRINOX pancreatic cancer cohort and look
forward to enrolling the first patient as soon as possible.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Dirk Arnold, M.D., Ph.D., Director of
Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial
commented, “One of the reasons for pancreatic cancer’s poor survival rate is
that it effectively evades the immune system and can induce an
immunosuppressive tumor microenvironment (TME)<sup>2</sup>. Pelareorep is an
attractive combination partner because of its ability to address both issues by
activating the innate and adaptive immune systems while driving the remodeling
of the tumor microenvironment. Positive results from the Phase 2 study
evaluating pelareorep combined with atezolizumab and chemotherapy reported last
fall support the potential use of these agents together. I am hopeful that the
combination of pelareorep and mFOLFIRINOX (with or without atezolizumab) will
yield positive response data and advance the development of new treatment
options for patients with pancreatic cancer.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“This study is designed to evaluate whether
pelareorep can enhance outcomes in patients receiving mFOLFIRINOX, one of the
most commonly used metastatic pancreatic cancer treatments. Combining
pelareorep with mFOLFIRINOX represents an expansion of our existing pancreatic
cancer program and maximizes the potential of pelareorep-based combination
therapies to benefit pancreatic cancer patients,” commented Thomas Heineman,
M.D., Ph.D., Chief Medical Officer at Oncolytics. “The mFOLFIRINOX cohort
utilizes a screened selection design </span><span lang="DE-CH" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-ansi-language: DE-CH;">within a Simon two-stage approach that will also allow evaluation of the
contribution of atezolizumab to the pelareorep/mFOLFIRINOX combination. </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">In
addition, this study is designed to provide valuable translational assessments,
such as the expansion of tumor-infiltrating lymphocytes (TILs) in the blood,
which has been associated with tumor responses. We look forward to building on
PanCAN’s strong relationships with the pancreatic cancer community and
furthering our collaboration with <span style="mso-no-proof: yes;">AIO-Studien-gGmbH</span>
(AIO) on the GOBLET study.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">BioLineRx
Ltd. (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/BLRX?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">NASDAQ: BLRX</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">), a commercial stage biopharmaceutical
company pursuing life-changing therapies in oncology and rare diseases </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/biolinerx-announces-first-patient-dosed-120000825.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">recently announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"> that the first patient has been dosed in the
randomized CheMo4METPANC Phase 2 combination clinical trial evaluating the
company's CXCR4 inhibitor motixafortide, the PD-1 inhibitor cemiplimab, and
standard of care chemotherapies gemcitabine and nab-paclitaxel, versus
gemcitabine and nab-paclitaxel alone, in first-line PDAC. The
investigator-initiated trial is being conducted in collaboration with Columbia
University and is the first large, multi-center, randomized study evaluating
motixafortide with a PD-1 inhibitor and first-line PDAC chemotherapies.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">"Pancreatic
ductal adenocarcinoma (PDAC) has had limited responses to traditional
immunotherapy, resulting in a poor prognosis for patients and an urgent need
for new treatment approaches," said Philip Serlin, Chief Executive Officer
of BioLineRx. "We are encouraged by our early pilot data and look forward
to continuing to advance the expanded, randomized Phase 2 CheMo4METPANC trial
for patients living with this cancer."<o:p></o:p></span></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">From the news:</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"> Findings from the single-arm pilot phase of
the CheMo4METPANC trial were shared by Dr. Gulam Manji, MD, PhD, of Columbia
University at the 10th Annual Immuno-Oncology (IO) 360° Summit in Brooklyn, New
York on Thursday, February 29, 2024. The findings were previously presented
during an oral presentation at the American Association of Cancer Research
(AACR) Special Conference on Pancreatic Cancer in Boston, Massachusetts,
September 28, 2023. As of July 2023, 7 of the 11 patients (64%) in the pilot
phase experienced a partial response (PR) of which 5 (45%) were confirmed PRs
at the time of the data cut; one patient experienced resolution of the hepatic
(liver) metastatic lesion; and three patients (27%) experienced stable disease,
resulting in a disease control rate of 91%.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">From the news:</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"> Motixafortide, BioLineRx's lead therapeutic
candidate, was approved by the U.S. Food & Drug Administration (FDA) in
September 2023, in combination with filgrastim (G-CSF), to mobilize
hematopoietic stem cells for collection and subsequent autologous
transplantation in patients with multiple myeloma, under the brand name
APHEXDA®. Motixafortide is also being evaluated in a Phase 1 clinical trial
evaluating motixafortide as a monotherapy and in combination with natalizumab
for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in
sickle cell disease (SCD).<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Immuneering
Corporation (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/IMRX?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Nasdaq: IMRX</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">), a clinical-stage oncology company seeking
to develop and commercialize universal-RAS/RAF medicines for broad populations
of cancer patients </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/immuneering-receives-fda-fast-track-130000095.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">announced in February</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"> that the FDA granted Fast Track designation
for its lead clinical-stage program, IMM-1-104, for the treatment of patients
with PDAC who have failed one line of treatment. IMM-1-104 is designed to
provide universal-RAS activity through deep cyclic inhibition of the MAPK
pathway with once-daily oral dosing.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">“We welcome
FDA’s decision to grant Fast Track designation for IMM-1-104. Our Phase 1/2a
study is designed to evaluate IMM-1-104 in pancreatic cancer, as well as a
number of other tumor types associated with the RAS pathway. We look forward to
a data-rich 2024 as we plan to provide multiple readouts from our study this
year,” said Ben Zeskind, Ph.D., Co-founder and Chief Executive Officer of
Immuneering.<o:p></o:p></span></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">From the news:</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"> Vincent Chung, M.D., FACP, Professor,
Department of Medical Oncology and Therapeutics Research, is the principal
investigator of the Phase 1/2a clinical study with IMM-1-104 at City of Hope,
one of the largest cancer research and treatment organizations in the United
States.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">“The FDA’s
decision reinforces the importance of developing effective, novel treatments to
improve the health outcomes of patients with pancreatic ductal adenocarcinoma.
The development of well-tolerated oral medicines would improve the lives of
these patients. City of Hope offers many clinical trials testing innovative
treatments for people with pancreatic cancer," Chung said.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">Candel Therapeutics, Inc.(</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/CADL?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">Nasdaq: CADL</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">), a clinical stage biopharmaceutical company
focused on developing multimodal biological immunotherapies to help patients
fight cancer, </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/candel-therapeutics-receives-fda-fast-130000211.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">previously announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"> that the FDA granted Fast Track Designation
for its lead investigational adenovirus asset CAN-2409 plus prodrug
(valacyclovir) for the treatment of patients with PDAC to improve overall
survival.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">“We are pleased with the FDA's decision to grant Fast Track
Designation for CAN-2409 in pancreatic cancer,” said Paul Peter Tak, MD, PhD,
FMedSci, President and CEO of Candel. “This milestone follows our first interim
data report from the randomized phase 2 clinical trial in patients with
borderline resectable PDAC that showed prolonged and sustained survival after
experimental treatment with CAN-2409, especially when compared to real-world
data on patients receiving radiotherapy treatment. Candel remains on track to
release updated overall survival data from the interim analysis of this clinical
trial in the second quarter of 2024. We are grateful to the patients,
caregivers, investigators and clinical sites that have taken part in this
clinical trial.”<o:p></o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;">With lives at stake and market opportunity in front of
them, the race is on for companies aiming to fast track solutions for
pancreatic cancer. It’s a race worth winning!<o:p></o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="text-align: justify;"><b style="mso-bidi-font-weight: normal;"><span lang="DE" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-ansi-language: DE;">References<o:p></o:p></span></b></p>
<p class="MsoListParagraphCxSpFirst" style="line-height: normal; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;"><!--[if !supportLists]--><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Verdana; mso-fareast-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt "Times New Roman";">
</span></span></span><!--[endif]--><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">Botta G, et al. SWI/SNF
complex alterations as a biomarker of immunotherapy efficacy in pancreatic
cancer. JCI Insight. 2021;</span><span lang="EN-US"><a href="http://insight.jci.org/6/18"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">6(18)</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">:e150453. </span><span lang="EN-US"><a href="https://doi.org/10.1172/jci.insight.150453"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">https://doi.org/10.1172/jci.insight.150453</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">. <o:p></o:p></span></p>
<p class="MsoListParagraphCxSpLast" style="line-height: normal; mso-list: l0 level1 lfo1; text-align: justify; text-indent: -18.0pt;"><!--[if !supportLists]--><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Verdana; mso-fareast-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt "Times New Roman";">
</span></span></span><!--[endif]--><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">Yoon JH, et al.
Immunotherapy for pancreatic cancer. World J Clin Cases. 2021 May
6;9(13):2969-2982. doi: 10.12998/wjcc.v9.i13.2969. PMID: 33969083; PMCID:
PMC8080736.<o:p></o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Research more biotech stocks with Investorideas Biotech
stock directory <o:p></o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US"><a href="https://www.investorideas.com/BIS/Stock_List.asp"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">https://www.investorideas.com/BIS/Stock_List.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p style="background: white; margin-bottom: .0001pt; margin: 0cm;"><strong><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">About Investorideas.com - Big
Investing Ideas</span></strong><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p></o:p></span></p>
<p style="background: white; margin-bottom: .0001pt; margin: 0cm;"><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Investorideas.com</span></a></span><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all. Our original branded content includes podcasts such as Exploring
Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for sectors including mining, crypto, renewable
energy, gaming, biotech, tech, sports and more. Public companies within the
sectors we cover can use our news publishing and content creation services to
help tell their story to interested investors. Paid content is always
disclosed.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Disclaimer/Disclosure:</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> </span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
management and IR of each company directly regarding specific questions. Disclosure:
This article featuring Oncolytics Biotech Inc. is a </span><span lang="EN-US"><a href="https://www.investorideas.com/News-Upload/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">paid for</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> article at InvestorIdeas.com. More disclaimer
info: </span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Global investors must adhere to regulations of each country. Please
read Investorideas.com privacy policy: </span><span lang="EN-US"><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">https://www.investorideas.com/About/Private_Policy.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">Follow us on Twitter</span><span lang="EN-US"><a href="https://twitter.com/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"> </span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">@investorideas <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">Follow us on Facebook</span><span lang="EN-US"><a href="https://www.facebook.com/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.facebook.com/Investorideas"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">https://www.facebook.com/Investorideas</span></a></span><u><span lang="EN-US" style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">Follow us on YouTube</span><span lang="EN-US"><a href="https://www.youtube.com/c/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.youtube.com/c/Investorideas"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">https://www.youtube.com/c/Investorideas</span></a></span><u><span lang="EN-US" style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: normal;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Contact Investorideas.com <o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">800-665-0411<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqJX2L2J_o5qhulPipQPtG4jh7P8hkX-wvD7HtNDjbeDACxKhk8CIWWhLJFVbTLVuNqQ3_CcH3DKmziOX3uZSJGuJ_2cOLz-syLQDFMNrp2E0ihuo8AUSUy_TvAnXNvAWdeiZUEhwwaUn3LSPYWSgj_jybPgk3LtOEbFIwamktBoH6xkvC3ckV9Fs_VTPk/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjqJX2L2J_o5qhulPipQPtG4jh7P8hkX-wvD7HtNDjbeDACxKhk8CIWWhLJFVbTLVuNqQ3_CcH3DKmziOX3uZSJGuJ_2cOLz-syLQDFMNrp2E0ihuo8AUSUy_TvAnXNvAWdeiZUEhwwaUn3LSPYWSgj_jybPgk3LtOEbFIwamktBoH6xkvC3ckV9Fs_VTPk/s1600/BIS.gif" width="100" /></a></div><br /><p class="MsoNormal" style="background: white;"><br /></p>
<p class="MsoNormal" style="background: white; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Biotech Industry Stocks- investing ideas in biotechnology
stocks, medical technology and life sciences<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Like Biotech Stocks? View our </span><span lang="EN-US"><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News Alerts on Biotech Stocks</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-14970875221962124612024-03-05T07:51:00.000-08:002024-03-05T07:51:24.255-08:00Increasing Incidence Of Pancreatic Cancer Leading To A $6.85 Billion Dollar Market Size For New Treatments; @FNMgroup @Oncolytics<p> </p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTNHRnq4vsj7WoI1a-zg4ZwFnJ0iVVzXBzAL4ymL7s5dnO-P78RzYzV4qsy9s3fR70BCySApEsLgw3zE11-xoJMVRu571OSWtpg8Zz9UohyphenhypheneHOTBQ-c2qLQa_slxe_OTGxNG3olFtQUccUJTxTOeBKbrYyZ7Ntz7kjVPv55bxasfS8jWG9q-JN6ztZzB7o/s400/ONCY%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="174" data-original-width="400" height="139" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhTNHRnq4vsj7WoI1a-zg4ZwFnJ0iVVzXBzAL4ymL7s5dnO-P78RzYzV4qsy9s3fR70BCySApEsLgw3zE11-xoJMVRu571OSWtpg8Zz9UohyphenhypheneHOTBQ-c2qLQa_slxe_OTGxNG3olFtQUccUJTxTOeBKbrYyZ7Ntz7kjVPv55bxasfS8jWG9q-JN6ztZzB7o/s320/ONCY%20Logo.jpg" width="320" /></a></div><br /><p></p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi2ragi6dTckiNTuff2MrK4-qZRGHlotmBa4W-gWMVtplKmgzwuBvdPnGCnxKgcdeka04NZh8H38ZLVvyPiqReFjmmzJEM7ZDKcJCtAmMZr954_mJcW6rx7g0Z5KsSBIvlwtuc_vPjw3EbU3-2995mxcDOroeWfDZFwcPxwh-IqOEIbPVIDZUXZ0QdJoa7G/s1149/FNM.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="663" data-original-width="1149" height="185" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi2ragi6dTckiNTuff2MrK4-qZRGHlotmBa4W-gWMVtplKmgzwuBvdPnGCnxKgcdeka04NZh8H38ZLVvyPiqReFjmmzJEM7ZDKcJCtAmMZr954_mJcW6rx7g0Z5KsSBIvlwtuc_vPjw3EbU3-2995mxcDOroeWfDZFwcPxwh-IqOEIbPVIDZUXZ0QdJoa7G/s320/FNM.png" width="320" /></a></div><br /><b style="mso-bidi-font-weight: normal;"><br /></b><p></p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-language: EN-CA;"><a href="https://www.financialnewsmedia.com/increasing-incidence-of-pancreatic-cancer-leading-to-a-6-85-billion-dollar-market-size-for-new-treatments/"><span style="color: windowtext; text-decoration: none; text-underline: none;">Increasing
Incidence Of Pancreatic Cancer Leading To A $6.85 Billion Dollar Market Size
For New Treatments</span></a>; </span></b><b style="mso-bidi-font-weight: normal;"><span style="color: #0f1419; font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: "Segoe UI";">@FNMgroup<span style="mso-spacerun: yes;"> </span>@Oncolytics</span></b><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-language: EN-CA;"><o:p></o:p></span></b></p>
<p style="background: #F9F9F9; margin-bottom: .0001pt; margin: 0cm;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p style="background: #F9F9F9; margin-bottom: .0001pt; margin: 0cm;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Palm
Beach, FL – March 5, 2024 – <a href="https://www.financialnewsmedia.com/" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><em style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif"; text-decoration: none; text-underline: none;">FN Media Group</span></em></a><em style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";"> News
Commentary </span></em>– Pancreatic cancer is one of the leading causes of
cancer death globally. The increasing incidence of this cancer across the U.S.
and other parts of the world is one of the factors driving the need for the
drugs used in the treatment. Moreover, the prevalence is significantly higher
in the geriatric population compared to other types of cancers. Thus, an
increase in the geriatric population is one factor driving the pancreatic
cancer treatment market growth. The incidence is significantly higher in the geriatric
population above 65 years of age compared to other types of cancers. A <a href="https://www.fortunebusinessinsights.com/pancreatic-cancer-treatment-market-101989" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">report</span></a> from
Fortune Business Insights said that: “the pancreatic cancer treatment market
size is projected to grow to USD 6.85 billion by 2029, exhibiting a CAGR of
15.7% during 2022-2029. North America dominated the global market with a share
of 46.97% in 2022. The increase in the number of patients suffering from the
condition has increased the demand for the drugs used in treatment. These are
some factors driving the growth during the forecast period. Companies
engaged in manufacturing cancer drugs have increased their focus on R&D
activities to develop new drugs for pancreatic cancer treatment. Additionally,
the companies operating in the market have received approval from several
regulatory bodies, such as the U.S. Food and Drug Administration (FDA), the
Medicines and Healthcare Products Regulatory Agency (MHRA) (U.K.), among others,
thereby propelling the growth of the market. Moreover, new testing technologies
are being adopted by hospitals and diagnostic centers to diagnose cancer. The
increase in the diagnosis rates is driving the demand for drugs, thereby
providing opportunities for the players.” Active biotech and pharma
companies in the markets this week include <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">Oncolytics Biotech<sup style="box-sizing: border-box;">®</sup> Inc.</span></strong> (NASDAQ:
ONCY) (TSX: ONC), <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">Ocean Biomedical, Inc. </span></strong>(NASDAQ: OCEA), <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">LAVA
Therapeutics N.V. </span></strong>(NASDAQ: LVTX), <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">Merck
& Co., Inc.</span></strong> (NYSE: MRK), <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">AbbVie
Inc. </span></strong>(NYSE: ABBV).<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="background: #F9F9F9; margin-bottom: .0001pt; margin: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Read this in full at <a href="https://www.financialnewsmedia.com/increasing-incidence-of-pancreatic-cancer-leading-to-a-6-85-billion-dollar-market-size-for-new-treatments/">https://www.financialnewsmedia.com/increasing-incidence-of-pancreatic-cancer-leading-to-a-6-85-billion-dollar-market-size-for-new-treatments/</a><o:p></o:p></span></b></p>
<p style="background: #F9F9F9; margin-bottom: .0001pt; margin: 0cm;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Fortune Business Insights continued: “Shifting the focus of key
players in extensive R&D activities to develop new drugs and an increase in
funding for cancer research led to the development of new drugs for treatment.
Additionally, several pharmaceutical companies are involved in clinical trials
to develop new drugs and explore the potential of the molecule to treat the
disease. Thus, with the increased funding for R&D activities,
companies are focused on developing new drugs, thereby contributing to the
overall rise in demand for drugs for pancreatic type of cancer treatment. Thus,
increasing aging population and rising government initiatives to create
awareness for the diagnosis of the condition are some factors propelling the
market growth.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Oncolytics Biotech<sup style="box-sizing: border-box;">®</sup> Inc.</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">(NASDAQ:
ONCY) (TSX: ONC) Files Amendment to Initiate New Pancreatic Cancer GOBLET
Cohort Supported by PanCAN – </span></strong><em style="box-sizing: border-box;"><b><span style="font-family: "Verdana","sans-serif";">US$5M grant supports study of
pelareorep in combination with modified FOLFIRINOX +/- atezolizumab</span></b></em><strong><span style="font-family: "Verdana","sans-serif";"> – </span></strong>Oncolytics
Biotech® Inc., a clinical-stage immunotherapeutics company focused on oncology,
today announced it has submitted an amendment to GOBLET to initiate a new Phase
1/2 cohort evaluating pelareorep in combination with modified FOLFIRINOX
(mFOLFIRINOX) with and without atezolizumab (Tecentriq®) in patients with newly
diagnosed metastatic pancreatic ductal adenocarcinoma (PDAC). This amendment
will be reviewed by the Paul Ehrlich Institute (PEI; Germany’s regulatory body)
for approval before patient enrollment can begin. The cohort, the fifth of the
GOBLET gastrointestinal cancer study, is being supported by the US$5 million
Therapeutic Accelerator Award from the Pancreatic Cancer Action Network
(PanCAN), an innovative program established to accelerate the development of
new treatments for pancreatic cancer.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">“We are enthusiastic to have the support of PanCAN to expand the
evaluation of pelareorep in pancreatic cancer and explore mFOLFIRINOX as
another combination that could improve outcomes for patients. Notably, this
patient population is newly diagnosed patients who are receiving first-line
treatment. Chemotherapies, including either mFOLFIRINOX or gemcitabine and
nab-paclitaxel, are the backbone treatment regimens of pancreatic cancer
therapy. Evaluating pelareorep in combination with these widely used regimens
is an important step in our broad clinical development program,” said Dr. Matt
Coffey, President and Chief Executive Officer of Oncolytics. “Last fall, we
reported a 62% objective response rate for the GOBLET PDAC cohort studying
pelareorep in combination with the checkpoint inhibitor atezolizumab in addition
to gemcitabine and nab-paclitaxel (<a href="https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">link to the PR</span></a>, <a href="https://oncolyticsbiotech.com/wp-content/uploads/2023/10/ESMO_2023_PDAC_poster-FINAL1a.pdf" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">link to the poster</span></a>).
This response is about three times that of historical controls and forms the
basis of the registrational program, expected to begin this year. Therefore, we
are enthusiastic about this new mFOLFIRINOX pancreatic cancer cohort and look
forward to enrolling the first patient as soon as possible.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum
Hamburg, and primary investigator of the GOBLET trial, commented, “One of the
reasons for pancreatic cancer’s poor survival rate is that it effectively
evades the immune system and can induce an immunosuppressive tumor
microenvironment (TME). Pelareorep is an attractive combination partner because
of its ability to address both issues by activating the innate and adaptive
immune systems while driving the remodeling of the tumor microenvironment.
Positive results from the Phase 2 study evaluating pelareorep combined with
atezolizumab and chemotherapy reported last fall support the potential use of
these agents together. I am hopeful that the combination of pelareorep and
mFOLFIRINOX (with or without atezolizumab) will yield positive response data
and advance the development of new treatment options for patients with
pancreatic cancer.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">“This study is designed to evaluate whether pelareorep can
enhance outcomes in patients receiving mFOLFIRINOX, one of the most commonly
used metastatic pancreatic cancer treatments. Combining pelareorep with
mFOLFIRINOX represents an expansion of our existing pancreatic cancer program
and maximizes the potential of pelareorep-based combination therapies to
benefit pancreatic cancer patients,” commented Thomas Heineman, M.D., Ph.D.,
Chief Medical Officer at Oncolytics. “The mFOLFIRINOX cohort utilizes a
screened selection design within a Simon two-stage approach that will also
allow evaluation of the contribution of atezolizumab to the
pelareorep/mFOLFIRINOX combination. In addition, this study is designed to
provide valuable translational assessments, such as the expansion of
tumor-infiltrating lymphocytes (TILs) in the blood, which has been associated
with tumor responses. We look forward to building on PanCAN’s strong
relationships with the pancreatic cancer community and furthering our collaboration
with AIO-Studien-gGmbH (AIO) on the GOBLET study.” <em style="box-sizing: border-box;"><b><span style="font-family: "Verdana","sans-serif";">CONTINUED</span></b></em><strong><span style="font-family: "Verdana","sans-serif";">…</span></strong> <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">Read
these full press releases and more news for ONCY at:</span></strong> <a href="https://www.financialnewsmedia.com/news-oncy/" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">https://www.financialnewsmedia.com/news-oncy/</span></a><u style="box-sizing: border-box;"> </u><o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><em style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Other recent developments in
the biotech industry of note for cancer events include:</span></em><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Ocean Biomedical, Inc.
(NASDAQ: OCEA),</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> a biopharma company which endeavors
to accelerate the development of compelling discoveries from top research
scientists, recently <a href="https://finance.yahoo.com/news/ocean-biomedical-nasdaq-ocea-announces-130100542.html" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">congratulated</span></a> its <a href="https://www.globenewswire.com/Tracker?data=cOQp6VAjwJDkkTl76IoNWlpvrqsNPNzGIWMIlmn24FH5YlvOxnzhIl_RlFoJLFz_PWSVplPPWrCKiV-x7j2pLTc7STN511QclFw-wAEyD9F9wqnxTD15sJB7tlMKqwoJk-Smmn8ReuCvzCgguYaoUl-CGRr94WgqccRVCJGWLIlxyLcKwucHCDuZA-xjLa8NDTI5dUeuXvlpt2IEzoB9siaMKCfdl6khzd1PsMlj6zu3II7ZkrRMCr9vLCZNZ9rzA2_5iCN1KhkMc-iR1mkFGFSPD1KxNakB0ykjQr0mq78V6k3YJavLganJzBq64YZUIvfNLw1E0AG-JHImKYasmWZd5jFaRetVe1lm-IbYaZottQuCv0cs28e6flR7v3ks8b0-hp7QBbS78r_ql9cVYyzz-lH7rNmfd7jQnX5lhtVjEB-6n8zjEVl78cAUvT5TQ0zHSok9oexg9n93Qqd2kw==" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">joint venture partner</span></a>,
Virion Therapeutics, LLC, a clinical-stage biotechnology company
developing T cell-based immunotherapies, for the acceptance of their
abstract highlighting the first-ever human data from its novel checkpoint
modifier immunotherapy for HBV functional cure, for late breaker oral
presentation at the upcoming 33rd Annual Meeting of
APASL (The Asian Pacific Association for the Study of the Liver), taking
place in Kyoto, Japan from March 27-31, 2024.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">The late breaker presentation will highlight the safety data
observed, to date, in the ongoing Phase 1B clinical trial of VRON-0200. “This
accepted abstract highlights Virion’s commitment to finding a functional cure
for chronically HBV-infected patients – and the first-ever human data for a
genetically encoded checkpoint modifier T cell vaccine of any kind. VRON-0200
is uniquely developed to stimulate a patient’s own immune response to the
virus. Additionally, its mechanism of action and intramuscular administration
were designed to limit safety issues for this novel therapy,” said Dr. Sue
Currie, COO of Virion, and one of the study authors. “We look forward to
sharing these late breaking clinical HBV data at APASL, one of the leading
meetings on the treatment of liver diseases in the world.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">LAVA Therapeutics
N.V. (NASDAQ: LVTX),</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> recently <a href="https://finance.yahoo.com/news/lava-therapeutics-announces-collaboration-merck-120000910.html" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">announced</span></a> that
it has entered into a clinical trial collaboration and supply agreement with <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">Merck
& Co., Inc.</span></strong> <strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">(NYSE: MRK), </span></strong>Rahway,
NJ, USA to evaluate its anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in
combination with LAVA-1207, a Gammabody<strong style="box-sizing: border-box;"><span style="font-family: "Verdana","sans-serif";">®</span></strong> designed to
target the prostate-specific membrane antigen (PSMA) to trigger the potent and
preferential killing of PSMA-positive tumor cells, in patients with therapy
refractory metastatic castration-resistant prostate cancer (mCRPC).<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Under the terms of the agreement, Merck & Co., Inc., Rahway,
NJ, USA will provide pembrolizumab for the dose escalation and expansion phases
of LAVA’s ongoing Phase 1/2a study of LAVA-1207 (<a href="https://www.globenewswire.com/Tracker?data=PWGM_7C4iQ2pKWVimsk-l75O3ZT_lBKz0SNs_9-zhUH8X9a0SIqDJRLYszQc1upHcAQIqDGqR-Mq4MLCk8ppnLDQFxMASmxC-NKgKLCyww_ng1BHSlh-PQYJHdGaaa5fUUUImjuseg8Ws-vEJjxsVDRQ3tgAS7OHV1VW02RG4GMeQ-ONa2RLAoQcIxnKWarmrIn6EHfxdyzhH8zJweFl_2I1MVbAhtKV-OMAba4zd5CGL_f8oO-1-bqWW_-ZxgFHM5ANVePMfbuczNKZaAtqn1iMR68GkgmuKGnzX4l6eISdXJD9K3B2l40-__jSFppPatZk7a_3Utb4PktCyCYXgHcZy1dC9oQsH1BIhQV7q3gsMOQfOAdqYSdaYKyWfTZlGfmhfo8Xk0_xqH87hslSvCPiyXH6mdb2msTeJEWH3f7aYWa9YZR5M_gIe7k7_NfPsMxNYg8iHNAKwjNy1DqlVcQ2SlYOGLYQDduUHaN_-e01A27EYNNC1u3OJ2FKn8pu3P6LxsCn8Y7yct1Uql4PuFcAfYYRtuVWx-oC2gdWykXBjT9RpTrFw0mQskCbkt3NcFjDPLDZnt522w0Ylk6q-3aLMdI8g6cbtO-8zFVTj4tlP5M7lgSpcBcvgpF3-ak0KBRB5_qAaTomuF0ReQ8emiW5PSLfneR2H0fG_zp0cYsL59CwZdsC_Bt_-MKkamm4j5zjTJHSlmEB1FKwZ6VmAwKrpq5Og6ZVe_QHQ02eqemo6uG2sLmpe4ucCkst1NHy" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">NCT05369000</span></a>), with
the combination arm expected to be initiated in the first half of 2024.
Enrollment and dose escalation will also continue in the LAVA-1207 monotherapy
and interleukin-2 arms of the study.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">“We are excited to work with Merck & Co., Inc., Rahway, NJ,
USA as we continue to unlock the therapeutic potential of LAVA-1207 and explore
its potential capabilities in combination with KEYTRUDA®,” said Stephen Hurly,
President and Chief Executive Officer, LAVA. “To date, LAVA-1207 has demonstrated
a favorable safety profile and shown preliminary signs of anti-tumor activity.
Prostate cancer has presented challenges for immune checkpoint therapies in the
past – we are hopeful the combination of our products may deliver important
clinical outcomes.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">AbbVie Inc. (NYSE: ABBV)</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> and
OSE Immunotherapeutics SA, a clinical-stage immunotherapy
company, recently <a href="https://finance.yahoo.com/news/abbvie-ose-immunotherapeutics-announce-partnership-050500481.html" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">announced</span></a> a
strategic partnership to develop OSE-230, a monoclonal antibody designed to
resolve chronic and severe inflammation, currently in the pre-clinical
development stage.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">OSE-230 is a first-in-class monoclonal antibody designed to
activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. Activation
of ChemR23 may offer a novel mechanism for the resolution of chronic
inflammation, modulating functions of both macrophages and neutrophils.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">“This collaboration underscores our commitment to expanding our
immunology portfolio with the ultimate goal of improving the standard of care
for patients living with inflammatory diseases globally,” said Jonathon
Sedgwick, Ph.D., senior vice president and global head of discovery research,
AbbVie. “By leveraging our expertise in immunology drug development, we
look forward to advancing OSE-230, which offers a novel mechanism-of-action to
treat chronic inflammation.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">“We are very pleased to collaborate with AbbVie, a global leader
in the development and commercialization of innovative medicines, to drive our
OSE-230 program forward,” said Nicolas Poirier, chief executive officer,
OSE Immunotherapeutics. “This partnership represents a major milestone in our
company’s progress and recognizes the value of our innovative R&D
capabilities. I would like to thank all our employees who helped us reach this
milestone through dedication and hard work.”<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><i><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">About FN Media Group:</span></i></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">At FN Media Group, via our top-rated online news portal at
www.financialnewsmedia.com, we are one of the very few select firms providing
top tier one syndicated news distribution, targeted ticker tag press releases
and stock market news coverage for today’s emerging companies.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Follow us on Facebook to
receive emerging news updates:</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <a href="https://www.facebook.com/financialnewsmedia" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">https://www.facebook.com/financialnewsmedia</span></a><o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Follow us on Twitter for real
time Breaking News:</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <a href="https://twitter.com/FNMgroup" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">https://twitter.com/FNMgroup</span></a><o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><strong style="box-sizing: border-box;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Follow and us on Linkedin:</span></strong><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <a href="https://www.linkedin.com/in/financialnewsmedia/" style="box-shadow: none; box-sizing: border-box; color: var( --e-global-color-accent );"><span style="text-decoration: none; text-underline: none;">https://www.linkedin.com/in/financialnewsmedia/</span></a><o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">DISCLAIMER: FN Media Group LLC (FNM), which owns and
operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party
publisher and news dissemination service provider, which disseminates
electronic information through multiple online media channels. FNM is NOT
affiliated in any manner with any company mentioned herein. FNM and its
affiliated companies are a news dissemination solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNM’s market
updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this
release is intended to be strictly informational and is NEVER to be construed
or interpreted as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a licensed
financial professional before considering any level of investing in
stocks. All material included herein is republished content and details
which were previously disseminated by the companies mentioned in this
release. FNM is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks. For current services
performed FNM was compensated forty nine hundred dollars for news coverage of
the current press releases issued by Oncolytics Biotech<sup style="box-sizing: border-box;">®</sup> Inc.
by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY
NAMED IN THIS RELEASE.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">This release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. “Forward-looking statements” describe
future expectations, plans, results, or strategies and are generally preceded by
words such as “may”, “future”, “plan” or “planned”, “will” or “should”,
“expected,” “anticipates”, “draft”, “eventually” or “projected”. You are
cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors, and
other risks identified in a company’s annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements
included herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date hereof and
FNM undertakes no obligation to update such statements.<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Contact Information:<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757<o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> <o:p></o:p></span></p>
<p style="-webkit-text-stroke-width: 0px; background: #F9F9F9; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; margin-bottom: .0001pt; margin: 0cm; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;"><span style="color: #3a3a3a; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">SOURCE: FN Media Group<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-59354463808704024042024-03-04T09:21:00.000-08:002024-03-04T09:21:50.957-08:00 Eyeing AI Tech Stocks: (Nasdaq: $KSCP) (NYSE: $PATH) (CBOE: $VHAI) (NYSE: $SYRA)<p> <b style="text-align: center;"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Eyeing AI Tech Stocks:</span></b><span lang="EN-US" style="text-align: center;"> </span><b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">(Nasdaq: $KSCP) (NYSE: $PATH) (CBOE: $VHAI) (NYSE: $SYRA)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Biotech Stock Additions: (Nasdaq: $TELO) (Nasdaq: $MGX) (Nasdaq: $IMUX) (Nasdaq: $VTYX)<o:p></o:p></span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjm0wbzkOxV04im9eypkJxlX3gdN4pONOC8AW9QBO6EEibBjjiY4JotFNgLOkYlrNzCoBywVKdYtFKZj1cLSB0k_L5w5pFVIldBv4ZHH1BdOu8gMazaHmlTmiyK-2Mz7QXHNTNYs_UVtURMV5XJyla52KgJYrBR0r4ANVzCUZc_G2SfPLgOc8MtwTdLwDE/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjm0wbzkOxV04im9eypkJxlX3gdN4pONOC8AW9QBO6EEibBjjiY4JotFNgLOkYlrNzCoBywVKdYtFKZj1cLSB0k_L5w5pFVIldBv4ZHH1BdOu8gMazaHmlTmiyK-2Mz7QXHNTNYs_UVtURMV5XJyla52KgJYrBR0r4ANVzCUZc_G2SfPLgOc8MtwTdLwDE/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">March 4, 2024 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the AI (artificial intelligence) Tech and Biotech sectors.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at: </span></b><a href="https://www.investorideas.com/news/2024/main/03041Stocks.asp">https://www.investorideas.com/news/2024/main/03041Stocks.asp</a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest tech companies are all involved in various aspects of the Artificial Intelligence (AI)/Robotics sector with applications in public safety, RPA solutions for business, cloud computing and healthcare technology.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The latest biotech companies are involved in the treatment of age related disease, genetics medicines and autoimmune disease treatments.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/TSS/Stock_List.asp#Robotics"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">AI Tech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.knightscope.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Knightscope, Inc.</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (<a href="https://finance.yahoo.com/quote/KSCP?.tsrc=fin-srch">Nasdaq: KSCP</a>) builds cutting-edge technologies to improve public safety, and our long-term ambition is to make the United States of America the safest country in the world. We are Autonomous Security Robots (ASRs). We use a unique combination of self-driving technology, robotics, artificial intelligence (A.I.) and electric "vehicles" to provide humans with extra eyes, ears and a voice on the ground. We can be in multiple locations at the same time, helping you protect the places people live, work, study and visit.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://www.uipath.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">UiPath</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/PATH?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE:PATH)</span></a><span class="MsoHyperlink"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span><span class="MsoHyperlink"><span lang="EN-US" style="color: windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt;">is on a mission to uplevel knowledge work so more people can work more creatively, collaboratively, and strategically. The AI-powered UiPath Business Automation Platform combines the leading robotic process automation (RPA) solution with a full suite of capabilities to understand, automate, and operate end-to-end processes, offering unprecedented time-to-value. For organizations that need to evolve to survive and thrive through increasingly changing times, UiPath is The Foundation of Innovation™.<o:p></o:p></span></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://vocodia.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Vocodia Holdings Corp</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/VHAI?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CBOE: VHAI</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is an AI software company that build practical AI functions and makes them easily obtainable for businesses on cloud-based platform solutions at low costs and scalable to multiagent vast enterprise solutions. Vocodia is a conversational AI software developer and provider that offers scalable enterprise-level AI sales and customer service solutions which allow for AI sales representatives to reduce human labor costs and responsibilities while increasing the reach and efficacy of human-led, purposeful, agenda driven and conversational communications. Vocodia deliver its patent pending conversational AI software in the form of Digital Intelligent Sales Agents (the "DISAs"), which are built with AI software programmed to sound and feel human and to perform business tasks that require humans to converse with one another effectively, and thus to provide the best representation for each of its customers' businesses.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://www.syrahealth.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Syra Health Corp.</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/SYRA?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: SYRA</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. Syrenity transforms mental health care through personalized, proactive AI interventions, offering users customizable tools like assessments, cognitive therapy, and telehealth. This innovative blend of technology and compassionate support redefines the mental well-being journey.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNoSpacing"><a href="https://telomirpharma.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Telomir Pharmaceuticals, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/TELO?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:TELO</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to affect age reversal. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of Telomir-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><a href="https://metagenomi.co/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Metagenomi, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/MGX?.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:MGX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived toolbox. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. Metagenomi believes its diverse and modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://imux.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Immunic, Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (<a href="https://finance.yahoo.com/quote/IMUX?.tsrc=fin-srch">Nasdaq: IMUX</a>) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, for which it is currently in preparations for a phase 2 clinical trial. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://ventyxbio.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Ventyx Biosciences, Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/VTYX?.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasadq:VTYX</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting TYK2, S1P1R and NLRP3, positioning us to become a leader in the development of oral immunology therapies. Ventyx is headquartered in San Diego, California.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/"><span style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span lang="EN-US" style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;"> is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.<o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQvHf9eAW9PSgGTI3xlb6EO8lE9PVmERETMa1hKPGw8ugNfeYfUibuFMVEDgZxQGlPjA5FLP5tOHMBZ16dfTFq694iPMnouexUF1JI9MucobRFZnqa_FwkgNix_0aeuKhjJQJ5gxyAp9GbaIzA62SZQYF2ZxaCg-3bfcY9RBWQryG5utVEVPgxT0JmdsA/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQvHf9eAW9PSgGTI3xlb6EO8lE9PVmERETMa1hKPGw8ugNfeYfUibuFMVEDgZxQGlPjA5FLP5tOHMBZ16dfTFq694iPMnouexUF1JI9MucobRFZnqa_FwkgNix_0aeuKhjJQJ5gxyAp9GbaIzA62SZQYF2ZxaCg-3bfcY9RBWQryG5utVEVPgxT0JmdsA/s320/social-media%20ICONS.png" width="320" /></a></div><br /><p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><br /><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-32880861175060955742024-02-21T09:40:00.000-08:002024-02-21T09:41:57.834-08:00 Focus on Biotech & AI Stocks: (Nasdaq: $IMTX) (Nasdaq: $MDAI) (NASDAQ: $BFRG) (CSE: $INVR.CN)<p> <b style="text-align: center;"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 12pt;">Focus on Biotech & AI Stocks: (Nasdaq: $IMTX) (Nasdaq: $MDAI) (NASDAQ: $BFRG) (CSE: $INVR.CN)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 12pt;">Stocks to Watch in Tech & Cybersecurity - (Nasdaq: $KSPI) (Nasdaq: $CCTG) (Nasdaq: $HUBC) (Nasdaq: $GEN)<o:p></o:p></span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span face="Verdana, "sans-serif"" style="font-size: 12pt;"> </span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiSPyn4TOdc36pqCEyGkAKPPy1uCl7gNVa0L8QBUc3JyZeFQV4KznbbjbDuWyYYLrfDeC1L4B221iRuXxqshXkmGfz0f-47wKVJIzhouOaQGgSV-vPx0AtBNFzRd3Emmh01kNpda-QuRarTCRH7oA8kMemzBNhl2WExSuv-MFYMRjc5Qycwf3koagQ9VRE/s1024/II%20newsletter.jpg" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiSPyn4TOdc36pqCEyGkAKPPy1uCl7gNVa0L8QBUc3JyZeFQV4KznbbjbDuWyYYLrfDeC1L4B221iRuXxqshXkmGfz0f-47wKVJIzhouOaQGgSV-vPx0AtBNFzRd3Emmh01kNpda-QuRarTCRH7oA8kMemzBNhl2WExSuv-MFYMRjc5Qycwf3koagQ9VRE/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">February 21, 2024 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Investorideas.com</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;">, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech, AI, Tech and Cybersecurity sectors.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Read this in full at </span></b><a href="https://www.investorideas.com/news/2024/main/02211Stocks.asp">https://www.investorideas.com/news/2024/main/02211Stocks.asp</a><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">The newest biotech companies work with T-cell therapies for cancer treatment and use AI (artificial intelligence) for medical diagnosis and treatments.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">The latest tech companies are involved in AI (artificial intelligence) fintech and interconnect products.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">The newest cybersecurity companies are both Nasdaq-listed and provide services around the world.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Biotech/Life Sciences Directories</span></b></a><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://immatics.com/"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Immatics N.V.</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/IMTX?.tsrc=fin-srch"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Nasdaq:IMTX</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">) combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://www.spectral-ai.com/"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Spectral AI, Inc.</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/MDAI?p=MDAI&.tsrc=fin-srch"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Nasdaq: MDAI</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">) is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://bullfrogai.com/"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">BullFrog AI Holdings, Inc</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/BFRG?p=BFRG&.tsrc=fin-srch"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">NASDAQ:BFRG</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">) is a technology-enabled drug development company using Artificial Intelligence and machine learning to enable the successful development of pharmaceuticals and biologics. Through its collaborations with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform to create and analyze networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/TSS/Stock_List.asp"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Tech Directories</span></b></a><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://inveriteinsights.com/"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Inverite Insights Inc</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">. (</span><a href="https://ca.finance.yahoo.com/quote/INVR.CN?p=INVR.CN&.tsrc=fin-srch"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">CSE:INVR</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">) is a Vancouver-based, AI-driven software provider specializing in real-time financial data. With a vast database of over seven billion financial data points from more than four million unique Canadian consumers transactions, Inverite empowers businesses to transact more effectively with consumers through innovative software-as-a-service (SaaS) and risk-model-as-a-service (RMaaS) solutions.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><a href="https://kaspi.kz/"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Joint Stock Co Kaspi.kz</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/KSPI?p=KSPI&.tsrc=fin-srch"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Nasdaq:KSPI</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;">) operates a two-sided Super App business model: the Kaspi.kz Super App for consumers and the Kaspi Pay Super App for merchants and entrepreneurs. Kaspi.kz's offerings include payments, marketplace and fintech solutions for both consumers and merchants.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><a href="https://www.ccsc-interconnect.com/"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">CCSC Technology International Holdings Ltd</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/CCTG?p=CCTG&.tsrc=fin-srch"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Nasdaq:CCTG</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;">) is a Hong Kong-based company that engages in the sale, design and manufacturing of interconnect products. The Company specializes in customized interconnect products, including connectors, cables and wire harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. The Company produces both OEM (“original equipment manufacturer”) and ODM (“original design manufacture”) interconnect products for manufacturing companies that produce end products, as well as electronic manufacturing services (“EMS”) companies that procure and assemble products on behalf of such manufacturing companies. The Company has a diversified global customer base located in more than 25 countries throughout Asia, Europe and the Americas.<o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp#CyberSecurity"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Cybersecurity Directories</span></b></a><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">:</span></b><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://hubsecurity.com/"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">HUB Cyber Security Ltd</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/HUBC?p=HUBC&.tsrc=fin-srch"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Nasdaq: HUBC</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">) was established in 2017 by veterans of the elite intelligence units of the Israeli Defense Forces. The Company specializes in unique cyber security solutions protecting sensitive commercial and government information. The company debuted an advanced encrypted computing solution to prevent hostile intrusions at the hardware level while introducing a novel set of data theft prevention solutions. HUB Security operates in over 30 countries and provides innovative cybersecurity computing appliances and a wide range of cybersecurity services worldwide.<o:p></o:p></span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></b></p><p class="MsoNormal"><a href="https://www.gendigital.com/us/en/"><span face="Verdana, "sans-serif"" style="background: white; font-size: 10pt;">Gen Digital Inc</span></a><span face="Verdana, "sans-serif"" style="background: white; color: #1d2228; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/GEN?.tsrc=fin-srch"><span face="Verdana, "sans-serif"" style="background: white; font-size: 10pt;">NASDAQ: GEN</span></a><span face="Verdana, "sans-serif"" style="background: white; color: #1d2228; font-size: 10pt;">) is a global company dedicated to powering Digital Freedom through its trusted Cyber Safety brands, Norton, Avast, LifeLock, Avira, AVG, ReputationDefender and CCleaner. The Gen family of consumer brands is rooted in providing safety for the first digital generations. Now, Gen empowers people to live their digital lives safely, privately, and confidently today and for generations to come. Gen brings award-winning products and services in cybersecurity, online privacy and identity protection to nearly 500 million users in more than 150 countries. <o:p></o:p></span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></b></p><p class="MsoNoSpacing"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" style="font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/"><span face="Verdana, "sans-serif"" style="background: white; font-size: 10pt;">Investorideas.com</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="background: white; font-size: 10pt;"> is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.<o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span face="Verdana, "sans-serif"" style="color: #333333; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Investorideas.com</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span face="Verdana, "sans-serif"" style="color: #337ab7; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span face="Verdana, "sans-serif"" style="color: #337ab7; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span face="Verdana, "sans-serif"" style="color: #23527c; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span face="Verdana, "sans-serif"" style="color: #23527c; font-size: 10pt;"></span></span><span face="Verdana, "sans-serif"" style="font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span face="Verdana, "sans-serif"" style="font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">https://www.investorideas.com/Advertise/</span></a><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">https://twitter.com/Investorideas</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Dawn Van Zant</span></a><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span face="Verdana, "sans-serif"" style="font-size: 10pt;">Cali Van Zant</span></a><span face="Verdana, "sans-serif"" style="font-size: 10pt;"></span><span face="Verdana, "sans-serif"" style="font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span face="Verdana, "sans-serif"" lang="EN-US" style="font-size: 10pt;">800 665 0411</span></b> </p><p class="MsoNormal"><o:p> </o:p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtvf0O4JxYmdkXrom2PCuP-_i2GVhDhbn1dL_yl561WZtQda5J385-9gvvNrvMz-Gc4D7pLgId_WcOAJC_DnXy6O-u0JK_Pae-8u4phyphenhyphenazbxkVjHwbZqfBD99WPiSdnXw7xZDLgyOCizBRroKIv0O4Lo-0ioy6VeXS8DHNQjy4UFNTjMr-g5AHRIjbdpQ/s343/social-media%20ICONS.png" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtvf0O4JxYmdkXrom2PCuP-_i2GVhDhbn1dL_yl561WZtQda5J385-9gvvNrvMz-Gc4D7pLgId_WcOAJC_DnXy6O-u0JK_Pae-8u4phyphenhyphenazbxkVjHwbZqfBD99WPiSdnXw7xZDLgyOCizBRroKIv0O4Lo-0ioy6VeXS8DHNQjy4UFNTjMr-g5AHRIjbdpQ/s320/social-media%20ICONS.png" width="320" /></a></div><div><br /></div>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-68457793963092938732024-02-21T08:29:00.000-08:002024-02-21T08:29:17.502-08:00Breaking Medical Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) Enters Into Materials Transfer Agreement for Santersus AG’s NucleoCapture and HemoNucleoCapture Devices <p> </p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Breaking Medical
Technology Stock News: Aethlon Medical </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Arial;">(NASDAQ: $AEMD) </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Enters Into Materials Transfer Agreement for<a name="_Hlk158899557">
Santersus </a>AG’s NucleoCapture and HemoNucleoCapture Devices <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential
Synergies With its First-in-Class Hemopurifier® Blood Filtration System<o:p></o:p></span></i></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhez28od2ZAYBSoMysdNAtnM8oEgm5qFhznrbMr4PJGM5CSKgF-QNMMBrOCamprEpWZ7aQoEwxwNj8jZ_5qLLpfEb1s-Pz8tpHqpxANf2bOcvtLHQ3lMNYgpAFzxfEyhxfmEErDdFSiTvgmepcZQ-rtGGXeSjnLO87mRbNFN4a8HYTE0XO9x9ga0Nfjp7kI/s400/AEMD%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="140" data-original-width="400" height="112" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhez28od2ZAYBSoMysdNAtnM8oEgm5qFhznrbMr4PJGM5CSKgF-QNMMBrOCamprEpWZ7aQoEwxwNj8jZ_5qLLpfEb1s-Pz8tpHqpxANf2bOcvtLHQ3lMNYgpAFzxfEyhxfmEErDdFSiTvgmepcZQ-rtGGXeSjnLO87mRbNFN4a8HYTE0XO9x9ga0Nfjp7kI/s320/AEMD%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt;">SAN DIEGO, CA, February 21, 2024 -- </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">(Investorideas.com
Newswire) </span><span lang="EN-US"><a href="https://www.aethlonmedical.com/"><span style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Aethlon Medical, Inc.</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"> </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">(</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/AEMD?p=AEMD&.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">NASDAQ:AEMD</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">), </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">a medical
therapeutic company focused on developing products to treat cancer and
life-threatening infectious diseases, today announced that it entered into a
Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately
held therapeutic medical device company, for Santersus’ NucleoCapture and
HemoNucleoCapture devices.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing" style="margin-bottom: 14.4pt;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Read this in full at: </span><span lang="EN-US"><a href="https://www.investorideas.com/news/2024/02211AEMD-NucleoCapture-HemoNucleoCapture-Devices.asp">https://www.investorideas.com/news/2024/02211AEMD-NucleoCapture-HemoNucleoCapture-Devices.asp</a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Under the terms
of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture
devices, designed to remove Neutrophil Extracellular Traps (NETs), which are
toxic to tissues and organs and are implicated in the pathophysiology of cancer,
sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in
organ transplantation. <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Aethlon will perform
initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture
devices, alone, and in combination with Aethlon’s Hemopurifier® -- a
therapeutic blood filtration system designed to bind and remove harmful
exosomes and life-threatening viruses from blood and other biological fluids --
to assess their ability to remove important targets in samples from cancer
patients, as well as from perfusates from kidneys that have undergone machine
perfusion as part of the renal transplantation process.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">"We look
forward to initiating pre-clinical studies shortly, to expand upon the data that
Santersus has generated in sepsis and liver and lung transplantation, and more
importantly, to explore potential synergies with our Hemopurifier, initially in
oncology and renal transplantation, as well as other potential indications,”
stated James Frakes, Interim Chief Executive Officer and Chief Financial
Officer of Aethlon Medical. “Our belief is that the NETs removed by the
NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators
removed by our Hemopurifier, could have an additive or synergistic effect in
both the cancer and kidney transplant settings. The signing of the MTA
represents an important milestone for both companies, as it is the first step toward
a potential future collaboration.” <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><a name="OLE_LINK2"></a><a name="OLE_LINK1"><span style="mso-bookmark: OLE_LINK2;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt;">“</span></span></a><span style="mso-bookmark: OLE_LINK1;"><span style="mso-bookmark: OLE_LINK2;"><span lang="EN-US" style="background: white; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Our
collaboration with Aethlon has provided us with research and development
partners with expertise and capabilities to help <span style="mso-spacerun: yes;"> </span>advance our NucleoCapture technology platform forward
in important fields, such as oncology and kidney transplantation. </span></span></span><span style="mso-bookmark: OLE_LINK2;"></span><span style="mso-bookmark: OLE_LINK1;"></span><span lang="EN-US" style="background: white; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt;">We are excited to continue
building on the progress we've made in Santersus thus far and on taking the
next steps forward in executing on our plans to advance NucleoCapture
technology,” commented Scott Maguire, Chairman of Santersus. </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US" style="background: white; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt;">“NETs are being increasingly
recognized as an important element in cancer progression and metastasis. We
believe extracorporeal removal of NETs using </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt;">NucleoCapture either alone or in combination with
Hemopurifier technology might create a transformational treatment option for
patients receiving immune checkpoint <span style="background: white;">inhibitors
or CAR T cell therapies.”</span><span style="mso-bidi-font-weight: bold;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">About Santersus AG<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm; vertical-align: baseline;"><span lang="EN-US" style="color: black; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-GB;">Santersus AG is a clinical stage privately held
therapeutic apheresis Anglo-Swiss company. In clinical trials, Santersus’
flagship medical device, NucleoCapture, has demonstrated the removal from patient
blood of Neutrophil Extracellular Traps (NETs). NETs are fibers of decondensed
DNA decorated with cytotoxic proteins that have been released from activated
neutrophils. NETs have been recognized as one of the major driving factors in
the development of sepsis, cancer, acute organ failure, autoimmune flares, and
neurodegeneration, including Alzheimer’s disease. NucleoCapture has been
granted designation as a Breakthrough Device by the US Food & Drug
Administration (FDA). </span><span lang="EN-US" style="color: black; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-language: EN-GB;">NucleoCapture
blood purification technology is based on biocompatible, highly porous polymer
beads conjugated with proprietary human recombinant histone H1.3 protein.
Histone H1.3 protein was created in nature to act as the ultimate human DNA
binding and compacting protein with single digit nanomolar DNA binding
constants. As a result, in clinical trials Santersus has demonstrated that a
single pass of NETs contaminated blood through the NucleoCapture device results
in over 95% removal of NETs. Santersus has developed </span><span lang="EN-US" style="color: black; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-GB;">NucleoCapture
for the treatment of sepsis, primary graft dysfunction after lung
transplantation, reconditioning of extended criteria donor organs for liver and
lung transplantation and Alzheimer’s disease. <o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm; vertical-align: baseline;"><span lang="EN-US" style="color: black; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-GB;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm; vertical-align: baseline;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Additional information can be found at </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;"><a href="http://www.santersus.com/"><span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">www.Santersus.com</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm; vertical-align: baseline;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm; vertical-align: baseline;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">About Aethlon and the Hemopurifier®<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Aethlon Medical
is a medical therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and in pre-clinical studies, the Hemopurifier has
demonstrated the removal of harmful exosomes from biological fluids, utilizing
its proprietary lectin-based technology. This action has potential applications
in cancer, where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Additional
information can be found at </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="http://www.aethlonmedical.com/"><span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">www.AethlonMedical.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">Forward Looking Statements<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect,"
"intend," "plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to successfully raise
additional capital and to complete development of the Hemopurifier and to
successfully demonstrate the utility of the Hemopurifier in cancer and
infectious diseases; the Company’s ability to demonstrate synergies of the
Hemopurifier with the </span></i><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">NucleoCapture and HemoNucleoCapture devices;
the Company’s ability to enter into a future collaboration with Santersus; the
Company’s ability to complete the internal binding study of relevant
extracellular vesicles;</span></i><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"> the Company’s ability to commence and manage its clinical trials; and
other potential risks. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could cause
results to differ materially from those anticipated in forward-looking
statements can be found under the caption "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in
the Company's other filings with the Securities and Exchange Commission,
including its quarterly Reports on Form 10-Q. All forward-looking statements
contained in this press release speak only as of the date on which they were
made. Except as may be required by law, the Company does not intend, nor does
it undertake any duty, to update this information to reflect future events or
circumstances.</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Company Contact:</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Jim Frakes</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Interim Chief Executive Officer and Chief Financial Officer</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Aethlon Medical, Inc. <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="mailto:Jfrakes@aethlonmedical.com"><span style="color: windowtext; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; text-decoration: none; text-underline: none;">Jfrakes@aethlonmedical.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"> <span style="mso-spacerun: yes;"> </span><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Investor Contact:</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Susan Noonan</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">S.A. Noonan Communications, LLC</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="mailto:susan@sanoonan.com"><span style="color: windowtext; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; text-decoration: none; text-underline: none;">susan@sanoonan.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"> <span style="mso-spacerun: yes;"> </span><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">917-513-5303<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 107%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-fareast-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-CA;">Aethlon Medical Inc. (Nasdaq:AEMD) is a featured
biotech stock on Investorideas.com<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-fareast-language: EN-CA;">More info on AEMD at
Investorideas.com Visit: </span><span lang="EN-US"><a href="https://www.investorideas.com/CO/AEMD/"><span style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/CO/AEMD/</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;">
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US"><a href="https://lp.constantcontactpages.com/sl/AGDqOB2"><span style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-style: italic; mso-bidi-theme-font: minor-latin;">Get News Alerts on Aethlon Medical</span></a></span><span lang="EN-US" style="color: #404040; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-style: italic; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 191;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">Disclaimer/Disclosure:</span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"> is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/About/News/Clientspecifics.asp</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">
</span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire</span><span lang="EN-US"><a href="https://www.investorideas.com/News-Upload/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/News-Upload/</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"> Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a></span><u><span lang="EN-US" style="color: #23527c; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiwjCv-FB0smSuWmyJVmf0WyloqlqALFN41h9Ml3ip95Nkf7w5fed8fdoEqmwBdaFJWZWIY2FG0CAhj7kv92p8pyN2RmW42kwyY7gcxX8NXANSs2CQmllAWvqkVgOefp9uBqGEayPNuyBGibBhwU_CFwp8gzrLKTYBgpVnfZKqqdu_82q4IQAvBpbSBfB8x/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiwjCv-FB0smSuWmyJVmf0WyloqlqALFN41h9Ml3ip95Nkf7w5fed8fdoEqmwBdaFJWZWIY2FG0CAhj7kv92p8pyN2RmW42kwyY7gcxX8NXANSs2CQmllAWvqkVgOefp9uBqGEayPNuyBGibBhwU_CFwp8gzrLKTYBgpVnfZKqqdu_82q4IQAvBpbSBfB8x/s1600/BIS.gif" width="100" /></a></div><br /><p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm;"><br /></p>
<p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;">Biotech
Industry Stocks- investing ideas in biotechnology stocks, medical technology
and life sciences<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;">Like Biotech
Stocks? View our </span><span lang="EN-US"><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;"><o:p></o:p></span></p><p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><br /></p>
<p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><span lang="EN-US"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News Alerts on Biotech Stocks</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-39944805059002683152024-02-16T07:53:00.000-08:002024-02-16T07:53:19.832-08:00 Focus on Biotech Stocks: (NASDAQ: $CRDL) (NASDAQ: $KA) (TSXV: $MDCX.V) (OTCQB: $SKYE)<p> <b style="text-align: center;"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Focus on Biotech Stocks: (NASDAQ: $CRDL) (NASDAQ: $KA) (TSXV: $MDCX.V) (OTCQB: $SKYE)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Life Sciences Stocks to Watch: (NASDAQ: $ACHV) (NASDAQ: $NRBO) (Nasdaq: $BTSG) (NASDAQ: $AIMD)</span></i></b><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"><o:p></o:p></span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMyDAUNU52Xel1Os_x14n_LMA8fMOfqfd4JKRcoQqkjjjp8agR2ScYQgLiSDhm5rfxpdC5pUwiSS3fb6ieKuMcrbdD0go2n1BgBaykUv8z6PWPgfV8Wo8FAyjHHYgJ0MYgXJjaBixYRPD-xafr0uZBWbL6raX8DFkypZRgFFb09j7XgDvtUv0qhqa_Dx8/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgMyDAUNU52Xel1Os_x14n_LMA8fMOfqfd4JKRcoQqkjjjp8agR2ScYQgLiSDhm5rfxpdC5pUwiSS3fb6ieKuMcrbdD0go2n1BgBaykUv8z6PWPgfV8Wo8FAyjHHYgJ0MYgXJjaBixYRPD-xafr0uZBWbL6raX8DFkypZRgFFb09j7XgDvtUv0qhqa_Dx8/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">February 16, 2024 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Biotech sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at: </span></b><a href="https://www.investorideas.com/news/2024/main/02161Stocks.asp">https://www.investorideas.com/news/2024/main/02161Stocks.asp</a><o:p></o:p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest biotech companies are involved in treatment of heart disease, cancer, eye disease, </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">nicotine addiction, women’s health and home health care.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> <o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech/Life Sciences Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.cardiolrx.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cardiol Therapeutics Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/CRDL?p=CRDL&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: CRDL</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) (</span><a href="https://ca.finance.yahoo.com/quote/CRDL.TO?p=CRDL.TO&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">TSX: CRDL</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.<o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><a href="https://kinetabio.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Kineta, Inc.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/KA?p=KA&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: KA</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges with current cancer therapy. The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27.<o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><a href="https://medicuspharma.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Medicus Pharma Ltd</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://ca.finance.yahoo.com/quote/MDCX.V?p=MDCX.V&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">TSXV:MDCX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials. Through our diverse experience and extensive industry network, we are building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviate pain and suffering. Utilizing a thesis driven collaborative process, we identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization. Skinject Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell and squamous cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The company currently has an FDA approved phase 2 trial actively recruiting patients.<o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><a href="https://skyebioscience.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Skye Bioscience, Inc.</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/SKYE?p=SKYE&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">OTCQB: SKYE</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is focused on unlocking the pharmaceutical potential of the endocannabinoid system to treat diseases with metabolic, inflammatory, and fibrotic processes. Backed by leading life science venture investors, Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with significant clinical and commercial differentiation. Nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1, showed a favorable safety and tolerability profile in a Phase 1 study. Skye plans to start a Phase 2 clinical trial in obesity comparing monotherapy and combination arms of nimacimab and a GLP-1R agonist in mid-2024. SBI-100 Ophthalmic Emulsion, a CB1 agonist, is currently being studied in a Phase 2 clinical trial of patients with glaucoma and ocular hypertension, with interim data expected in Q1 2024.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal" style="background: white;"><a href="https://achievelifesciences.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Achieve Life Sciences, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/ACHV?p=ACHV&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: ACHV</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. There are an estimated 28 million adults in the United States alone who smoke combustible cigarettes. Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually. More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke. In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping. In 2023, approximately 2.1 million middle and high school students in the United States reported using e-cigarettes. Currently, there are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://www.neurobopharma.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NeuroBo Pharmaceuticals, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/NRBO?p=NRBO&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: NRBO</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><a href="https://www.brightspringhealth.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">BrightSpring Health Services, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/BTSG?p=BTSG&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:BTSG</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is the parent company of leading healthcare service lines that provide complementary home- and community-based pharmacy and provider health solutions for complex populations in need of specialized and/or chronic care. Through the company’s high-quality and impactful pharmacy, primary care and home health care, and rehabilitation and behavioral health services, and through its skilled and dedicated employees, we provide comprehensive care and clinical solutions in all 50 states to over 400,000 customers, clients and patients daily.<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://www.ainos.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Ainos, Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/AIMD?p=AIMD&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ:AIMD</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA® interferon therapeutics, and synthetic RNA-driven preventative medicine. The company's products include VELDONA® clinical-stage human therapeutics, VELDONA® Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. The lead POCT candidate, Ainos Flora, is intended to be a telehealth-friendly POCT for women's health and certain common STIs.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read Investor Ideas latest Biotech stock commentary<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p style="background: white; margin: 0cm 0cm 0.0001pt;"><a href="https://www.investorideas.com/news/2024/biotech/02151Cancer-Immunotherapy-Stocks.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cancer Immunotherapy Stocks to Watch (NASDAQ: ONCY) (TSX: ONC) (Nasdaq: CADL) (Nasdaq: BNTX) (NASDAQ: IMTX)</span></a><u><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></u></p><p style="background: white; margin: 0cm 0cm 0.0001pt;"><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">February 15, 2024 Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology.</span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/"><span style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span lang="EN-US" style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;"> is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.<o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411<o:p></o:p></span></b></p><p class="MsoNormal"><b></b></p><div class="separator" style="clear: both; text-align: center;"><b><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQ2MsqBs_yutVhztGmnrXIunjJtSfR6pOcFRrcbdU-UHjPFl6XP-44Gx7LhTBh7DRzGlP_-nDRckT3PPLGQkKDd2lPu49NCdGu2gyH70QOUWrlB7I_Vx7ESh-VwONntQp2xQJacavEnrp1JMBnGRLYe-dzYB2Y-Z7cPLhA_25x__zxQMRFsIL6LKzhMAw/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQ2MsqBs_yutVhztGmnrXIunjJtSfR6pOcFRrcbdU-UHjPFl6XP-44Gx7LhTBh7DRzGlP_-nDRckT3PPLGQkKDd2lPu49NCdGu2gyH70QOUWrlB7I_Vx7ESh-VwONntQp2xQJacavEnrp1JMBnGRLYe-dzYB2Y-Z7cPLhA_25x__zxQMRFsIL6LKzhMAw/s320/social-media%20ICONS.png" width="320" /></a></b></div><b><br /><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><br /></span></b><p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><br /><p class="MsoNormal"><o:p> </o:p></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-91861966563646252752024-02-15T09:06:00.000-08:002024-02-15T09:06:01.104-08:00Breaking Life Sciences News: Pressure BioSciences (OTCQB: $PBIO) Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing; @ir_pressurebio <p> </p><p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Arial;">Breaking Life
Sciences News: </span></b><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%;">Pressure
BioSciences </span></b><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;">(OTCQB: $PBIO)
</span></b><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%;">Completes Relocation into
New Manufacturing Facility, Consolidating R&D with Expanded UltraShear
Equipment Development and Contract Manufacturing; </span></b><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;">@ir_pressurebio<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%;">Relocation
Delivers Substantially Increased Manufacturing Space, Vastly Improved Operating
Efficiencies, and Measurable Cost Savings for Unencumbered Growth through
Multi-Year Expansion Plans<o:p></o:p></span></i></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhFJFvcv9UEUato90WyY1q_tEYl1CJGjKlnG9Yrm7Dx9ZeytIkMkdD_-Rq_tFryi1OxN1mBOKaW4OR5ocdz21UiscfTmTyleWJ1VEZy3uQj-terHZ9-eHzCbKdBHO31IHY5wRwtLTtr-Z29uEsqpbQGzxeZsL4U2nqwI3PKZA7Qzntliq7i1UjtrtBshvsA/s532/PBIO%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="133" data-original-width="532" height="80" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhFJFvcv9UEUato90WyY1q_tEYl1CJGjKlnG9Yrm7Dx9ZeytIkMkdD_-Rq_tFryi1OxN1mBOKaW4OR5ocdz21UiscfTmTyleWJ1VEZy3uQj-terHZ9-eHzCbKdBHO31IHY5wRwtLTtr-Z29uEsqpbQGzxeZsL4U2nqwI3PKZA7Qzntliq7i1UjtrtBshvsA/s320/PBIO%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">CANTON, Mass., Feb. 15, 2024 <span style="mso-spacerun: yes;"> </span>--</span></b><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"> </span><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">(Investorideas.com
Newswire) Pressure BioSciences, Inc. (</span></b><a href="https://finance.yahoo.com/quote/PBIO?p=PBIO&.tsrc=fin-srch"><b style="mso-bidi-font-weight: normal;"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">OTCQB: PBIO</span></b></a><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">)</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> </span><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(“PBIO” or the “Company”),
a leading innovator in high-pressure nanotechnology and a pioneer in the
development of novel, broadly-enabling, pressure-based instruments and
nanoemulsion products and services for the health & wellness, food &
beverage, pharmaceutical, and other industries, today celebrated a significant
milestone in its accelerating growth journey. The Company announced the
consolidation of its Boston area operations, uniting all of its personnel into
a single, cutting-edge facility designed to accommodate expanded R&D
capabilities, advanced equipment development and production, formulation
services, and contract manufacturing based on its patented Ultra Shear
Technology (UltraShear™ or UST™) platform. The new building is currently being
transformed into a state-of-the-art manufacturing facility.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Read
this news, featuring PBIO in full at </span><a href="https://www.investorideas.com/news/2024/cannabis/02151PBIO-UltraShear-Equipment-Development.asp">https://www.investorideas.com/news/2024/cannabis/02151PBIO-UltraShear-Equipment-Development.asp</a></b><b style="mso-bidi-font-weight: normal;"><span style="color: black; font-family: "Arial","sans-serif"; mso-fareast-font-family: Arial;"><o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Strategically
located in the Boston suburb of Canton, MA, the new facility will provide PBIO
with a larger, more efficient space to continue its groundbreaking work in high
pressure nanotechnology platform development – and UltraShear technology in
particular. The state-of-the-art facility is to be equipped with the latest
modern utilities and amenities, and will house dedicated areas for R&D,
equipment production, formulation services, and product manufacturing. This move,
consolidating R&D with all other departments of the Company, aims to
streamline and achieve new production efficiencies, reduce costs, and foster
innovation within a collaborative and dynamic work environment.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Ken
Micciche, PBIO’s Director of Business Development, commented: “We are very
excited about the opportunities this consolidation and expansion presents. The
move reinforces our commitment to accelerating development and production
capabilities, delivering exceptional products and services, advancing the field
of high-pressure nanotechnology, fostering collaborations with academic and
industry partners, and supporting our expected explosive growth in the
direct-to-consumer area, led by our newly acquired subsidiary company Uncle
Bud’s Health & Wellness.”<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Key Features of the New Facility:<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Product
Manufacturing Suites: PBIO is committed to meeting the increasing demand for
its innovative nanoemulsion products, delivering breakthrough performance in
fast and enhanced absorption of oil-soluble nutrients and therapeutics. The new
facility will house several GMP-compliant contract manufacturing suites,
equipped with the latest technology to ensure the efficient and precise
production of high-quality products.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Advanced
R&D Laboratory: PBIO is investing in the development of a cutting-edge
research and development laboratory, where its team of highly trained and
experienced experts will continue to push the boundaries of high-pressure
nanotechnology. The laboratory will focus on developing groundbreaking solutions
in nanoemulsions and other products for use in nutraceuticals, cosmeceuticals,
pharmaceuticals, bioprocess, and other areas.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">State-of-the-Art
Equipment Manufacturing: The facility features a dedicated space for the
manufacturing of advanced equipment and components incorporating
state-of-the-art materials and designs used in the production of nanoemulsions
and other products. This will enable PBIO to expand production capacity in
UltraShear equipment installations, while maintaining stringent quality control
and ensuring the total reliability of its products.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Formulation
Services: With a focus on providing comprehensive solutions, PBIO currently
offers limited formulation services to its UltraShear clients. With the Canton
site’s expanded space and equipment, the Company’s Formulation Services are
expected to expand and grow significantly, as it collaborates closely with
customers to develop customized formulations tailored to their specific needs
and requirements, spanning a diversity of major market applications from
nutraceuticals to cosmeceuticals/skincare, pharmaceuticals, food &
beverages, and natural, organic agrochemicals.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Demo
Laboratory: A dedicated Demo Laboratory will showcase the Company’s
cutting-edge UltraShear technology platform, allowing stakeholders to witness
PBIO’s unique and far-reaching capabilities firsthand.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">John
Hollister, PBIO’s Director of Sales and Marketing, added: “Unlike our previous
site, the new facility provides the needed environment for us to accomplish our
aggressive commercial goals over the next few years. Our new facility – with
its significantly increased manufacturing space – gives us the ability to
expand manufacturing capabilities to meet the already increasing demand for our
products. Our growth is no longer encumbered by our facilities.”<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">About Uncle Bud’s Health and Wellness<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Launched
in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud’s has
rapidly captured an innovative leadership role in the Hemp Seed Oil,
Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle
Bud’s brand is revered for its unwavering commitment to domestic manufacturing
excellence, setting benchmarks for its organic, preservative-free, non-GMO
standards and its ethical cruelty-free practices. Uncle Bud’s is dedicated to
the highest-quality formulations and to continuous improvement, guided by the
latest scientific research and development innovations – including the
revolutionary performance breakthroughs delivered by PBIO’s patented
UltraShear™ processing platform. Uncle Bud’s diverse product portfolio
addresses an ever-broadening spectrum of consumer needs, encompassing pain
relief, sophisticated skincare solutions, personal wellness and athletic
recovery products, and specialized pet care items. Learn More:
www.unclebudshemp.com * Follow On Social Media: @UncleBuds_Hemp.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">About Pressure BioSciences, Inc.<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Pressure
BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative,
broadly enabling, high pressure-based solutions for a range of industries,
including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and
agrochemical, as well as food and beverage manufacturing. Our patented enabling
platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of
pressure to control bio-molecular interactions (such as cell lysis and
biomolecule extraction) safely and reproducibly. PCT-based products are used
for biomarker and target discovery, drug design and development,
biotherapeutics characterization and quality control, soil & plant biology,
forensics, and counter-bioterrorism applications. Our patented BaroFold™
technology platform, allowing us to enter the bio-pharma contract services and
GMP manufacturing equipment sector. We have also developed the scalable and
high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which
allows for the creation of stable nanoemulsions of otherwise immiscible fluids.
It also allows for the preparation of higher quality, homogenized, extended
shelf-life or room temperature-stable low-acid liquid foods that cannot be
effectively preserved using existing non-thermal technologies. Our commitment
to innovation and cutting-edge technology has established PBIO as a leader in
the high-pressure industry, providing unique and effective solutions to our
customers.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Forward Looking Statements<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">This
press release contains forward-looking statements. These statements relate to
future events or our future financial performance and involve known and unknown
risks, uncertainties and other factors that may cause our or our industry's
actual results, levels of activity, performance, or achievements to be
materially different from any future results, levels of activity, performance
or achievements expressed, implied, or inferred by these forward-looking
statements. In some cases, you can identify forward-looking statements by
terminology such as "may," "will," "should,"
"could," "would," "expects," "plans,"
"intends," "anticipates," "believes,"
estimates," "predicts," "projects,"
"potential" or "continue" or the negative of such terms and
other comparable terminology. These statements are only predictions based on
our current expectations and projections about future events. You should not
place undue reliance on these statements. In evaluating these statements, you
should specifically consider various factors. Actual events or results may
differ materially. These and other factors may cause our actual results to
differ materially from any forward-looking statement. These risks,
uncertainties, and other factors include, but are not limited to, the risks and
uncertainties discussed under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2022, and
other reports filed by the Company from time to time with the SEC. The Company
undertakes no obligation to update any of the information included in this
release, except as otherwise required by law.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">For
more information about PBIO, Uncle Bud’s, and this press release, please click
on the following website links:<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><a href="http://www.pressurebiosciences.com/">http://www.pressurebiosciences.com</a>
<span style="mso-spacerun: yes;"> </span><a href="http://www.unclebudshemp.com/">www.unclebudshemp.com</a>
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Please
visit us on Facebook, LinkedIn, and Twitter.<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Press Contacts:<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Richard
T. Schumacher, President & CEO<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(508)
230-1828 (T)<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">John
B. Hollister, Director of Sales and Marketing<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(805)
908-5719 (T)<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Kenneth
F. Micciche, Director of Business Development<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(508)
230-1828 (T)<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Disclaimer/Disclosure:</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content
on our site. </span><a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">Disclosure</span></a><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> Learn more about publishing your news release
and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/News-Upload/</span></a><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><a href="https://www.investorideas.com/About/"><b><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/</span></b></a><b><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></b></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Sign up for free stock news alerts at
Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><a href="https://www.investorideas.com/Resources/Newsletter.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/Resources/Newsletter.asp</span></a><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhjsxxRk2zxEiBRj5r5vlYdUlPudGylK-9GHc6zU9A0XCB50_XQ-4TuS020HJ2_fvtTFMwuOuBDHQo5a2Pjk45JuWOsFKoUNhaAuuVUTl19pAzM_UJeExM3jYgi9-93zFyelpPaXCJJgxGTL-AlKvz6_I818blw3K2uh6nivvDp9Xvy1VP4MxNgVgWpKF7y/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhjsxxRk2zxEiBRj5r5vlYdUlPudGylK-9GHc6zU9A0XCB50_XQ-4TuS020HJ2_fvtTFMwuOuBDHQo5a2Pjk45JuWOsFKoUNhaAuuVUTl19pAzM_UJeExM3jYgi9-93zFyelpPaXCJJgxGTL-AlKvz6_I818blw3K2uh6nivvDp9Xvy1VP4MxNgVgWpKF7y/s1600/BIS.gif" width="100" /></a></div><br /><p class="MsoNormal" style="background: white;"><br /></p>
<p class="MsoNormal" style="background: white; mso-outline-level: 3;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Biotech Industry Stocks- investing ideas in biotechnology
stocks, medical technology and life sciences<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Like Biotech Stocks? View our </span><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News Alerts on Biotech Stocks</span></a><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><span style="mso-spacerun: yes;"> </span><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><span style="mso-spacerun: yes;"> </span><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-71284314240639599712024-02-15T07:43:00.000-08:002024-02-15T07:43:05.109-08:00Cancer Immunotherapy Stocks to Watch (NASDAQ: $ONCY) (TSX: $ONC.TO) (Nasdaq: $CADL) (Nasdaq: $BNTX) (NASDAQ: $IMTX) @Oncolytics @CandelTx @BioNTech_Group @immatics<p> </p><p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Cancer Immunotherapy Stocks to Watch (NASDAQ: $ONCY)
(TSX: $ONC.TO) (Nasdaq: $CADL) (Nasdaq: $BNTX) (NASDAQ: <span style="mso-spacerun: yes;"> </span>$IMTX) @Oncolytics @CandelTx @BioNTech_Group
@immatics<o:p></o:p></span></b></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Tapping into Immune
Systems for Next Generation Treatments<span style="mso-spacerun: yes;"> </span><o:p></o:p></span></i></b></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></b></p><div class="separator" style="clear: both; text-align: center;"><b style="mso-bidi-font-weight: normal;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhfYyhpt4whfx5r-p6DmrHspd3FsYTqKzALCTKqT0o32Yt9J9osOTPQKVX00zZ2PX4gE1KG9mCWIPJPEsUnsFmHpT-InFQ-ycqqWWFI9QHSwDzeXUHJ2LXT8_Dkzf4-wmAmxnTY4WV0u2nPVHwUa8qjEdtqDlT0NQomZHSBPcYeWVDqsSGrsSOdUX6BnzzG/s400/ONCY%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="174" data-original-width="400" height="139" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhfYyhpt4whfx5r-p6DmrHspd3FsYTqKzALCTKqT0o32Yt9J9osOTPQKVX00zZ2PX4gE1KG9mCWIPJPEsUnsFmHpT-InFQ-ycqqWWFI9QHSwDzeXUHJ2LXT8_Dkzf4-wmAmxnTY4WV0u2nPVHwUa8qjEdtqDlT0NQomZHSBPcYeWVDqsSGrsSOdUX6BnzzG/s320/ONCY%20Logo.jpg" width="320" /></a></b></div><b style="mso-bidi-font-weight: normal;"><br /></b><p></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">February 15,
2024 - </span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"><span style="mso-spacerun: yes;"> </span></span></a><a href="https://www.investorideas.com/"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">, a global investor news source covering
biotech and pharma stocks issues a sector snapshot on cancer immunotherapy featuring
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Oncolytics Biotech<sup>®</sup> Inc. (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/ONCY?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">NASDAQ:
ONCY</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">) </span><span lang="EN-US"><a href="https://ca.finance.yahoo.com/quote/ONC.TO?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(TSX:
ONC</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">), a clinical-stage immunotherapeutics
company focused on oncology.</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;">Read this in full at </span></b><span lang="EN-US"><a href="https://www.investorideas.com/news/2024/biotech/02151Cancer-Immunotherapy-Stocks.asp">https://www.investorideas.com/news/2024/biotech/02151Cancer-Immunotherapy-Stocks.asp</a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">According to the </span><span lang="EN-US"><a href="https://cancerprogressreport.aacr.org/progress/cpr23-contents/cpr23-spotlight-on-immunotherapy-pushing-the-frontier-of-cancer-medicine/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;">American Association for Cancer Research</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"> “Cancer immunotherapeutics work by unleashing
the power of a patient’s immune system to fight cancer and, over the last
decade, have emerged as one of the most exciting new approaches to cancer
treatment.”<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%;">“The prolific
growth in the cancer immunotherapy sector, fuelled by technological advances
and a high prevalence of cancer-related cases, is set to significantly enhance
the global market landscape. The market, which was valued at US$ 96.40 billion
in 2023, is estimated to achieve a remarkable CAGR of 10.02% between the years
2023 and 2030, with projections placing its value at approximately US$ 188.11
billion by the end of the decade,” reports </span><span lang="EN-US"><a href="https://www.researchandmarkets.com/reports/5909470/cancer-immunotherapy-market-size-global?utm_source=GNE&utm_medium=PressRelease&utm_code=fd2zjl&utm_campaign=1933460+-+Global+Cancer+Immunotherapy+Market+to+Reach+%24188.11+Billion+by+2030%2c+Propelled+by+Innovative+Treatments+and+Rising+Incidence+Rates&utm_exec=jocamsai"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%;">ResearchandMarkets</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%;">.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Oncolytics Biotech<sup>®</sup> Inc. (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/ONCY?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">NASDAQ:
ONCY</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">) </span><span lang="EN-US"><a href="https://ca.finance.yahoo.com/quote/ONC.TO?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">(TSX:
ONC</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">) is developing pelareorep, a unique
immunotherapy with the power to awaken the immune system and unlock its
antitumor potential. Pelareorep is delivered intravenously and is systemically
active, setting it apart from other immunotherapies that must be injected into
the tumor.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">The Company just </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/oncolytics-biotech-initiates-enrollment-expansion-120000287.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">
the expansion of enrollment for the anal cancer cohort of the GOBLET study
evaluating pelareorep in combination with atezolizumab (Tecentriq<sup>®</sup>)
in patients with second-line or later unresectable squamous cell carcinoma of
the anal canal (SCCA). The study was expanded based on positive data from Stage
1 of the study, presented at the 2<sup>nd</sup> International Multidisciplinary
Anal Cancer Conference (IMACC) in November 2023 (</span><span lang="EN-US"><a href="https://oncolyticsbiotech.com/press_releases/oncolytics-announces-the-anal-cancer-cohort-of-the-goblet-phase-1-2-study-of-pelareorep-and-atezolizumab-has-met-the-success-criteria-for-efficacy/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">link
to the PR</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">, </span><span lang="EN-US"><a href="https://oncolyticsbiotech.com/wp-content/uploads/2023/11/Imacc-2023-.pdf"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">link
to the poster</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">).<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“These exciting clinical data, which exceed
the Simon two-stage success criteria, provide strong support to expand the
evaluation of pelareorep in patients with advanced anal cancer. The results
reported at IMACC 2023 showed that the combination of pelareorep and
atezolizumab provided a 37.5% objective response rate, including one patient
with a long-lasting complete response, and good overall tolerability. These
data represent a meaningful contrast to recent clinical trial results which
show that patients with second-line or later anal carcinoma treated with
checkpoint inhibitor therapy experienced response rates of 10-14%<sup>1-3</sup>,”
said <a name="_Hlk158621808">Dr. Matt Coffey, President and Chief Executive
Officer of Oncolytics</a>.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“We begin the Stage 2 expansion with
substantial optimism for patients and the potential of pelareorep, especially
considering the initial efficacy signal observed for pelareorep-based therapy
in pancreatic cancer. There is currently no established standard therapy for
patients with anal carcinoma who have failed first-line treatment. Continued
positive results could potentially expand the opportunity for pelareorep beyond
the lead indications of breast cancer and pancreatic cancer and open the door
to a rapid regulatory pathway in this rare and significantly under-served
patient population,” continued Dr. Coffey.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Dirk Arnold, M.D., Ph.D., Director of
Asklepios Tumorzentrum Hamburg and primary investigator of the GOBLET trial,
commented, “One of the most difficult challenges in my practice is the limited
number of treatment options that are available for patients with advanced anal
cancer who have progressed on first-line therapy. I am enthusiastic about the
expansion of this cohort because it will enable the continued evaluation of the
pelareorep/atezolizumab combination and could provide important confirmatory
data that may lead to better treatment options for patients with this
late-stage disease.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 107%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%;">“We look forward to
building on the oncology community’s enthusiastic reception of the IMACC 2023
data by expanding enrollment in the anal carcinoma cohort and incorporating
additional sites into the study,” commented Thomas Heineman, M.D., Ph.D., Chief
Medical Officer at Oncolytics. “Careful consideration of recently published
clinical trial results indicates that a modest expansion of fewer than 20
patients will be sufficient to solidify the efficacy signal we have observed to
date and lay the groundwork for a potential future registrational study in this
population. We look forward to continuing our excellent collaboration with the
clinical sites and investigators at AIO and hope to report additional results
in 2025.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-no-proof: yes;">The GOBLET (<b>G</b>astrointestinal
tum<b>O</b>rs exploring the treatment com<b>B</b>inations with the oncolytic
reovirus pe<b>L</b>ar<b>E</b>orep and an<b>T</b>i-PD-L1) study is a phase 1/2
multiple indication study in advanced or metastatic gastrointestinal tumors.
The study is being conducted at 12 centers in Germany and is being managed by
AIO-Studien-gGmbH. The co-primary endpoints of the study are objective response
rate (ORR) assessed at week 16 and safety. Key secondary and exploratory
endpoints include additional efficacy assessments and evaluation of potential
biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage
design with Stage 1 comprising four treatment groups:<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-no-proof: yes;"><o:p> </o:p></span></p>
<ol start="1" style="margin-top: 0cm;" type="1">
<li class="MsoNormal" style="line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">Pelareorep in
combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1<sup>st</sup> line
advanced/metastatic pancreatic cancer patients;<o:p></o:p></span></li>
</ol>
<p class="MsoNormal" style="margin-left: 36.0pt; text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-no-proof: yes;"><o:p> </o:p></span></p>
<ol start="2" style="margin-top: 0cm;" type="1">
<li class="MsoNormal" style="line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">Pelareorep in
combination with atezolizumab in 1<sup>st</sup> line MSI
(microsatellite instability)-high metastatic colorectal cancer patients;<o:p></o:p></span></li>
</ol>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-no-proof: yes;"><o:p> </o:p></span></p>
<ol start="3" style="margin-top: 0cm;" type="1">
<li class="MsoNormal" style="line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">Pelareorep in
combination with atezolizumab and TAS-102 in 3<sup>rd</sup> line
metastatic colorectal cancer patients; and<o:p></o:p></span></li>
</ol>
<p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-no-proof: yes;"><o:p> </o:p></span></p>
<ol start="4" style="margin-top: 0cm;" type="1">
<li class="MsoNormal" style="line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt; text-align: justify;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-no-proof: yes;">Pelareorep in
combination with atezolizumab in 2<sup>nd</sup> line advanced and
unresectable anal cancer patients.<o:p></o:p></span></li>
</ol>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-no-proof: yes;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Candel Therapeutics, Inc.(</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/CADL?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Nasdaq:CADL</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">),
a clinical stage biopharmaceutical company focused on developing multimodal
biological immunotherapies to help patients fight cancer had big gains on news
as it </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/3110-receives-fda-fast-track-123000266.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">
that the US Food and Drug Administration (FDA) granted Fast Track Designation
for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1
(HSV-1) oncolytic viral immunotherapy candidate – for the treatment of patients
with recurrent high-grade glioma (HGG) to improve overall survival.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“Receiving FDA Fast Track Designation for
CAN-3110 reinforces the critical need to find effective treatment options for
patients with recurrent HGG and further supports the potential of CAN-3110 to
address the challenges that the standard of care and conventional therapies
have failed to meet,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO
of Candel. “As recently published in Nature, a strong local and systemic
anti-tumoral response and improved survival in patients with recurrent HGG was
observed following a single injection of CAN-3110. We look forward to reporting
additional data, including the potential benefits from multiple injections of
CAN-3110, from the ongoing phase 1b clinical trial in the second half of 2024.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">From
the news continued:</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"> In October 2023, Candel
and academic collaborators at the Brigham and Women’s Hospital published
results from the ongoing phase 1b clinical trial in Nature, demonstrating that
CAN-3110 was well tolerated with no dose-limiting toxicity reported. The
investigators observed a nearly doubling of the expected median overall
survival (mOS) after a single CAN-3110 injection, achieving a mOS of ~12
months, compared to historical reports of less than 6 to 9 months in this
therapy-resistant condition. Positive HSV-1 serology was a predictor of
response and was associated with improved survival (mOS in this population
reached 14 months). Increased infiltrating immune cells in the tumor
microenvironment and expansion of the T cell repertoire after administration
were also associated with improved survival, suggesting that CAN-3110 can
elicit both a local and systemic antitumoral response.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“Recurrent HGG is one of the most
aggressive malignancies for which there is no cure, representing a significant
and urgent unmet need,” said Antonio Chiocca, MD, PhD, Head of Department of
Neurosurgery at Brigham and Women’s Hospital, Professor at Harvard Medical
School, and Principal Investigator. “With Fast Track Designation, I look
forward to the potential of accelerating the development of CAN-3110 and the
possibility of bringing this differentiated therapy to patients with recurrent
high-grade glioma as we strive to improve outcomes and provide hope for
patients and their families.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">BioNTech (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/BNTX?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Nasdaq:BNTX</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">),
an immunotherapy company pioneering novel therapies for cancer and other
serious diseases and Autolus Therapeutics plc, a clinical-stage
biopharmaceutical company developing next-generation programmed T cell
therapies, recently </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/biontech-autolus-announce-strategic-car-104500300.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">
a strategic collaboration aimed at advancing both companies’ autologous CAR-T
programs towards commercialization, pending regulatory authorizations. In
connection with the strategic collaboration, the companies entered into a
license and option agreement and a securities purchase agreement.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">“The collaboration with Autolus enables us
to expand our BNT211 program into trials for multiple cancer indications in a
cost-efficient way. Autolus' state-of-the-art manufacturing facilities’ set-up
for clinical and commercial supply will enhance our own capacities in addition
to our existing U.S. supply network and the ongoing expansion of our site in
Gaithersburg, Maryland,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of
BioNTech. “Furthermore, this collaboration grants us access to Autolus' precise
cell targeting tools to further support BioNTech’s development of in vivo cell
therapy and antibody-drug conjugate candidates."<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">From
the news continued:</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"> “We see a remarkable
opportunity to leverage our core capabilities, accelerate pipeline programs,
realize cost-efficiencies and expand opportunities beyond autologous cell
therapies,” said Dr. Christian Itin, CEO of Autolus. “We look forward to
investing a portion of the capital raised on delivering on obe-cel’s path in
adult acute lymphoblastic leukemia, potentially offering another treatment
option for patients where there is still an unmet medical need. This
collaboration creates a path for accelerating our respective oncology pipeline
programs and broadening the use of Autolus’ technology outside of autologous
cell therapy applications.”<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">BioNTech has agreed to purchase $200
million of Autolus’ American Depositary Shares in a private placement. BioNTech
will have a right to appoint a director to the Board of Autolus.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US"><a href="https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-cancer-immunotherapy-pharmaceutical/?cf-view"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Pharmaceutical Technology</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> reports, “Immatics (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/IMTX?.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">NASDAQ: IMTX</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">) is one of
the leading patent filers in cancer immunotherapy. The biopharmaceutical
company is focused on the development of T cell immunotherapies to fight
against cancer. Immatics combines the discovery of targets for cancer
immunotherapies with the development of the right T cell receptors with the
goal of enabling a robust and specific T cell response against targets. It is
committed to delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer. Bristol-Myers Squibb and Fate
Therapeutics are some of the other key patent filers in cancer immunotherapy.” <o:p></o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;">In mid-January<span style="mso-spacerun: yes;">
</span>Immatics </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/immatics-announces-pricing-175-million-013000520.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">announced</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> the pricing of an underwritten public
offering of 15,925,000 ordinary shares at a public offering price of $11.00 per
share. The gross proceeds from the offering, before deducting the underwriting
discount and offering expenses, are expected to be approximately $175 million.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;">For investors looking for the next trends in biotech, </span><span lang="EN-US"><a href="https://www.pharmaceutical-technology.com/data-insights/innovators-immuno-oncology-cancer-immunotherapy-pharmaceutical/?cf-view"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Pharmaceutical Technology</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"> also reports, “Cancer
immunotherapy has shown remarkable success in treating various types of cancers
and has revolutionized cancer treatment in recent years.”<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Research more biotech stocks with Investorideas Biotech
stock directory <o:p></o:p></span></p>
<p class="MsoNoSpacing"><span lang="EN-US"><a href="https://www.investorideas.com/BIS/Stock_List.asp"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">https://www.investorideas.com/BIS/Stock_List.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p style="background: white; margin-bottom: .0001pt; margin: 0cm;"><strong><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">About Investorideas.com - Big
Investing Ideas</span></strong><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p></o:p></span></p>
<p style="background: white; margin-bottom: .0001pt; margin: 0cm;"><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Investorideas.com</span></a></span><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all. Our original branded content includes podcasts such as Exploring
Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for sectors including mining, crypto, renewable
energy, gaming, biotech, tech, sports and more. Public companies within the
sectors we cover can use our news publishing and content creation services to
help tell their story to interested investors. Paid content is always
disclosed.<o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Disclaimer/Disclosure:</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> </span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
management and IR of each company directly regarding specific questions. Disclosure:
This article featuring Oncolytics Biotech Inc. is a </span><span lang="EN-US"><a href="https://www.investorideas.com/News-Upload/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">paid for</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> article at InvestorIdeas.com. More disclaimer
info: </span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Global investors must adhere to regulations of each country. Please
read Investorideas.com privacy policy: </span><span lang="EN-US"><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">https://www.investorideas.com/About/Private_Policy.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">Follow us on Twitter</span><span lang="EN-US"><a href="https://twitter.com/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"> </span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">@investorideas <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">Follow us on Facebook</span><span lang="EN-US"><a href="https://www.facebook.com/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.facebook.com/Investorideas"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">https://www.facebook.com/Investorideas</span></a></span><u><span lang="EN-US" style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 137%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">Follow us on YouTube</span><span lang="EN-US"><a href="https://www.youtube.com/c/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.youtube.com/c/Investorideas"><span style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;">https://www.youtube.com/c/Investorideas</span></a></span><u><span lang="EN-US" style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 137%; mso-fareast-font-family: Verdana;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: normal;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">Contact Investorideas.com <o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;">800-665-0411<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjocrkJx_0m8eqWH7rlvvuFAbU6n4dBfQueHF1Dpchj_3ULDZR8IVIMzN1Xfar5GpRaT7IWTYzTwprDGsTu2NG0rH4lfEszOYc6LwuftJu6f10zUS4MJU3VVZZPgRVTlLexvMmLsTM99em-W-CGYHTW549WmXuYZbIIqrsklGU0ujgGExXTKt3aO-ZofCAl/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjocrkJx_0m8eqWH7rlvvuFAbU6n4dBfQueHF1Dpchj_3ULDZR8IVIMzN1Xfar5GpRaT7IWTYzTwprDGsTu2NG0rH4lfEszOYc6LwuftJu6f10zUS4MJU3VVZZPgRVTlLexvMmLsTM99em-W-CGYHTW549WmXuYZbIIqrsklGU0ujgGExXTKt3aO-ZofCAl/s1600/BIS.gif" width="100" /></a></div><br /><p class="MsoNormal" style="background: white;"><br /></p>
<p class="MsoNormal" style="background: white; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Biotech Industry Stocks- investing ideas in biotechnology
stocks, medical technology and life sciences<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Like Biotech Stocks? View our </span><span lang="EN-US"><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News Alerts on Biotech Stocks</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: Verdana;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-75140537532204587902024-02-14T13:56:00.000-08:002024-02-14T13:56:22.750-08:00Breaking Medical Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) Announces Fiscal Third Quarter Financial Results and Provides Corporate Update <p> </p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-ansi-language: EN-CA; mso-bidi-font-family: Calibri; mso-fareast-language: EN-CA; mso-no-proof: yes;"><v:shapetype coordsize="21600,21600" filled="f" id="_x0000_t75" o:preferrelative="t" o:spt="75" path="m@4@5l@4@11@9@11@9@5xe" stroked="f">
<v:stroke joinstyle="miter">
<v:formulas>
<v:f eqn="if lineDrawn pixelLineWidth 0">
<v:f eqn="sum @0 1 0">
<v:f eqn="sum 0 0 @1">
<v:f eqn="prod @2 1 2">
<v:f eqn="prod @3 21600 pixelWidth">
<v:f eqn="prod @3 21600 pixelHeight">
<v:f eqn="sum @0 0 1">
<v:f eqn="prod @6 1 2">
<v:f eqn="prod @7 21600 pixelWidth">
<v:f eqn="sum @8 21600 0">
<v:f eqn="prod @7 21600 pixelHeight">
<v:f eqn="sum @10 21600 0">
</v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:f></v:formulas>
<v:path gradientshapeok="t" o:connecttype="rect" o:extrusionok="f">
<o:lock aspectratio="t" v:ext="edit">
</o:lock></v:path></v:stroke></v:shapetype><v:shape alt="Description: aethlon_logo" id="Picture_x0020_1" o:spid="_x0000_i1026" style="height: 54.6pt; mso-wrap-style: square; visibility: visible; width: 144.6pt;" type="#_x0000_t75">
<v:imagedata o:title="aethlon_logo" src="file:///C:\Users\Home\AppData\Local\Temp\msohtmlclip1\01\clip_image001.jpg">
<o:lock aspectratio="f" v:ext="edit">
</o:lock></v:imagedata></v:shape></span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p><div class="separator" style="clear: both; text-align: center;"><b style="mso-bidi-font-weight: normal;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhmpCFDhO2BE00nGC_9rHS7tvQjHHJRWLZ1lgQpWUddYY3SzEnQz-QcyQ7dAgyV2mQD-s_IGQVHrTYnDnFtSa5gyzzbFlI5gXOr9csLeWl3CQQG6DMY4KiwSA5-ki9NGsCdB9c52Zc8yLEpgaU-x0AhWu2cNbAiz9ABFX-TEX57T76CsBOwCVQjvk9FsbEC/s400/AEMD%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="140" data-original-width="400" height="112" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhmpCFDhO2BE00nGC_9rHS7tvQjHHJRWLZ1lgQpWUddYY3SzEnQz-QcyQ7dAgyV2mQD-s_IGQVHrTYnDnFtSa5gyzzbFlI5gXOr9csLeWl3CQQG6DMY4KiwSA5-ki9NGsCdB9c52Zc8yLEpgaU-x0AhWu2cNbAiz9ABFX-TEX57T76CsBOwCVQjvk9FsbEC/s320/AEMD%20Logo.jpg" width="320" /></a></b></div><b style="mso-bidi-font-weight: normal;"><br /></b><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p align="center" class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1; text-align: center;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Breaking Medical
Technology Stock News: </span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri;">Aethlon Medical </span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Arial;">(NASDAQ: $AEMD) </span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri;">Announces Fiscal Third Quarter Financial Results
and Provides Corporate Update<o:p></o:p></span></b></p>
<p align="center" class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1; text-align: center;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p align="center" class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1; text-align: center;"><b style="mso-bidi-font-weight: normal;"><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri;">Conference Call to be Held Today at 4:30 p.m. ET<o:p></o:p></span></i></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">SAN DIEGO, CA, February 14, 2024 -- </span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">(Investorideas.com
Newswire) </span></b><span lang="EN-US"><a href="https://www.aethlonmedical.com/"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Aethlon
Medical, Inc.</span></b></a></span><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"> </span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">(</span></b><span lang="EN-US"><a href="https://finance.yahoo.com/quote/AEMD?p=AEMD&.tsrc=fin-srch"><b style="mso-bidi-font-weight: normal;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">NASDAQ:AEMD</span></b></a></span><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">),</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">a medical therapeutic company focused on developing products to treat
cancer and life-threatening infectious diseases</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">, today reported financial results for its fiscal third quarter ended December
31, 2023 and provided an update on recent developments.</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: "Times New Roman";"> </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p class="MsoNoSpacing"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Read this news, featuring AEMD in full at </span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><a href="https://www.investorideas.com/news/2024/02141AEMD-Q3-Results-and-Corporate-Update.asp">https://www.investorideas.com/news/2024/02141AEMD-Q3-Results-and-Corporate-Update.asp</a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Company Updates<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Aethlon
Medical is continuing the research and clinical development of its Hemopurifier<b>®</b>,
a therapeutic blood filtration system designed to bind and remove harmful
exosomes and life-threatening viruses from blood and other biological fluids. These
qualities of the Hemopurifier have potential applications in oncology, where
cancer associated exosomes may promote immune suppression and metastasis, and
in <a name="_Hlk158372416">life-threatening infectious diseases</a>. Aethlon is
also investigating the use of the Hemopurifier in the organ transplant setting,
initially focusing on the potential removal of viruses and exosomes with
harmful cargo from recovered kidneys. <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-font-weight: bold;">In October 2023, Aethlon received clearance from the Drug Controller
General of India (DCGI), the country’s central drug authority, to conduct a
phase 1 safety, feasibility and dose-finding trial of the Hemopurifier in
patients with solid tumors who have stable or progressive disease during
anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®. The trial is
expected to begin following completion of an in vitro binding study of relevant
targets, and subsequent approval by the respective Ethics Boards of interested
sites in India. <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-bidi-font-weight: bold; mso-highlight: yellow;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">“In addition
to an interested initial site in India, we have two interested sites in
Australia that are also awaiting the data from our in vitro binding study,”
stated James Frakes, Interim Chief Executive Officer and Chief Financial
Officer. “Our in vitro binding study of relevant oncology targets is complex
and stands on the cutting edge of extracellular vesicle science. Our goal is to
quantify the potential impact of our Hemopurifier on plasma from cancer
patients that have been treated with anti-PD-1 monotherapy treatment in order
to provide pre-clinical evidence to support our trial design. <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">“While our
research and development team has started to quantify our internal data, the
results, to date, are somewhat inconclusive. Therefore, while our internal team
continues to finetune their work, in parallel we have engaged several third-party
laboratories to independently perform assays on the samples.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">“We are also maintaining
a position in the use of our Hemopurifier as a treatment against
life-threatening viral infections through our COVID-19 trial in India. We have
two participating sites for this trial -- the Medanta Medicity Hospital and
Maulana Azad Medical College, or MAMC. One patient has been treated thus far, however,
we have been informed by our contract research organization that a new COVID-19
subvariant was recently detected in India. Our COVID-19 trial in India remains
open in the event that there are COVID-19 admissions to the intensive care
units at our two participating sites. <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">“Finally, since
being named interim Chief Executive Officer three months ago, I have focused
our efforts on our oncology program, as well as on reducing our expenses. As previously
reported, we disclosed some interesting pre-clinical proof on concept data of
the Hemopurifier in organ transplantation. As a result, we plan to submit one
or more articles for publication on our pre-clinical data,” concluded Mr.
Frakes.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Financial Results for the Third Quarter Ended December
31, 2023<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><a name="_Hlk75335766"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">As of December 31, 2023, Aethlon Medical had a cash balance of
approximately $8.0 million. <span style="background: yellow; mso-highlight: yellow;"><o:p></o:p></span></span></a></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><o:p> </o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Consolidated operating expenses for the three
months ended December 31, 2023 were approximately $3.6 million, compared to $2.8
million for the three months ended December 31, 2022. This increase of
approximately $717,000, or 25.2%, in the 2023 period was due to increase in
payroll and related expenses of approximately $871,000, offset by decreases in general
and administrative expenses of approximately $92,000 and in professional fees
of approximately $61,000.<o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><o:p> </o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">The $871,000 increase in payroll and related expenses
was primarily due to separation expenses for our former chief executive officer
of $873,000 and an increase in salary expense of $81,000 associated with an
increase in average headcount, offset by a decrease in stock-based compensation
of $83,000</span></span><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";">.</span></span><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><span style="mso-spacerun: yes;"> </span><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">The $92,000 decrease in general and
administrative expenses was primarily due to a decrease in clinical trial
expense of approximately $399,000 and a $33,000 decrease in travel and
conferences expenses. Decreases were offset by a $284,000 increase in supplies
for manufacturing and research and development expense, a $31,000 increase in
insurance expense, a $13,000 increase in depreciation expense and a $12,000
increase in outside services and repairs. The increase in insurance expense
included $16,000 of health insurance related to the separation agreement with
our former chief executive officer</span></span><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";">.</span></span><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><span style="mso-spacerun: yes;"> </span><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">The $61,000 decrease in professional fees was due
to a $54,000 decrease in scientific consulting, a $22,000 decrease in
marketing, a $21,000 decrease in recruiting and a net $33,000 decrease in
contract labor related to general research and development. These decreases
were offset by an increase of $44,000 in legal expenses relating to the reverse
stock split, an $11,000 increase in director fees associated with the addition
of a new director and a $14,000 increase in investor</span></span><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-fareast-font-family: "Times New Roman";"> </span></span><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">relations and
accounting fees.<o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><span style="mso-spacerun: yes;"> </span><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">As a result of the changes in expenses noted
above, the company’s net loss increased to $3.6 million for the three months
ended December 31, 2023, from $2.8 million in the three months ended December 31,
2022.<o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><span style="mso-bookmark: _Hlk75335766;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><span style="mso-spacerun: yes;"> </span></span></span><span style="mso-bookmark: _Hlk75335766;"></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="color: black; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">The condensed consolidated balance
sheet for December 31, 2023, and the condensed consolidated statements of
operations for the three- and nine-month periods ended December 31</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: "Times New Roman";">, 2023
and 2022</span><span lang="EN-US" style="color: black; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"> follow at the end of this release.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><a name="_Hlk118875164"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Conference Call<o:p></o:p></span></b></a></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="background: white; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Aethlon Medical will hold a
conference call today, Wednesday, February 14, 2023, at 4:30 p.m. ET to review
its financial results for its fiscal third quarter ended December 31, 2023 and
recent corporate developments. </span></span><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Interested parties can register for the
conference by navigating to </span></span><a href="https://dpregister.com/sreg/10186345/fb902976dd"><span style="mso-bookmark: _Hlk118875164;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">https://dpregister.com/sreg/10186345/fb902976dd</span></b></span></a><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">. Please note
that registered participants will receive their dial-in number upon
registration. <o:p></o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="background: yellow; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-highlight: yellow;"><o:p> </o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Interested parties without internet access or who
are unable to pre-register, may dial in as follows: <o:p></o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">Participant Dial In (Toll Free): 1-844-836-8741<br />
Participant International Dial In: 1-412-317-5442<br style="mso-special-character: line-break;" />
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character: line-break;" />
<!--[endif]--><o:p></o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">All callers should ask for the Aethlon Medical,
Inc. conference call. <o:p></o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;">A replay of the call will be available
approximately one hour after the end of the call through March 14, 2024. The
replay can be accessed via Aethlon Medical's website or by dialing
1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada toll free
at 1-855-669-9658. The replay conference ID number is 7691190.<o:p></o:p></span></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="mso-bookmark: _Hlk118875164;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></span></p>
<span style="mso-bookmark: _Hlk118875164;"></span>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri;">About Aethlon and the Hemopurifier®</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">Aethlon Medical is a medical therapeutic company focused on developing
the Hemopurifier, a clinical stage immunotherapeutic device which is designed
to combat cancer and life-threatening viral infections and for use in organ
transplantation. In human studies, the Hemopurifier has demonstrated the
removal of life-threatening viruses and in pre-clinical studies, the
Hemopurifier has demonstrated the removal of harmful exosomes from </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri;">biological fluids,</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"> utilizing its proprietary lectin-based technology. This action has
potential applications in cancer, where exosomes may promote immune suppression
and metastasis, and in life-threatening infectious diseases. The Hemopurifier
is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device
indicated for the treatment of individuals with advanced or metastatic cancer
who are either unresponsive to or intolerant of standard of care therapy, and
with cancer types in which exosomes have been shown to participate in the
development or severity of the disease. The Hemopurifier also holds an FDA
Breakthrough Device designation and an open Investigational Device Exemption
(IDE) application related to the treatment of life-threatening viruses that are
not addressed with approved therapies.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">Additional information can be found at </span><span lang="EN-US"><a href="http://www.aethlonmedical.com/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">www.AethlonMedical.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Forward-Looking Statements<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect,"
"intend," "plan," "project," "will,"
"projections," "estimate," "potentially" or similar
expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to raise additional
capital and to successfully complete development of the Hemopurifier; the
Company’s ability to successfully demonstrate the utility of the Hemopurifier
in cancer and infectious diseases and in the transplant setting; the Company’s
ability to initiate its oncology clinical trials in India and Australia; the
Company’s ability to manage and successfully complete its clinical trials, if
initiated; the Company’s ability to maintain its Nasdaq listing; the Company’s
ability to successfully manufacture the Hemopurifier in sufficient quantities
for its clinical trials, and other potential risks. The foregoing list of risks
and uncertainties is illustrative, but is not exhaustive. Additional factors
that could cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended
March 31, 2023, and in the Company's other filings with the Securities and
Exchange Commission, including its quarterly Reports on Form 10-Q. All
forward-looking statements contained in this press release speak only as of the
date on which they were made. Except as may be required by law, the Company
does not intend, nor does it undertake any duty, to update this information to
reflect future events or circumstances.</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></i></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Company Contact:</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Jim Frakes</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Interim Chief Executive Officer and Chief Financial Officer</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Aethlon Medical, Inc. </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US"><a href="mailto:Jfrakes@aethlonmedical.com"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Jfrakes@aethlonmedical.com</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Investor Contact:</span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">Susan Noonan</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">S.A. Noonan Communications, LLC</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US"><a href="mailto:susan@sanoonan.com"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">susan@sanoonan.com</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;"> </span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;">917-513-5303<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri; mso-fareast-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-language: EN-CA;">Aethlon
Medical Inc. (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com<o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-language: EN-CA;">More info on AEMD at Investorideas.com Visit: </span></b><span lang="EN-US"><a href="https://www.investorideas.com/CO/AEMD/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">https://www.investorideas.com/CO/AEMD/</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US"><a href="https://lp.constantcontactpages.com/sl/AGDqOB2"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-style: italic; mso-bidi-theme-font: minor-latin;">Get News Alerts on Aethlon Medical</span></a></span><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="color: #404040; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-style: italic; mso-bidi-theme-font: minor-latin; mso-themecolor: text1; mso-themetint: 191;"><o:p></o:p></span></b></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;">Disclaimer/Disclosure:</span></b><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;"> is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;">https://www.investorideas.com/About/News/Clientspecifics.asp</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;"> </span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Arial;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">Learn more about publishing
your news release and our other news services on the Investorideas.com newswire</span><span lang="EN-US"><a href="https://www.investorideas.com/News-Upload/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://www.investorideas.com/News-Upload/</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"> Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://www.investorideas.com/About/Private_Policy.asp</span></a></span><u><span lang="EN-US" style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US"><a href="https://www.investorideas.com/BIS/"><span lang="EN-CA" style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-ansi-language: EN-CA; mso-fareast-language: EN-CA; mso-no-proof: yes; text-decoration: none; text-underline: none;"><v:shape alt="Description: Description: BiotechIndustryStocks.com - A Leading Global Investor Website for Biotech Industry Stocks" href="https://www.investorideas.com/BIS/" id="Picture_x0020_2" o:button="t" o:spid="_x0000_i1025" style="height: 75pt; mso-wrap-style: square; visibility: visible; width: 75pt;" type="#_x0000_t75">
<v:fill o:detectmouseclick="t">
<v:imagedata o:title=" BiotechIndustryStocks" src="file:///C:\Users\Home\AppData\Local\Temp\msohtmlclip1\01\clip_image002.gif">
</v:imagedata></v:fill></v:shape></span></a></span><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgCSOcYRx5sw4IrFerqnbL7lTi8SjePCTxLh5VJJTzSrLPwf27ydZ8OxaBMHcnCj688s4Yws53-DS3NwyD-4aoJgfaLxuEfx096WZ16IP2xLYkXn-5OW8MC6y3pOXmxQoAwB7bvKhkoZMqsfmSIn8ggORHF8A-pKwIJM1UysgPULKGObiRU3e4O_eroxSsf/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgCSOcYRx5sw4IrFerqnbL7lTi8SjePCTxLh5VJJTzSrLPwf27ydZ8OxaBMHcnCj688s4Yws53-DS3NwyD-4aoJgfaLxuEfx096WZ16IP2xLYkXn-5OW8MC6y3pOXmxQoAwB7bvKhkoZMqsfmSIn8ggORHF8A-pKwIJM1UysgPULKGObiRU3e4O_eroxSsf/s1600/BIS.gif" width="100" /></a></div><br />Biotech Industry Stocks-
investing ideas in biotechnology stocks, medical technology and life sciences<o:p></o:p><p></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;">Like Biotech Stocks? View our </span><span lang="EN-US"><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News Alerts on Biotech Stocks</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 107%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 107%; mso-bidi-font-family: Calibri;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-85923231641230857482024-02-14T07:47:00.000-08:002024-02-14T07:47:24.889-08:00 Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies; @FNMgroup @Oncolytics<p> <b><span style="color: #0f1419; font-family: Verdana, "sans-serif"; font-size: 12pt; line-height: 18.4px;">Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies</span>; @FNMgroup @Oncolytics</b></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjgjBLsFAbopZ0Rs_eNvgDEAWlNiLtiB9JysOyNSi6RWD1m7FpfqLZdwRd7tfdbYtzYJOpXbpm0dbcoX5d6NnIflCd0HPDgRluvYiJtLpnejcwlmdg_Wiez4ZwAugkgjFHFJ8QFmhKbSbl4apP-AjPJucaLd20OUcVmrYS574EDAH6oXSD_UGn7Dn2-bRU/s1149/FNM.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="663" data-original-width="1149" height="185" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjgjBLsFAbopZ0Rs_eNvgDEAWlNiLtiB9JysOyNSi6RWD1m7FpfqLZdwRd7tfdbYtzYJOpXbpm0dbcoX5d6NnIflCd0HPDgRluvYiJtLpnejcwlmdg_Wiez4ZwAugkgjFHFJ8QFmhKbSbl4apP-AjPJucaLd20OUcVmrYS574EDAH6oXSD_UGn7Dn2-bRU/s320/FNM.png" width="320" /></a></div><br /><p></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Palm Beach, FL – February 14, 2024 – FN Media Group News Commentary –</span></b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: “More than 8,000 people in the U.S. are diagnosed with anal cancer each year. Due to higher rates of the human papilloma virus, a key risk factor, it affects women more than men. If found early, the disease can be successfully treated. Several types of tumors may be found in the anus. While some of them are malignant (cancer), others are benign (not cancer) or precancerous (may develop into cancer). The main types of anal cancer are: Carcinoma in situ is early cancer or precancerous cells. They are only on the surface cells of the anal canal. This also may be called Bowen’s disease; Squamous cell cancer (carcinoma) forms in the cells that line the anus. This is the most common type of anal cancer; Adenocarcinomas develop in the glands around the anus; and Skin cancers, including basal cell and melanoma, often are found when they are in advanced stages. A report from Market Research Future projected that: “The Anal cancer market is anticipated to reach USD 1,638.5 Million by 2030 at 8.6% CAGR… through 2030. It said: “Anal cancer is a rare type of cancer that begins in the anus, which is the orifice at the rectum’s end. Anal cancer has one of the highest rates of occurrence and prevalence in the globe. Lifestyle issues, aging, and diet are thought to be the primary causes of anal cancer. According to the World Health Organization (WHO), an increase of roughly 70% in anal cancer cases is projected globally over the Anal Cancer Market Analysis period (2030). Squamous cell carcinoma, which develops from cells around or in the anal entrance or, in rare cases, in the anal canal, is the most common type of anal cancer. This malignancy is frequently linked to the human papillomavirus (HPV), with HPV malignancies or cervical cancers having a significant chance of progressing to anal cancer. Anal cancer has no specific symptoms; however, it might cause bleeding from the anal area, a tumor or swelling near the anus, or a change in bowel habits.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), Exelixis, Inc. (NASDAQ: EXEL), Pfizer Inc. (NYSE: PFE), BioXcel Therapeutics, Inc. (NASDAQ: BTAI), Bristol Myers Squibb (NYSE: BMY).<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Read this in full at </span></b><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"><a href="https://www.financialnewsmedia.com/anal-cancer-treatment-market-expected-to-reach-1-63-billion-by-2030-as-latest-clinical-studies-focus-on-new-therapies/">https://www.financialnewsmedia.com/anal-cancer-treatment-market-expected-to-reach-1-63-billion-by-2030-as-latest-clinical-studies-focus-on-new-therapies/</a><o:p></o:p></span></b></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">The report continued: “The income earned by medications used to treat anal cancer, as well as other screening tests, kits, and medical devices used to diagnose colorectal cancer, is tracked in the study. The high spending on public health initiatives, as well as the rapid rise in global healthcare expenditure and research and development expenditure in the field of oncology, are projected to provide substantial potential prospects and increase the market size. The Americas are likely to lead the anal cancer market because of the increased prevalence of anal cancer. Europe is predicted to represent the second-largest share of the anal cancer market because of the increased prevalence of anal cancer and the presence of significant market participants. In The Middle East and Africa, due to the high incidence rate of anal cancer, the market is likely to develop gradually throughout the forecast period.”<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort – Successful Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion – Oncolytics Biotech® Inc., a clinical-stage immunotherapeutics company focused on oncology, today announced the expansion of enrollment for the anal cancer cohort of the GOBLET study evaluating pelareorep in combination with atezolizumab (Tecentriq®) in patients with second-line or later unresectable squamous cell carcinoma of the anal canal (SCCA). The study was expanded based on positive data from Stage 1 of the study, presented at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC) in November 2023 (link to the PR, link to the poster).<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">“These exciting clinical data, which exceed the Simon two-stage success criteria, provide strong support to expand the evaluation of pelareorep in patients with advanced anal cancer. The results reported at IMACC 2023 showed that the combination of pelareorep and atezolizumab provided a 37.5% objective response rate, including one patient with a long-lasting complete response, and good overall tolerability. These data represent a meaningful contrast to recent clinical trial results which show that patients with second-line or later anal carcinoma treated with checkpoint inhibitor therapy experienced response rates of 10-14%,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics.”<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">“We begin the Stage 2 expansion with substantial optimism for patients and the potential of pelareorep, especially considering the initial efficacy signal observed for pelareorep-based therapy in pancreatic cancer. There is currently no established standard therapy for patients with anal carcinoma who have failed first-line treatment. Continued positive results could potentially expand the opportunity for pelareorep beyond the lead indications of breast cancer and pancreatic cancer and open the door to a rapid regulatory pathway in this rare and significantly under-served patient population,” continued Dr. Coffey.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, commented, “One of the most difficult challenges in my practice is the limited number of treatment options that are available for patients with advanced anal cancer who have progressed on first-line therapy. I am enthusiastic about the expansion of this cohort because it will enable the continued evaluation of the pelareorep/atezolizumab combination and could provide important confirmatory data that may lead to better treatment options for patients with this late-stage disease.”<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">“We look forward to building on the oncology community’s enthusiastic reception of the IMACC 2023 data by expanding enrollment in the anal carcinoma cohort and incorporating additional sites into the study,” commented Thomas Heineman, M.D., Ph.D., Chief Medical Officer at Oncolytics. “Careful consideration of recently published clinical trial results indicates that a modest expansion of fewer than 20 patients will be sufficient to solidify the efficacy signal we have observed to date and lay the groundwork for a potential future registrational study in this population. We look forward to continuing our excellent collaboration with the clinical sites and investigators at AIO and hope to report additional results in 2025.” CONTINUED… Read these full press releases and more news for ONCY at: https://www.financialnewsmedia.com/news-oncy/ <o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Other recent developments in the biotech industry of note for cancer events include:<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Exelixis, Inc. (NASDAQ: EXEL) recently announced detailed results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT. The detailed findings are being presented during Oral Abstract Session A: Prostate Cancer at 7:55 a.m. PST on January 25 at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU).<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">“Patients with metastatic castration-resistant prostate cancer with prior progression on a novel hormone therapy and who have measurable soft tissue metastasis experience the worst outcomes among advanced prostate cancer patients and have limited treatment options,” said Neeraj Agarwal, M.D., FASCO, Senior Director for Clinical Research at Huntsman Cancer Institute at the University of Utah and the global lead investigator of the trial. “CONTACT-02 is the only phase 3 study evaluating a tyrosine kinase inhibitor and an immune checkpoint inhibitor to show a statistically significant improvement in progression-free survival and a trend for overall survival in these patients. I am encouraged by these results and the potential for cabozantinib plus atezolizumab to be a widely available treatment option for our patients.”<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Arvinas, Inc. (ARVN) and Pfizer Inc. (NYSE: PFE) recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of vepdegestrant (ARV-471) for monotherapy in the treatment of adults with estrogen receptor (ER) positive/human growth epidermal growth factor 2 (HER2) negative (ER+/HER2-) locally advanced or metastatic breast cancer previously treated with endocrine-based therapy. Vepdegestrant is a novel oral PROteolysis Targeting Chimera (PROTAC®) ER degrader that is being jointly developed by Arvinas and Pfizer.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">As described by the FDA, Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to patients earlier. Vepdegestrant as a monotherapy is being studied in the ongoing Phase 3 VERITAC-2 clinical trial, which is evaluating vepdegestrant or fulvestrant in patients with locally advanced or metastatic ER+/HER2- breast cancer who have been previously treated with an endocrine-based therapy.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, recently announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">“The FDA’s Fast Track designation for the investigation of BXCL701 in SCNC is an important recognition of our most advanced immuno-oncology asset and an acknowledgment of its potential to address the considerable unmet medical need in these patients. At the same time, it further validates the unique AI-based drug re-innovation approach that we used to discover this asset,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “BXCL701 has already demonstrated considerable potential in our clinical trials to date, and we plan to further define its development path while exploring strategic options for our OnkosXcel Therapeutics subsidiary.”<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Bristol Myers Squibb (NYSE: BMY) recently announced two regulatory acceptances for applications for neoadjuvant Opdivo (nivolumab) with chemotherapy followed by surgery and adjuvant Opdivo for the perioperative treatment of resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics Application (sBLA) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024. In late January, the European Medicines Agency (EMA) validated the type II variation application which confirms the submission is complete and begins the start of the EMA’s centralized review process.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">“Between 30% to 55% of non-small cell lung cancer patients who undergo surgery will experience disease recurrence. We are working to expand options that improve outcomes for patients with resectable disease, as part of our comprehensive approach to the treatment of multiple types of cancer, including and especially in earlier stages,” said Abderrahim Oukessou, M.D., vice president, thoracic cancers global program lead, Bristol Myers Squibb. “With CheckMate -77T, we have evaluated the potential for neoadjuvant immunotherapy to induce pathological complete response and the role of perioperative Opdivo treatment in reducing the likelihood that the cancer will return and help make extended survival possible for patients. The acceptance of these applications underscores our impactful progress in addressing unmet needs across several non-small cell lung cancer treatment settings and brings us one step closer to offering a new perioperative Opdivo-based regimen to patients who may benefit.”<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">About FN Media Group:<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">At FN Media Group, via our top-rated online news portal at www.financialnewsmedia.com, we are one of the very few select firms providing top tier one syndicated news distribution, targeted ticker tag press releases and stock market news coverage for today’s emerging companies.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> <o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Follow us on Facebook to receive emerging news updates: https://www.facebook.com/financialnewsmedia<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Follow us on Twitter for real time Breaking News: https://twitter.com/FNMgroup<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Follow and us on Linkedin: https://www.linkedin.com/in/financialnewsmedia/<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">DISCLAIMER: FN Media Group LLC (FNM), which owns and operates FinancialNewsMedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated thirty nine hundred dollars for news coverage of the current press releases issued by Oncolytics Biotech® Inc. by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> <o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Contact Information:<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757<o:p></o:p></span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;"> </span></p><p class="MsoNormal" style="margin-bottom: 0.0001pt;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt; line-height: 15.3333px;">SOURCE: FN Media Group</span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-80288075341270130912024-02-07T08:13:00.000-08:002024-02-07T08:13:00.086-08:00Breaking Medical Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024<p> </p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Breaking Medical
Technology Stock News: Aethlon Medical </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Arial;">(NASDAQ: $AEMD) </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">to Release Fiscal Third Quarter Financial Results and Host
Conference Call on February 14, 2024<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhuXa1PXzk34-n68XiDUMi3FV48ymFs6TqSxnOmf6lP2WpDm1AV29d9Czmo6Pbhuoq67u6NCklJK01E3dtSu2gmKcmGfOEuJubO5yxzneBhHxT8sOfy-kZywkS8RC9bAucR7Pf_13vYu9jUzTCNOz2U7oSfBIebtDeitN6Vl76SvOR0fltbomSGOMLSQ_5h/s400/AEMD%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="140" data-original-width="400" height="112" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhuXa1PXzk34-n68XiDUMi3FV48ymFs6TqSxnOmf6lP2WpDm1AV29d9Czmo6Pbhuoq67u6NCklJK01E3dtSu2gmKcmGfOEuJubO5yxzneBhHxT8sOfy-kZywkS8RC9bAucR7Pf_13vYu9jUzTCNOz2U7oSfBIebtDeitN6Vl76SvOR0fltbomSGOMLSQ_5h/s320/AEMD%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">SAN DIEGO, CA, February
7, 2024 – (Investorideas.com Newswire) </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="https://www.aethlonmedical.com/"><span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">Aethlon Medical, Inc.</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"> </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">(</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/AEMD?p=AEMD&.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">NASDAQ:AEMD</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">), </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">a medical therapeutic
company focused on developing products to treat cancer and life threatening
infectious diseases, today announced that it will issue financial results for
its fiscal third quarter ended December 31, 2023, at 4:15 p.m. ET on Wednesday,
February 14, 2024.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: 14.4pt;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Read this news,
featuring AEMD in full at </span><span lang="EN-US"><a href="https://www.investorideas.com/news/2024/02071AEMD-Q3-Fiancial-Results.asp">https://www.investorideas.com/news/2024/02071AEMD-Q3-Fiancial-Results.asp</a></span><span lang="EN-US" style="mso-bidi-font-family: Arial;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Management will
host a conference call on Wednesday, February 14, 2023 at 4:30 p.m. ET to
review financial results and recent corporate developments. Following
management’s formal remarks, there will be a question and answer session.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Interested
parties can register for the conference by navigating to </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="https://dpregister.com/sreg/10186345/fb902976dd"><span style="mso-bidi-font-family: Calibri; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">https://dpregister.com/sreg/10186345/fb902976dd</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">. Please note
that registered participants will receive their dial-in number upon
registration.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Interested
parties without internet access or unable to pre-register may dial in by
calling: <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">PARTICIPANT DIAL
IN (TOLL FREE): 1-844-836-8741<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">PARTICIPANT
INTERNATIONAL DIAL IN: 1-412-317-5442<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">All callers
should ask for the Aethlon Medical, Inc. conference call.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">A replay of the
call will be available approximately one hour after the end of the call through
March 14, 2024. The replay can be accessed via Aethlon Medical’s website or by
dialing 1-877-344-7529 (domestic) or 1-412-317-0088 (international) or Canada
toll free at 1-855-669-9658. The replay conference ID number is 7691190.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">About Aethlon and the Hemopurifier®<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Aethlon Medical
is a medical therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and harmful exosomes from blood utilizing its proprietary
lectin-based technology. This action has potential applications in cancer,
where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">Additional
information can be found at </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="http://www.aethlonmedical.com/"><span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">www.AethlonMedical.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin;">Forward Looking Statements<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-font-kerning: 1.0pt;">This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may," "believe,"
"anticipate," "expect," "intend,"
"plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to successfully
complete development of the Hemopurifier and to successfully demonstrate the
utility of the Hemopurifier in cancer and infectious diseases and in the
transplant setting; the Company's ability to raise additional capital and to
maintain its Nasdaq listing; the Company's ability to successfully manufacture
the Hemopurifier in sufficient quantities for its clinical trials, and other potential
risks. The foregoing list of risks and uncertainties is illustrative, but is
not exhaustive. Additional factors that could cause results to differ
materially from those anticipated in forward-looking statements can be found
under the caption "Risk Factors" in the Company's Annual Report on
Form 10-K for the fiscal year ended March 31, 2023, and in the Company's other
filings with the Securities and Exchange Commission, including its quarterly
Reports on Form 10-Q. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Except as may be
required by law, the Company does not intend, nor does it undertake any duty,
to update this information to reflect future events or circumstances.</span></i><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Company Contact:</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Jim Frakes</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Chief Financial Officer</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Aethlon Medical, Inc. </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="mailto:Jfrakes@aethlonmedical.com"><span style="color: windowtext; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; text-decoration: none; text-underline: none;">Jfrakes@aethlonmedical.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"> <span style="mso-spacerun: yes;"> </span><span style="mso-bidi-font-weight: bold;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Investor Contact:</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">Susan Noonan</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;">S.A. Noonan Communications, LLC</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: "MS Mincho";"><br />
</span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-size: 10.0pt;"><a href="mailto:susan@sanoonan.com"><span style="color: windowtext; mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri; text-decoration: none; text-underline: none;">susan@sanoonan.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin; mso-fareast-font-family: Calibri;"> <span style="mso-spacerun: yes;"> </span><span style="mso-spacerun: yes;"> </span><span style="mso-spacerun: yes;"> </span><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;">917-513-5303<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-CA;">Aethlon Medical Inc. (Nasdaq:AEMD) is a featured biotech
stock on Investorideas.com<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-fareast-language: EN-CA;">More info on AEMD at
Investorideas.com Visit: </span><span lang="EN-US" style="font-family: "Verdana","sans-serif";"><a href="https://www.investorideas.com/CO/AEMD/">https://www.investorideas.com/CO/AEMD/</a>
<o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-bidi-font-weight: bold; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-font-style: italic; mso-bidi-theme-font: minor-latin;"><a href="https://lp.constantcontactpages.com/sl/AGDqOB2">Get News
Alerts on Aethlon Medical</a><span style="color: #404040; mso-themecolor: text1; mso-themetint: 191;"><o:p></o:p></span></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">Disclaimer/Disclosure:</span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"> is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/About/News/Clientspecifics.asp</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">
</span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire</span><span lang="EN-US"><a href="https://www.investorideas.com/News-Upload/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/News-Upload/</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"> Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a></span><u><span lang="EN-US" style="color: #23527c; font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%; margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 120%; mso-bidi-font-family: Arial; mso-bidi-font-size: 10.0pt;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhGRU0Ny3PnBNxj0W8RGR1V8_Xq9HL-rx03SGTydX3_uLJ_l52Uh2n68Tc7EkUBWBlY__kk4sdwEmY8ejQzw_QaC_5W1kq1z-qCkXCgZCnNidpfu04X998YVlkEFRBM9rqd3_7zV7CrWo2eyUosUh12N91dMbbHwIBqQtQ_dhRiCsaPCGmLD6J7TgK6NiEt/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhGRU0Ny3PnBNxj0W8RGR1V8_Xq9HL-rx03SGTydX3_uLJ_l52Uh2n68Tc7EkUBWBlY__kk4sdwEmY8ejQzw_QaC_5W1kq1z-qCkXCgZCnNidpfu04X998YVlkEFRBM9rqd3_7zV7CrWo2eyUosUh12N91dMbbHwIBqQtQ_dhRiCsaPCGmLD6J7TgK6NiEt/s1600/BIS.gif" width="100" /></a></div><br /><p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm;"><br /></p>
<p class="MsoNormal" style="background: white; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;">Biotech Industry
Stocks- investing ideas in biotechnology stocks, medical technology and life
sciences<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;">Like Biotech Stocks? View our </span><span lang="EN-US"><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-bottom: 14.4pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News Alerts on Biotech Stocks</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; line-height: 115%; mso-bidi-font-family: Calibri; mso-bidi-font-size: 10.0pt; mso-bidi-theme-font: minor-latin;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-50393151435795320412024-02-05T09:30:00.000-08:002024-02-05T09:30:24.693-08:00Breaking CBD News: Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences (OTCQB: $PBIO) UltraShear Processing for Revolutionary Product Effectiveness; @ir_pressurebio @UncleBuds_Hemp<p> </p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;">Breaking CBD News: Uncle Bud's to Launch New
Premium Health and Wellness Products Leveraging Pressure BioSciences (OTCQB: $PBIO)
UltraShear Processing for Revolutionary Product Effectiveness; @ir_pressurebio </span></b><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="background: white; color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-ansi-language: EN-US; mso-bidi-font-family: Arial;">@UncleBuds_Hemp</span></b><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;"><o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 4;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Multi-Patented Nanoemulsification Platform Enables Wide-Range of
Best-in-Class Health and Wellness Products - Revenue Impact of $5 Million in
2024 Anticipated with Further Acceleration in 2025 & Beyond<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 4;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 4;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Pressure BioSciences February 5th Investor Call to Discuss Impact of
Recent Uncle Bud's Acquisition<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 4;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgd2bnHTJ7Fn7qDDRQfUGbKUYEHMXedcRDvLoTpUQf2SYVDYKUsXWqIryRBbRqqVGUD-NhZa6RtxJu2M7wxrkIT9snULSur__vhyphenhyphenmwL-FouG7EV4isgK5Uv2aQEITQ6pfnsLGv486kucI9ty3uxMA8v0wJLU3auttnpApIExDMGMgJ5Tgul7IeKbw8eSxV2/s532/PBIO%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="133" data-original-width="532" height="80" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgd2bnHTJ7Fn7qDDRQfUGbKUYEHMXedcRDvLoTpUQf2SYVDYKUsXWqIryRBbRqqVGUD-NhZa6RtxJu2M7wxrkIT9snULSur__vhyphenhyphenmwL-FouG7EV4isgK5Uv2aQEITQ6pfnsLGv486kucI9ty3uxMA8v0wJLU3auttnpApIExDMGMgJ5Tgul7IeKbw8eSxV2/s320/PBIO%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">SOUTH
EASTON, Mass. - February 5, 2024 (Investorideas.com Newswire) Pressure
BioSciences, Inc. (<a href="https://finance.yahoo.com/quote/PBIO?p=PBIO&.tsrc=fin-srch"><span style="color: #337ab7; text-decoration: none; text-underline: none;">OTCQB: PBIO</span></a>)</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> ("PBIO" or the "Company"), a pioneer in the
development and distribution of broadly enabling pressure-based instruments,
consumables, and specialty process development and testing services across
global industries, including health and wellness, nutraceuticals, food and
beverage, cosmetics, biotherapeutics, and more, is hosting a teleconference
today (Monday, February 5th, 4:30PM EST) to discuss the recent acquisition of
natural health and wellness innovator Uncle Bud's ("UB"), as well as
other on-going opportunities.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Read this in full at </span><a href="https://www.investorideas.com/news/2024/cannabis/02051PBIO-CBD-Body-Revive-Spray.asp">https://www.investorideas.com/news/2024/cannabis/02051PBIO-CBD-Body-Revive-Spray.asp</a><o:p></o:p></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">CBD Body Revive Spray<o:p></o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgz-aghDwmOXFUA2feahqDzRXkNJoLqnD0YOkIufDgWWA60cS-IhzX8e1wnETA2YqhoQpRLIW8G2ny_lRWhRHQQKZypyXIxPcChW9e5K2l_liOmjrvWJFz40JbcJNHXMHgj1b0HHO2RfUO4lR8lIrU3xeXbtFplY_hCeUZWD4bPo7BgSSHH2sZOHE6yyOkO/s300/PBIO%20Spray.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="127" data-original-width="300" height="127" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgz-aghDwmOXFUA2feahqDzRXkNJoLqnD0YOkIufDgWWA60cS-IhzX8e1wnETA2YqhoQpRLIW8G2ny_lRWhRHQQKZypyXIxPcChW9e5K2l_liOmjrvWJFz40JbcJNHXMHgj1b0HHO2RfUO4lR8lIrU3xeXbtFplY_hCeUZWD4bPo7BgSSHH2sZOHE6yyOkO/s1600/PBIO%20Spray.jpg" width="300" /></a></div><br /><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><br /></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">CBD Body Revive Spray All Natural,
Fast Acting, Plant Based, Preservative Free, Best-in-Class,
UltraShear-processed Nano CBD<br />
<br />
...the first in a series of groundbreaking premium nanoemulsified products
designed to meet the needs of consumers looking for the highest quality and
performance in natural and effective wellness solutions. <a href="https://www.unclebudshemp.com/product/cbd-body-revive-spray-1200mg/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">Click here for
more info on Uncle Bud's Premium Collection.</span></a><br style="mso-special-character: line-break;" />
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character: line-break;" />
<!--[endif]--><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">In an exciting leap forward for
natural wellness enthusiasts, Uncle Bud's Health and Wellness ("Uncle
Bud's") is announcing the planned launch of its UltraShear-processed
"Premium Collection" of state-of-the-art nanoemulsified products. The
collection, highlighted by its flagship product - the CBD Body Revive Spray
with 1200mg of Nano CBD - will be processed with PBIO's multi-patented
UltraShear Technology™ (UltraShear™ or UST™), and is expected to redefine the
standards of effectiveness and quality in CBD and other products. These
products represent the pinnacle of innovation, quality, and commitment to
natural, clean wellness solutions. The Premium Collection launch is expected on
or before March 1, 2024.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Developed in collaboration with
scientists from Uncle Bud's parent PBIO, the UltraShear-processed Premium
Collection stands as a testament to Uncle Bud's dedication to harnessing the
power of science to amplify the benefits of natural ingredients. By utilizing
cutting-edge UltraShear Technology, Premium Collection products will offer
unparalleled speed of absorption and delivery of active ingredient dosing
payload more efficiently - for faster, more effective results.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Embodying Uncle Bud's commitment to
safety and environmental responsibility, all UltraShear Premium Collection
products will be crafted from 100% natural, clean ingredients, and GMO-free.
This meticulous attention to detail guarantees customers receive the highest
quality, most sustainable products available for integrating into their daily wellness
routines.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">For the launch of the new premium
products, Uncle Bud's is inaugurating a new website category dedicated
exclusively to the innovation and quality of the Premium Collection product
line. The launch of the initial product - CBD Body Revive Spray with 1200 mg of
Nano CBD for powerful, fast-acting relief in a convenient spray form - offers
an essential addition in any wellness regimen and marks the beginning of a
series of groundbreaking premium products designed to meet the needs of
consumers looking for the highest quality and performance in natural and
effective wellness solutions.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">"We are incredibly excited to
introduce the UltraShear-processed Premium Collection of innovative,
nanoemulsified products to our customers," said Bruno Schiavi, President
of Uncle Bud's. "This is a major milestone for us, combining the best of
science and nature to create a product line that not only meets but sets a new
benchmark for the highest standards of quality, purity, and
effectiveness." <a href="https://www.unclebudshemp.com/product/cbd-body-revive-spray-1200mg/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">Click here for
more info on Uncle Bud's Premium Collection.</span></a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">John Hollister, PBIO's Director of
Sales and Marketing, added: "What an exciting time for all stakeholders in
PBIO. With revenues of $5 million anticipated from Uncle Bud's in 2024,
combined with revenues of $5 million anticipated from historical PBIO
products/services, we believe total 2024 revenues could be 5X or more of our
historical annual revenue."<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Teleconference Information</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> <a href="https://ir.pressurebiosciences.com/press-releases/detail/466/pressure-biosciences-upcoming-investor-call-to-discuss"><span style="color: #337ab7; text-decoration: none; text-underline: none;">(click here for
more conference call details)</span></a><o:p></o:p></span></p>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Date: Monday, February 5, 2024. 4:30 pm ET (US).<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Call-in Number: 888-267-2918 (code: 973092).<o:p></o:p></span></li>
</ul>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Uncle Bud's</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Launched in 2018 with a trailblazing
hemp-based Pain Relief product, Uncle Bud's has rapidly captured an innovative
leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health
& Wellness industry. The Uncle Bud's brand is revered for its unwavering
commitment to domestic manufacturing excellence, setting benchmarks for its
organic, preservative-free, non-GMO standards and its ethical cruelty-free
practices. Uncle Bud's is dedicated to the highest-quality formulations and to
continuous improvement, guided by the latest scientific research and
development innovations - including the revolutionary performance breakthroughs
delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's
diverse product portfolio addresses an ever-broadening spectrum of consumer
needs, encompassing pain relief, sophisticated skincare solutions, personal
wellness and athletic recovery products, and specialized pet care items. Learn
More: <a href="https://www.unclebudshemp.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">www.unclebudshemp.com</span></a> *
Follow On Social Media: @UncleBuds_Hemp.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Pressure BioSciences, Inc.</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><br />
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing
innovative, broadly enabling, high pressure-based solutions for a range of
industries, including biotechnology, pharmaceutical, nutraceutical,
cosmeceutical, and agrochemical, as well as food and beverage manufacturing.
Our products utilize both constant and alternating pressure. Our patented enabling
technology platform, Pressure Cycling Technology (PCT), utilizes alternating
cycles of pressure to control bio-molecular interactions (such as cell lysis
and biomolecule extraction) safely and reproducibly. PCT-based products are
beginning to be widely used for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil &
plant biology, forensics, and counter-bioterrorism applications. We have
recently expanded our market opportunities with the acquisition of the
BaroFold™ patented technology platform, allowing us to enter the bio-pharma
contract services and GMP manufacturing equipment sector. We have also
developed the scalable and high-efficiency pressure-based UltraShear
Technology™ (UltraShear™) platform, which allows for the creation of stable
nanoemulsions of otherwise immiscible fluids. It also allows for the
preparation of higher quality, homogenized, extended shelf-life or room
temperature-stable low-acid liquid foods that cannot be effectively preserved
using existing non-thermal technologies. Our commitment to innovation and
cutting-edge technology has established PBIO as a leader in the high-pressure
industry, providing unique and effective solutions to our customers.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Forward Looking Statements</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><br />
This press release contains forward-looking statements. These statements relate
to future events or our future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause our or our
industry's actual results, levels of activity, performance, or achievements to
be materially different from any future results, levels of activity,
performance or achievements expressed, implied, or inferred by these
forward-looking statements. In some cases, you can identify forward-looking
statements by terminology such as "may," "will,"
"should," "could," "would," "expects,"
"plans," "intends," "anticipates,"
"believes," estimates," "predicts,"
"projects," "potential" or "continue" or the
negative of such terms and other comparable terminology. These statements are
only predictions based on our current expectations and projections about future
events. You should not place undue reliance on these statements. In evaluating
these statements, you should specifically consider various factors. Actual
events or results may differ materially. These and other factors may cause our
actual results to differ materially from any forward-looking statement. These
risks, uncertainties, and other factors include, but are not limited to, the
risks and uncertainties discussed under the heading "Risk Factors" in
the Company's Annual Report on Form 10-K for the year ended December 31, 2022,
and other reports filed by the Company from time to time with the SEC. The
Company undertakes no obligation to update any of the information included in
this release, except as otherwise required by law.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">For more information about PBIO,
Uncle Bud's, and this press release, please click on the following website
links:<br />
<a href="http://www.pressurebiosciences.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">http://www.pressurebiosciences.com</span></a> <a href="https://www.unclebudshemp.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">www.unclebudshemp.com</span></a><br style="mso-special-character: line-break;" />
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character: line-break;" />
<!--[endif]--><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Please visit us on Facebook,
LinkedIn, and Twitter.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Press Contacts</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Richard T. Schumacher, President
& CEO (508) 230-1828 (T)<br />
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)<br />
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Disclaimer/Disclosure:</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content
on our site. </span><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="color: #337ab7; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">Disclosure</span></a></span><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> More
disclaimer info: </span><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> Learn more about publishing your news release
and our other news services on the Investorideas.com newswire </span><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/News-Upload/</span></a></span><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg6lPT5CTls_aoA_8HkfAwj8Qw3lvNpyk8OVoTcQeLK6o5uDVuymlMM-AF0vxo67CiTvhiaIpzPLh3JvYFl2RLDRg-uf87ItP_AsbEHmfD9w2DDbtZ3AKxY-f5Wx6lGLFj1HkWWYaC77BnCJq__Q0SDqwL0w5YRipiOYoF54EEwCJ1UhyB7Lx7OtYFnuAAL/s299/Potcast%20logo.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="224" data-original-width="299" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEg6lPT5CTls_aoA_8HkfAwj8Qw3lvNpyk8OVoTcQeLK6o5uDVuymlMM-AF0vxo67CiTvhiaIpzPLh3JvYFl2RLDRg-uf87ItP_AsbEHmfD9w2DDbtZ3AKxY-f5Wx6lGLFj1HkWWYaC77BnCJq__Q0SDqwL0w5YRipiOYoF54EEwCJ1UhyB7Lx7OtYFnuAAL/w200-h150/Potcast%20logo.jpg" width="200" /></a></div><br /><p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><br /></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><a href="https://www.investorideas.com/About/"><b><span style="color: #337ab7; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/</span></b></a></span><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Sign up for free stock news alerts at
Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><a href="https://www.investorideas.com/Resources/Newsletter.asp"><span style="color: #337ab7; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; text-decoration: none; text-underline: none;">https://www.investorideas.com/Resources/Newsletter.asp</span></a></span><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-46811597294361589842024-02-01T10:15:00.000-08:002024-02-01T10:15:49.834-08:00Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds<p> </p><p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;">Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Upcoming Investor
Call to Discuss Recent Acquisition of Uncle Buds<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><b style="mso-bidi-font-weight: normal;"><i style="mso-bidi-font-style: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Uncle Bud's 2024 Revenue Expected to Increase
3-Fold to Approximately $5 Million, Fueled by UltraShear Processed Nanoemulsion
Product Introductions and Exciting New Market Opportunities<o:p></o:p></span></i></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgQgV6wReQaKLnor2Tn0uE19CLZshj_2R7hfhe4Qu4c7iBozhBmdhox3CEljkViAuKd3kIBnP1PsAUfnPxIIdbWlz0uQK-RrunCksjhU01wzeOjadPMNeoSRWkB-j6MuYxdO5oDBfTenKjhHxx2nqsgNU-PLK0N798FHe6Mt5DruOaMVk_NUN1riVHLvKrv/s532/PBIO%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="133" data-original-width="532" height="80" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgQgV6wReQaKLnor2Tn0uE19CLZshj_2R7hfhe4Qu4c7iBozhBmdhox3CEljkViAuKd3kIBnP1PsAUfnPxIIdbWlz0uQK-RrunCksjhU01wzeOjadPMNeoSRWkB-j6MuYxdO5oDBfTenKjhHxx2nqsgNU-PLK0N798FHe6Mt5DruOaMVk_NUN1riVHLvKrv/s320/PBIO%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">SOUTH EASTON, Mass.
- February 1, 2024 (Investorideas.com Newswire) Pressure BioSciences, Inc. (<a href="https://finance.yahoo.com/quote/PBIO?p=PBIO&.tsrc=fin-srch"><span style="color: #337ab7; text-decoration: none; text-underline: none;">OTCQB: PBIO</span></a>)</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> ("PBIO" or the "Company"), a
pioneer in the development and distribution of broadly enabling pressure-based
instruments, consumables, and specialty process development and testing
services across global industries, including nutraceuticals, food and beverage,
health and wellness, cosmetics, biotherapeutics, and more, today announced that
the Company will host a teleconference to discuss the recent strategic
acquisition of natural health and wellness innovator Uncle Bud's
("UB") in an all-stock transaction. In particular, the Company will
discuss its current, in-process move to new, more efficient manufacturing
space; the integration plan of the Uncle Bud's team and product offerings into
PBIO; and the significant growth expected from new UltraShear processed
nanoemulsion products, which are expected to catapult the Company's total
revenue by 5X to about $10M in 2024.<o:p></o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Read this news, featuring PBIO in
full at </span><a href="https://www.investorideas.com/news/2024/cannabis/02011PBIO-Investor-Call-Recent-Acquisition-Uncle-Buds.asp">https://www.investorideas.com/news/2024/cannabis/02011PBIO-Investor-Call-Recent-Acquisition-Uncle-Buds.asp</a><o:p></o:p></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UltraShear CBD Body Revive Spray<o:p></o:p></span></p><p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEho9AKB0qR2XAHz4MdOiVKXCio9DKKtmpi-Sm3TbfpG7y_lTKBrmU4irwERmJkyaQ6MWRzEJ6Zz4RILHgzreHqtKV5_IF6knOHCyMh2iXZeZ84LIDFgj_H9VzjQZvkn80koKSNiHYuG4sOlzASsEkKSJQOqt6whu1Dox5HBoZF-hHE3dddbhLHSxAlz6yaT/s300/PBIO%20Spray.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="127" data-original-width="300" height="127" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEho9AKB0qR2XAHz4MdOiVKXCio9DKKtmpi-Sm3TbfpG7y_lTKBrmU4irwERmJkyaQ6MWRzEJ6Zz4RILHgzreHqtKV5_IF6knOHCyMh2iXZeZ84LIDFgj_H9VzjQZvkn80koKSNiHYuG4sOlzASsEkKSJQOqt6whu1Dox5HBoZF-hHE3dddbhLHSxAlz6yaT/s1600/PBIO%20Spray.jpg" width="300" /></a></div><br /><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><br /></span><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">All
Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class Nano CBD<br style="mso-special-character: line-break;" />
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character: line-break;" />
<!--[endif]--><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Teleconference Information</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Format:
Company presentation followed by Q&A.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Date:
Monday, February 5, 2024. 4:30pm ET (US).<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Call-in
Number: 888-267-2918 (code: 973092).<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l2 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Replay: <a href="https://confsignup.callcia.com/Registration/Register?ConferenceId=973092"><span style="color: #337ab7; text-decoration: none; text-underline: none;">PBIO.Replay.020524</span></a><o:p></o:p></span></li>
</ul>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Transaction Significance</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Transaction
is expected to be immediately accretive and a major accelerator to PBIO's
top line revenue growth.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Combined
companies will be positioned to attract new growth investment, rapidly
strengthen the balance sheet, accelerate PBIO's path to profitability in
2024, and catalyze PBIO's drive to uplist to NASDAQ/NYSE in 2024.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB
leadership are experts in branding, spokesperson management, and
online/retail multimedia marketing.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB will
rapidly incorporate PBIO's best-in-class Nano-CBD into renowned and successful
CBD product lines.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Senior
management of UB/PBIO plan a dozen new nanoemulsion products for
commercial release in 2024.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB
already markets and sells many products in health & wellness that
expand well beyond Hemp and CBD.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB
continues building ongoing partnership with multi-Grammy award-winning
Toni Braxton - highly successful marketing ambassador leaps to embrace
combined PBIO/UB as continuing spokesperson.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB
enjoys strong following for leading hemp and CBD products, in extensive
variety of high profile news outlets and magazines online over many
years: <a href="https://www.unclebudshemp.com/press/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.unclebudshemp.com/press/</span></a>.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l0 level1 lfo2; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB
currently boasts 70+ products, 865K on-line members, and enviable sales
channels with leading large retailers.<o:p></o:p></span></li>
</ul>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Expected Financial Impact</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Acquisition
combines existing momentum and ready market execution power of Uncle
Bud's, with revolutionary product breakthroughs in absorption and speed of
action, enabled by PBIO's UltraShear nanoemulsions platform.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">PBIO forecasts
Uncle Bud's $1.6 million 2023 revenue tripling to approximately $5 million
in 2024.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: 7.5pt; mso-list: l1 level1 lfo3; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">PBIO
forecasts a 5-fold catapult forward in total Company revenues to
approximately $10 million in 2024.<o:p></o:p></span></li>
</ul>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Transaction Terms</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><br />
Please refer to the Form 8K filed on January 19, 2024.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Uncle Bud's</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Launched in 2018 with a trailblazing hemp-based
Pain Relief product, Uncle Bud's has rapidly captured an innovative leadership
role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health &
Wellness industry. The Uncle Bud's brand is revered for its unwavering
commitment to domestic manufacturing excellence, setting benchmarks for its
organic, preservative-free, non-GMO standards and its ethical cruelty-free
practices. Uncle Bud's is dedicated to the highest-quality formulations and to
continuous improvement, guided by the latest scientific research and
development innovations - including the revolutionary performance breakthroughs
delivered by PBIO's patented UltraShear™ processing platform. Uncle Bud's
diverse product portfolio addresses an ever-broadening spectrum of consumer
needs, encompassing pain relief, sophisticated skincare solutions, personal
wellness and athletic recovery products, and specialized pet care items. Learn
More: <a href="https://www.unclebudshemp.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">www.unclebudshemp.com</span></a> *
Follow On Social Media: @UncleBuds_Hemp.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Pressure BioSciences, Inc.</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><br />
Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing
innovative, broadly enabling, high pressure-based solutions for a range of industries,
including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and
agrochemical, as well as food and beverage manufacturing. Our products utilize
both constant and alternating pressure. Our patented enabling technology
platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of
pressure to control bio-molecular interactions (such as cell lysis and
biomolecule extraction) safely and reproducibly. PCT-based products are
beginning to be widely used for biomarker and target discovery, drug design and
development, biotherapeutics characterization and quality control, soil &
plant biology, forensics, and counter-bioterrorism applications. We have
recently expanded our market opportunities with the acquisition of the BaroFold™
patented technology platform, allowing us to enter the bio-pharma contract
services and GMP manufacturing equipment sector. We have also developed the
scalable and high-efficiency pressure-based UltraShear Technology™
(UltraShear™) platform, which allows for the creation of stable nanoemulsions
of otherwise immiscible fluids. It also allows for the preparation of higher
quality, homogenized, extended shelf-life or room temperature-stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. Our commitment to innovation and cutting-edge technology has
established PBIO as a leader in the high-pressure industry, providing unique
and effective solutions to our customers.<o:p></o:p></span></p>
<p class="MsoNormal"><strong><span style="background: white; color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: "Times New Roman"; mso-bidi-theme-font: minor-bidi;">Forward Looking
Statements</span></strong><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><br style="-webkit-text-stroke-width: 0px; box-sizing: border-box; font-variant-caps: normal; font-variant-ligatures: normal; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;" />
<span style="background: white;"><span style="-webkit-text-stroke-width: 0px; float: none; font-variant-caps: normal; font-variant-ligatures: normal; orphans: 2; text-align: start; text-decoration-color: initial; text-decoration-style: initial; text-decoration-thickness: initial; widows: 2; word-spacing: 0px;">This press release contains forward-looking
statements. These statements relate to future events or our future financial
performance and involve known and unknown risks, uncertainties and other
factors that may cause our or our industry's actual results, levels of
activity, performance, or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed,
implied, or inferred by these forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as "may,"
"will," "should," "could," "would,"
"expects," "plans," "intends,"
"anticipates," "believes," estimates,"
"predicts," "projects," "potential" or
"continue" or the negative of such terms and other comparable
terminology. These statements are only predictions based on our current
expectations and projections about future events. You should not place undue
reliance on these statements. In evaluating these statements, you should
specifically consider various factors. Actual events or results may differ
materially. These and other factors may cause our actual results to differ
materially from any forward-looking statement. These risks, uncertainties, and
other factors include, but are not limited to, the risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2022, and other reports
filed by the Company from time to time with the SEC. The Company undertakes no
obligation to update any of the information included in this release, except as
otherwise required by law.</span><o:p></o:p></span></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">For more information about PBIO,
Uncle Bud's, and this press release, please click on the following website
links:<br />
<a href="http://www.pressurebiosciences.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">http://www.pressurebiosciences.com</span></a> <a href="https://www.unclebudshemp.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">www.unclebudshemp.com</span></a><br />
Please visit us on Facebook, LinkedIn, and Twitter.<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Press Contacts</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Richard T. Schumacher, President
& CEO (508) 230-1828 (T)<br />
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)<br />
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Disclaimer/Disclosure:</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content
on our site. <a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="color: #337ab7; text-decoration: none; text-underline: none;">Disclosure</span></a> More
disclaimer info: <a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/Disclaimer.asp</span></a> Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire <a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/News-Upload/</span></a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEizBzvVEFHmEfBfwuQ_fe0HqoEKRxj7nTs3NJuPO0nUQ7JbkRndONlQToTlIoASxVTkpcDk8rU9y2N1JSARVw00P4_UcOs7VoHMQdfkHkikKNI0WGlsbzpg2QzRG-ToihyYR2n-5PvmVhkQb6TvhAkkonQNJsYYcrFzCc2gsTUfM75nTBAkFRk5G9_4Dknf/s299/Potcast%20logo.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="224" data-original-width="299" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEizBzvVEFHmEfBfwuQ_fe0HqoEKRxj7nTs3NJuPO0nUQ7JbkRndONlQToTlIoASxVTkpcDk8rU9y2N1JSARVw00P4_UcOs7VoHMQdfkHkikKNI0WGlsbzpg2QzRG-ToihyYR2n-5PvmVhkQb6TvhAkkonQNJsYYcrFzCc2gsTUfM75nTBAkFRk5G9_4Dknf/w200-h150/Potcast%20logo.jpg" width="200" /></a></div><br /><p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><br /></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><a href="https://www.investorideas.com/About/"><b><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Sign up for free stock news alerts at
Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; line-height: normal; margin-bottom: 7.5pt;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: "Times New Roman"; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><a href="https://www.investorideas.com/Resources/Newsletter.asp"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/Resources/Newsletter.asp</span></a><o:p></o:p></span></p>
<p class="MsoNormal"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-18258471247181053152024-01-24T08:16:00.000-08:002024-01-24T08:16:55.147-08:00 Biotech Stocks in Focus: (NYSE: $RCUS) (NASDAQ: $HUMA) (CSE: $BHSC.CN)<p> <b style="text-align: center;"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Biotech Stocks in Focus: (NYSE: $RCUS) (NASDAQ: $HUMA) (CSE: $BHSC.CN)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;">Defense, Energy, Homebuilder Stocks to Watch (TSXV: $VOL.V) (LSE: $PHAR.L) (NYSE: $MNR) (NASDAQ: $SKYX) (NYSE American: $NCL)<o:p></o:p></span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEidhqH_BxdlNXN83x4zX_C8_F6_0XWnMA4H5I_WcI84-Yqv9s-eTpUHyWKAZQ5kBVc7lx_8Leq2e-Q_C4UFr0WxapQFpzCGAtSQVA-2aPUlZoeUe2jgPXpUNWJf9YSwP8u53sQvg-4N-a8IwZ4Omqnx6cyEeV3miFYaZz-GVlB3POSoDLs_dvLlUyAckjU/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEidhqH_BxdlNXN83x4zX_C8_F6_0XWnMA4H5I_WcI84-Yqv9s-eTpUHyWKAZQ5kBVc7lx_8Leq2e-Q_C4UFr0WxapQFpzCGAtSQVA-2aPUlZoeUe2jgPXpUNWJf9YSwP8u53sQvg-4N-a8IwZ4Omqnx6cyEeV3miFYaZz-GVlB3POSoDLs_dvLlUyAckjU/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Arial, "sans-serif";"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">January 24, 2024 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces today’s roundup of new stocks to watch in Biotech, Defense, Energy and Homebuilder sectors.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at: </span></b><a href="https://www.investorideas.com/news/2024/main/01241Stocks.asp">https://www.investorideas.com/news/2024/main/01241Stocks.asp</a><o:p></o:p></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Today’s stocks have been added to Investor Ideas free lists of stock directories in each sector<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Newly added biotech companies are involved in biopharmaceuticals, tissue bioengineering and </span><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">nutraceutical health and wellness.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The latest defense company added provides aerial intelligence solutions using drones and aircraft.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest energy companies are in the oil and gas sector globally and in the U.S.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Homebuilder companies provide safe-smart platform technologies for electrical applications and </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">3D-printed flooring solutions, respectively.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://arcusbio.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Arcus Biosciences Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/RCUS?p=RCUS&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE:RCUS</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 A2a/A2b receptors) and HIF-2α.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><a href="https://humacyte.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Humacyte Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/HUMA?p=HUMA&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ:HUMA</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial product candidates, a portfolio of HAVs, are currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous (AV) access for hemodialysis, and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm HAV for AV access in hemodialysis was the first product candidate to receive the FDA’s RMAT designation and has also received FDA Fast Track designation. Humacyte’s 6mm HAV for urgent arterial repair following extremity vascular trauma also has received an RMAT designation. The HAV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.<o:p></o:p></span></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><a href="https://bioharvest.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">BioHarvest Sciences Inc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, (</span><a href="https://ca.finance.yahoo.com/quote/BHSC.CN?p=BHSC.CN&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE: BHSC</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) (</span><a href="https://finance.yahoo.com/quote/CNVCF?p=CNVCF&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">OTCQB: CNVCF</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow the active ingredients in plants, without the need to grow the underlying plant. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals - nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Defense Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://volatusaerospace.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Volatus Aerospace Corp</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://ca.finance.yahoo.com/quote/VOL.V?p=VOL.V&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">TSXV:VOL</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">; </span><a href="https://finance.yahoo.com/quote/VLTTF?p=VLTTF&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">OTCQB: VLTTF</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a leading international provider of aerial intelligence solutions, using drones and commercial aircraft. Volatus serves civil, public safety, and defense markets with imaging and inspection, security and surveillance, equipment sales and support, training, as well as R&D, design, and manufacturing. We are focused on introducing green and innovative drone solutions to supplement and replace traditional aircraft and helicopters for long-linear inspections such as pipeline, energy, rail, and cargo services. Volatus is committed to carbon neutrality; the fostering of a safe, equitable and inclusive workplace; and responsible governance.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/OGSN/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Energy Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.pharos.energy/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Pharos Energy Plc</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/PHAR.L?p=PHAR.L&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">LSE:PHAR</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is an independent energy company, engaged in the exploration, development, and production of oil and gas properties in Vietnam, Egypt, and China.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://machnr.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">MACH NATURAL RESOURCES LP</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/MNR?p=MNR&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE:MNR</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is an independent upstream oil and gas company focused on the acquisition, development and production of oil, natural gas and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas and the panhandle of Texas.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/Companies/HomebuilderStocks/HomebuilderStockList.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Homebuilder Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://skyplug.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">SKYX Platforms Corp</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/SKYX?p=SKYX&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ:SKYX</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with 77 U.S. and global patents and patent pending applications and over 60 lighting and home décor websites. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://www.northann.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Northann Corp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/NCL?p=NCL&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE American:NCL</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) specializes in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. Northann offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, primarily through its sales network in North America and Europe. The company aims to redefine the essence of modern flooring by offering stylish, durable, and ecologically conscious solutions.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/"><span lang="EN-US" style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span lang="EN-US" style="background: white; font-family: Verdana, "sans-serif"; font-size: 10pt;"> is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.<o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and tickertagstocknews.com<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></b></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhAIKjNvgAtkpfXvOGVOVN1foJwHj3eGBe9jqFzzhmNUlwXaO20Cjbdwj0Me9ZDYFN1062ked3-N_l7loYjcqXAfcfzAtnznEoysBI2lxm-25Njw9G6g86NmuFfAxwpopqZA_vYYSV9rmG8tqSNcrMgf5ZNi1YB5IMPW9rVQ_-i9qrEJSJ8kPj8VbjH_ZU/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhAIKjNvgAtkpfXvOGVOVN1foJwHj3eGBe9jqFzzhmNUlwXaO20Cjbdwj0Me9ZDYFN1062ked3-N_l7loYjcqXAfcfzAtnznEoysBI2lxm-25Njw9G6g86NmuFfAxwpopqZA_vYYSV9rmG8tqSNcrMgf5ZNi1YB5IMPW9rVQ_-i9qrEJSJ8kPj8VbjH_ZU/s320/social-media%20ICONS.png" width="320" /></a></div><br /><p></p><br /><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-29471518873003579042024-01-22T08:37:00.000-08:002024-01-22T08:37:09.952-08:00Breaking CBD News: Pressure BioSciences (OTCQB: $PBIO) Announces Closing of Uncle Bud's Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales; @ir_pressurebio<p> </p><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;">Breaking CBD News: Pressure BioSciences
(OTCQB: $PBIO) Announces Closing of Uncle Bud's Acquisition in All-Stock
Transaction, Completing UltraShear Nanoemulsions Forward Integration with World
Class Marketing & Sales; @ir_pressurebio<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 1;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA; mso-font-kerning: 18.0pt;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Merged Companies Will Introduce Revolutionary New Product Capabilities
Across Multiple Major Market Sectors, Expecting 2024 Revenues of Over $10
Million, Then Accelerating in Future Years<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-outline-level: 3;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhuOZMPioVzx9l1jds7hXhJhBiXl6WGVF8iWDPSqS0qzCO4-WcvYoD4xB42imKai5eKxmiV0qZyisTZ7ef3YJrqiMvbDIrMrSvrWb2IPAtwCCJ5nC-UTA4GwROed-D_B-XIIC6UZpU6CmrMe_zUpgYpbkG8U-bPWFZSXcVA5KgcDCydQRWJI1ZwJqC3Y-r3/s532/PBIO%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="133" data-original-width="532" height="80" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhuOZMPioVzx9l1jds7hXhJhBiXl6WGVF8iWDPSqS0qzCO4-WcvYoD4xB42imKai5eKxmiV0qZyisTZ7ef3YJrqiMvbDIrMrSvrWb2IPAtwCCJ5nC-UTA4GwROed-D_B-XIIC6UZpU6CmrMe_zUpgYpbkG8U-bPWFZSXcVA5KgcDCydQRWJI1ZwJqC3Y-r3/s320/PBIO%20Logo.jpg" width="320" /></a></div><br /><p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><br /></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">SOUTH
EASTON, Mass. - January 22, 2024 (Investorideas.com Newswire) Pressure
BioSciences, Inc. (<a href="https://finance.yahoo.com/quote/PBIO?p=PBIO&.tsrc=fin-srch"><span style="color: #337ab7; text-decoration: none; text-underline: none;">OTCQB: PBIO</span></a>)</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> ("PBIO" or the "Company"), a pioneer in the
development and distribution of broadly enabling pressure-based instruments,
consumables, and specialty process development and testing services across
global industries, including nutraceuticals, food and beverage, health and
wellness, cosmetics, biotherapeutics, and more, today announced the closing of
its acquisition of natural health and wellness leader Uncle Bud's
("UB") in an all-stock transaction. Incorporating UB's 70+ already
popular products, 865K member on-line community, existing sales channels online
and with leading large retailers, enviable celebrity spokesperson
relationships, and invaluable experience building successful consumer products
businesses, PBIO will leverage and integrate the Company's revolutionary
UltraShear™ technology (UltraShear™ or UST™) platform for further improved
nanoemulsified products that deliver industry-leading speed of action,
effective dosing payload delivery, and long-term stability. With these unique
product improvement and differentiation capabilities, PBIO intends to redefine
the basis of competition in multiple major market sectors, and to become a
leading provider of topicals and other consumer products.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Read this news, featuring PBIO in
full at </span><a href="https://www.investorideas.com/news/2024/cannabis/01221PBIO-Uncle-Bud-Acquisition-UltraShear-Nanoemulsions.asp">https://www.investorideas.com/news/2024/cannabis/01221PBIO-Uncle-Bud-Acquisition-UltraShear-Nanoemulsions.asp</a></b><b style="mso-bidi-font-weight: normal;"><span style="color: black; font-family: "Arial","sans-serif"; mso-bidi-font-family: "Times New Roman"; mso-bidi-theme-font: minor-bidi;"><o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjrZI0fT9UFnULng6jteNmGh9DOasSas_0by8MNHiRLXhygBQSf8SIrvZP9HIEyHYoh7l7IYTYDsYTK5C9QewMgkQHJIUKHTsZ_QjiSOG2wFKPsSnbD7-p04QHvUF64kyKIHZkXTZ2cAdTPS4XxgKApjpKdgCBPrtajKTPzpWJMiJfpANiHjqfOSh3lcnq4/s448/PBIO%20Braxton.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="445" data-original-width="448" height="318" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjrZI0fT9UFnULng6jteNmGh9DOasSas_0by8MNHiRLXhygBQSf8SIrvZP9HIEyHYoh7l7IYTYDsYTK5C9QewMgkQHJIUKHTsZ_QjiSOG2wFKPsSnbD7-p04QHvUF64kyKIHZkXTZ2cAdTPS4XxgKApjpKdgCBPrtajKTPzpWJMiJfpANiHjqfOSh3lcnq4/s320/PBIO%20Braxton.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Toni Braxton</span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Multi-award-winning singer,
songwriter, actress, and long-term Uncle Bud's advocate and spokesperson.<br style="mso-special-character: line-break;" />
<!--[if !supportLineBreakNewLine]--><br style="mso-special-character: line-break;" />
<!--[endif]--><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Transaction Terms</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Under the terms of the transaction,
PBIO acquired all assets and assumed selected liabilities of UB. In addition,
the parties agreed to an earnout for additional shares of PBIO Common Stock
based on the achievement of revenue and pre-tax income results in 2024. Upon
closing, all employees of UB became employees of PBIO and UB became the
Consumer Products Business Unit of PBIO. More definitive transaction terms will
be included in the Company's upcoming SEC filings.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Significance of the Transaction</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<ul style="margin-top: 0cm;" type="disc">
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">The transaction is expected to be immediately accretive and a major
accelerator to PBIO's top line revenue growth.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">The combined companies will be ideally positioned to attract new
growth investment, rapidly strengthen their balance sheet, accelerate
PBIO's path to profitability in 2024, and catalyze our drive to uplist to
NASDAQ/NYSE.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">The co-founders/senior management of UB are experts in branding,
celebrity spokesperson management, and online and retail multimedia
marketing.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB will rapidly incorporate PBIO's best-in-class Nano-CBD into
their already highly renowned and successful CBD products, for new market
breakaway potential!<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Senior management of UB and PBIO are already planning a dozen new
products that they believe could be formulated and released in 2024, just
using PBIO's existing UltraShear processed Nano CBD.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB markets and sells many products in the health & wellness
area that are unrelated to Hemp and CBD.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB has an ongoing partnership with multi-Grammy award-winning Toni
Braxton as a highly successful marketing ambassador - and Toni has
announced that she is excited to continue as a PBIO/UB spokesperson going
forward.<o:p></o:p></span></li>
<li class="MsoNormal" style="color: #333333; line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm; mso-list: l0 level1 lfo1; tab-stops: list 36.0pt;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-bidi-font-weight: bold; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">UB has been featured, as well as their
hemp and CBD products, in an extensive variety of high profile news
outlets and magazines online over the past several years: <a href="https://www.unclebudshemp.com/press/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.unclebudshemp.com/press/</span></a>.</span><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></li>
</ul>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Expected Financial Impact</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">PBIO's President and CEO, Richard T.
Schumacher, summarized: "This transaction combines the existing momentum
and ready market execution power of Uncle Bud's with the pivotal scientific and
product breakthrough of the UltraShear nanoemulsions processing platform for
record-setting product performance and long-term stability. In 2024 alone, we
are forecasting a 5-fold leap forward in PBIO revenues to over $10 million, but
this is only a steppingstone towards revolutionary impact and sales growth that
we expect to achieve across the nutraceuticals, cosmeceuticals, skincare,
food/beverage, agrochemical, and other major markets in the following
years."<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Jeffrey N. Peterson, PBIO's Chairman,
added: "Our Board and leadership team have carefully sought out this
strategic combination of Uncle Bud's marketing skill and power to combine with
PBIO's world class scientific innovation team. Specifically, this positions
PBIO with a fast forward integration capability that will allow us to
selectively set the timing and drive the pace of revolutionary change across
multiple major markets. This rapid growth engine provides a central platform to
leverage new growth capital, restructure and strengthen our balance sheet, and
complete our drive to uplist to a national stock exchange in 2024."<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Uncle Bud's</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Officially launched in September 2018
with one hero product, Uncle Bud's has experienced unequivocal growth. As a
leader in the Hemp and CBD space, Uncle Bud's takes pride in being Made in
America, GMO Free, Cruelty Free and Leaping Bunny Certified. The full range
includes Hemp & CBD products for pain relief, skincare, personal care, and
even pet care - all retailing under $45. To learn more about Uncle Bud's visit
unclebudshemp.com as well as their associated Instagram: @UncleBuds_Hemp;
Facebook: @UncleBuds_Hemp and Twitter: @UncleBuds_Hemp.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Pressure BioSciences, Inc.</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Pressure BioSciences, Inc. (OTCQB:
PBIO) is a global leader in providing innovative, broadly enabling, high
pressure-based solutions for a range of industries, including biotechnology,
pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food
and beverage manufacturing. Our products utilize both constant and alternating
pressure. Our patented enabling technology platform, Pressure Cycling
Technology (PCT), utilizes alternating cycles of pressure to control
bio-molecular interactions (such as cell lysis and biomolecule extraction)
safely and reproducibly. PCT-based products are beginning to be widely used for
biomarker and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterrorism applications. We have recently expanded our market
opportunities with the acquisition of the BaroFold™ patented technology
platform, allowing us to enter the bio-pharma contract services and GMP
manufacturing equipment sector. We have also developed the scalable and
high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform,
which allows for the creation of stable nanoemulsions of otherwise immiscible
fluids. It also allows for the preparation of higher quality, homogenized,
extended shelf-life or room temperature-stable low-acid liquid foods that
cannot be effectively preserved using existing non-thermal technologies. Our
commitment to innovation and cutting-edge technology has established PBIO as a
leader in the high-pressure industry, providing unique and effective solutions
to our customers.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Forward Looking Statements</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">This press release contains
forward-looking statements. These statements relate to future events or our
future financial performance and involve known and unknown risks, uncertainties
and other factors that may cause our or our industry's actual results, levels
of activity, performance, or achievements to be materially different from any
future results, levels of activity, performance or achievements expressed,
implied, or inferred by these forward-looking statements. In some cases, you
can identify forward-looking statements by terminology such as "may,"
"will," "should," "could," "would,"
"expects," "plans," "intends,"
"anticipates," "believes," estimates,"
"predicts," "projects," "potential" or
"continue" or the negative of such terms and other comparable
terminology. These statements are only predictions based on our current
expectations and projections about future events. You should not place undue
reliance on these statements. In evaluating these statements, you should
specifically consider various factors. Actual events or results may differ
materially. These and other factors may cause our actual results to differ
materially from any forward-looking statement. These risks, uncertainties, and
other factors include, but are not limited to, the risks and uncertainties
discussed under the heading "Risk Factors" in the Company's Annual
Report on Form 10-K for the year ended December 31, 2022, and other reports
filed by the Company from time to time with the SEC. The Company undertakes no
obligation to update any of the information included in this release, except as
otherwise required by law.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">For more information about PBIO,
Uncle Bud's, and this press release, please click on the following website
links:<br />
<a href="http://www.pressurebiosciences.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">http://www.pressurebiosciences.com</span></a> <a href="https://www.unclebudshemp.com/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">www.unclebudshemp.com</span></a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><br />
Please visit us on Facebook, LinkedIn, and Twitter.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Press Contacts</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Richard T. Schumacher, President
& CEO (508) 230-1828 (T)<br />
Jeffrey N. Peterson, Chairman (650) 812-8121 (T)<br />
Bruno Schiavi, President, PBIO Consumer Products (508) 230-1828 (T)<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Disclaimer/Disclosure:</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"> Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more.
Disclosure: this news for Pressure BioSciences, Inc. (PBIO) is paid for content
on our site. <a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="color: #337ab7; text-decoration: none; text-underline: none;">Disclosure</span></a> More
disclaimer info: <a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/Disclaimer.asp</span></a> Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire <a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/News-Upload/</span></a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p style="margin-bottom: .0001pt; margin: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica;"><span style="mso-spacerun: yes;"></span></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgYEFNEiFzLrmdmATfNhyMKCd3vurn9zecKNqm0G2Zatf-srh19AJMoHtdLiO-TqC2PZ0KVnppmlpkc07-h7vdW9Od_a0Z46ovD3bvd20e1vlN8yhWato_-g6aD54Km_65GgzuAm3HcmQ8ZTjuTbX29abUcd6Sj8kLxrIx_Ns6NNzDY7T3cJLRchOjioeL8/s299/Potcast%20logo.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="224" data-original-width="299" height="150" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgYEFNEiFzLrmdmATfNhyMKCd3vurn9zecKNqm0G2Zatf-srh19AJMoHtdLiO-TqC2PZ0KVnppmlpkc07-h7vdW9Od_a0Z46ovD3bvd20e1vlN8yhWato_-g6aD54Km_65GgzuAm3HcmQ8ZTjuTbX29abUcd6Sj8kLxrIx_Ns6NNzDY7T3cJLRchOjioeL8/w200-h150/Potcast%20logo.jpg" width="200" /></a></div><br /> <a href="https://www.investorideas.com/Audio/Potcasts.asp" target="_blank"><b><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt; text-decoration: none; text-underline: none;">Investorideas.com potcasts</span></b></a><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt;"> -
Listen to Investor Ideas Potcasts Cannabis News and Stocks on the Move</span><o:p></o:p><p></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Times New Roman","serif"; font-size: 12.0pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><a href="https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp">Check
out our stock directory of publicly traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE,
ASX Marijuana / Hemp Stocks plus the new psychedelic stock directory</a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Arial","sans-serif"; font-size: 10.5pt; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><a href="https://www.investorideas.com/Marijuana-Stocks/">Follow Pot
stocks news - Get News Alerts on Marijuana Stocks</a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">About Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><a href="https://www.investorideas.com/About/"><b><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/About/</span></b></a><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;">Sign up for free stock news alerts at
Investorideas.com</span></b><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: normal; margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Helvetica; mso-fareast-font-family: "Times New Roman"; mso-fareast-language: EN-CA;"><a href="https://www.investorideas.com/Resources/Newsletter.asp"><span style="color: #337ab7; text-decoration: none; text-underline: none;">https://www.investorideas.com/Resources/Newsletter.asp</span></a><o:p></o:p></span></p>
<p class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0cm;"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 115%;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-85229653048013061972023-12-08T07:41:00.000-08:002023-12-08T07:41:20.370-08:00 New #Investor Ideas in #Biotech (Nasdaq: $CADL) (NASDAQ: $PPBT) (Nasdaq: $RYZB) (Nasdaq: $HOWL)<p> <b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #Investor Ideas in #Biotech (Nasdaq: $CADL) (NASDAQ: $PPBT) (Nasdaq: $RYZB) (Nasdaq: $HOWL)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #stocks added to #lifesciences, #fintech and #defense directories (NASDAQ: $CELZ) (TSX: $KSI.TO) (Nasdaq: $NMRA) (OTCQX: $RDSNF) (OTCQB: $LVER) (Nasdaq: $OPTX)</span></i></b><b><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"><o:p></o:p></span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjKDqvk04s4xa0kU_qVBcvdFRM-DIxXm-2RcgO7OsU5SJTAa3fm_YUyy2MdvVW6z0fpBGEwccLWrx3nkuAnJUUQJG1MHIh_doICGI3f-5jIF8dD0FYItdxrh2GMDjar8hererhXtnoc_JK2cu9zfbZqn2lpVXIHF8wlg17sBYKzICpw4ZjxOzQVVjy-Gxo/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjKDqvk04s4xa0kU_qVBcvdFRM-DIxXm-2RcgO7OsU5SJTAa3fm_YUyy2MdvVW6z0fpBGEwccLWrx3nkuAnJUUQJG1MHIh_doICGI3f-5jIF8dD0FYItdxrh2GMDjar8hererhXtnoc_JK2cu9zfbZqn2lpVXIHF8wlg17sBYKzICpw4ZjxOzQVVjy-Gxo/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Arial, "sans-serif";"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">December 8, 2023 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Life Sciences, Fintech and Defense. Today’s stocks have been added to our lists of free stock directories in each sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at </span></b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><a href="https://www.investorideas.com/news/2023/main/12081Stocks.asp">https://www.investorideas.com/news/2023/main/12081Stocks.asp</a></span><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest biotech companies are involved in biopharmaceuticals, </span><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">radiopharmaceutical therapeutics, </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">biological therapeutics, </span><span style="color: #2b2b2b; font-family: Verdana, "sans-serif"; font-size: 10pt;">neuroscience programs and </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">medical devices.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The latest fintech company is involved in loan management, while the newest defense company is an </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">optics and photonics leader for aerospace and defense products.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added the </span></b><a href="https://www.investorideas.com/BIS/"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal" style="background: white;"><a href="https://www.candeltx.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Candel Therapeutics, Inc.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/CADL?p=CADL&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq: CADL</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens while creating a pro-inflammatory microenvironment at the site of injection. This leads to in situ vaccination against the injected tumor and uninjected distant metastases. Candel has established two clinical stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in NSCLC (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma. In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.<o:p></o:p></span></p><p class="MsoNormal" style="background: white;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><a href="https://purple-biotech.com/"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Purple Biotech Ltd</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/PPBT?p=PPBT&.tsrc=fin-srch"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ:PPBT</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline includes NT219, CM24 and IM1240. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. In a Phase 1/2 study of NT219, the Company is currently advancing it in a dose escalation as a monotherapy treatment of solid tumors, and in a dose escalation in combination with cetuximab for the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck (SCCHN) or colorectal adenocarcinoma (CRC). These studies will be followed by an expansion phase of NT219 at its recommended Phase 2 level in combination with cetuximab in patients with recurrent and metastatic SCCHN. CM24 is a humanized monoclonal antibody that blocks CEACAM1, an immune checkpoint protein that supports tumor immune evasion and survival through multiple pathways. The Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adenocarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both T cells and NK cells to mount a strong, localized immune response within the tumor microenvironment. The third arm specifically targets the Tumor Associated Antigen (TAA) 5T4 that is expressed in a variety of solid tumors and is correlated with advanced disease, increased invasiveness and poor clinical outcomes. IM1240 has a cleavable capping technology that confines the compound's therapeutic activity to the local tumor microenvironment, and thereby potentially increases the anticipated therapeutic window in patients. The Company's corporate headquarters are located in Rehovot, Israel.<o:p></o:p></span></p><p class="MsoNormal" style="background: white;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://rayzebio.com/"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">RayzeBio, Inc.</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;"> (</span><a href="https://finance.yahoo.com/quote/RYZB?p=RYZB&.tsrc=fin-srch"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">Nasdaq:RYZB</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">) is building a vertically integrated radiopharmaceutical therapeutics (RPT) company to treat various cancers, with its lead program in a Phase 3 clinical trial. RayzeBio has created a pipeline of multiple drug candidates in therapeutic areas with significant market opportunities. Much like antibody drug conjugates emerged as a new and transformative treatment modality in certain cancers, the company sees an opportunity for innovative radiopharmaceutical therapeutics to follow a similar path. RayzeBio believes its strategic investments in building a robust product pipeline, development capabilities, and manufacturing infrastructure position the company to be an industry-leading pioneer in the broad application of RPT for cancer.<o:p></o:p></span></p><p class="MsoNormal" style="vertical-align: middle;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> <o:p></o:p></span></p><p class="MsoNormal" style="background: white;"><a href="https://werewolftx.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Werewolf Therapeutics, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/HOWL?p=HOWL&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:HOWL</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.creativemedicaltechnology.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Creative Medical Technology Holdings Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/CELZ?p=CELZ&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ:CELZ</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a biotechnology company dedicated to the advancement of identifying and translating novel immediately deployable FDA registered biological therapeutics in the fields of immunotherapy, endocrinology, urology, gynecology and orthopaedics.<o:p></o:p></span></p><p class="MsoNormal" style="vertical-align: middle;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://kneat.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Kneat Solutions</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://ca.finance.yahoo.com/quote/KSI.TO?p=KSI.TO&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">TSX: KSI</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) a Canadian company with operational headquarters in Limerick, Ireland, develops and markets the next-generation Kneat Gx SaaS platform. Multiple business work processes can be configured on the platform from equipment to computer validation, through to quality document management. Kneat's software allows users to author, review, approve, execute testing online, manage any exceptions, and post-approve final deliverables in a controlled FDA 21 CFR Part 11/ EU Annex 11-compliant platform. Macro and micro report dashboards enable powerful oversight into all systems, projects and processes globally. Customer case studies are reporting productivity improvements in excess of 100% and a higher data integrity and compliance standard.<o:p></o:p></span></p><p class="MsoNormal" style="vertical-align: middle;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal" style="background: white;"><a href="https://neumoratx.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Neumora Therapeutics, Inc</span></a><span style="color: #2b2b2b; font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/NMRA?p=NMRA&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:NMRA</span></a><span style="color: #2b2b2b; font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.<o:p></o:p></span></p><p class="MsoNormal" style="vertical-align: middle;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://redsensemedical.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Redsense Medical AB</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/RDSNF?p=RDSNF&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">OTCQX: RDSNF</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is born-global medical device innovator established in Sweden. Redsense's mission is to improve the safety and quality of life for dialysis patients worldwide. The group has its main market in the United States as well as sales in Europe and Canada. Redsense promotes patient safety through highly cost-efficient fiber-optic monitoring of the blood access site during hemodialysis. The Redsense System immediately detects Venous Needle Dislodgement (VND) - a potentially life-threatening complication that causes 21 avoidable deaths per week worldwide. In essence, the Redsense alarm provides patients, nurses, and caregivers an extra pair of eyes; always alert, focused on one thing only, never looking away. Redsense products are used in both clinics and at home, daily and nocturnally. Today, the majority of treatments are performed in clinical settings, but home treatment is gaining popularity thanks to lower cost, increased convenience for the patient, improvements in technology and political initiative. The number of patients undergoing hemodialysis several times per week due to chronic kidney disease is approaching 4 million, worldwide. The projected growth rate is six percent annually, driven by ageing population and other factors. Every hemodialysis treatment carries the risk of VND. In the last years more than 1 million treatments have been conducted</span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added the </span></b><a href="https://www.investorideas.com/TSS/Stock_List.asp#Fintech"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Fintech Technology Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.lever.app/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Lever Global Corp.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/LVER?p=LVER&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">OTCQB:LVER</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a cutting-edge financial platform dedicated to assisting borrowers in navigating the complexities of loan management. With a suite of innovative tools and a user-centric approach, Lever is redefining the future of financial management.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added the </span></b><a href="https://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Defense Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal" style="background: white;"><a href="https://syntecoptics.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Syntec Optics Holdings, Inc.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/OPTX?p=OPTX&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Nasdaq:OPTX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) a 20-year optics and photonics leader for scientific and technical instruments and aerospace and defense products, has the mission of keeping American soldiers out of harm’s way, improving patient care and bringing more precision products to the consumer. Syntec Optics, headquartered in Rochester, NY, is one of the largest custom optics and photonics manufacturers in the United States. Operating for over two decades, Syntec Optics runs a state-of-the-art manufacturing facility with extensive core capabilities of various optics manufacturing processes, both horizontally and vertically integrated, to provide a competitive advantage for optics and photonics integrators. Syntec Optics recently launched new products, including Low Earth Orbit satellite optics and lightweight night vision goggle optics.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the</span><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Crypto Corner Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Play by Play Sports Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cannabis News and Stocks on the Move Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cleantech and Climate Change Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">,</span><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Exploring Mining Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Betting on Gaming Stocks Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and the</span><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">AI Eye Podcast</span></a><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">. </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Public companies within the sectors we cover use our news and content </span><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">services</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> to tell their story to interested investors. Paid for content is disclosed. <o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and tickertagstocknews.com<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></b></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411</span></b></p><p class="MsoNormal"><o:p> </o:p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhKL0HB3fY_ldQtFFDwRxoTNyttiNd-Uh5sguRSGzjMQy6kHoCLrnwENJA_LWTp9T8rwUiwIJS7QzybbBjbesDZH_V5vaUFrOyZm7T3QzBHhKlQjmyCvR9YU8W0w7pt_yHJ_3rLCjvh1u3wuyDxU1x3YKlvYN8wREcJZ2fwwG3MTWrmOrC4cP3ECinTMfQ/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhKL0HB3fY_ldQtFFDwRxoTNyttiNd-Uh5sguRSGzjMQy6kHoCLrnwENJA_LWTp9T8rwUiwIJS7QzybbBjbesDZH_V5vaUFrOyZm7T3QzBHhKlQjmyCvR9YU8W0w7pt_yHJ_3rLCjvh1u3wuyDxU1x3YKlvYN8wREcJZ2fwwG3MTWrmOrC4cP3ECinTMfQ/s320/social-media%20ICONS.png" width="320" /></a></div><div><br /></div>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-60983769038554559372023-12-04T07:42:00.000-08:002023-12-04T07:42:55.763-08:00Aethlon Medical (NASDAQ: $AEMD) Research/Media Alert: “Expect Focus on Oncology Studies; Cost Containment Efforts”<p> </p><p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Arial;">Aethlon Medical (NASDAQ: $AEMD) Research/Media Alert: <i style="mso-bidi-font-style: normal;">“Expect Focus on Oncology Studies; Cost
Containment Efforts”</i></span></b><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 12.0pt; mso-bidi-font-family: Arial;"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhvpo6H5CHBZN9JySkldt0JDz368OhcfgMb9s77ofO4hER8EEg64RumHTJgwMekUjgFrNuTGbVlo7JRQoGFQiYK8Dc7lUY2LUV9yTNzX3uWmuNQdzqc0KAs3md1KsajzmkT-lDiHjecAf0N4ZkWag0joeNeOFr6EgEs2u0C1hTJ-1FBMm8LKx-524myLW_g/s400/AEMD%20Logo.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="140" data-original-width="400" height="112" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhvpo6H5CHBZN9JySkldt0JDz368OhcfgMb9s77ofO4hER8EEg64RumHTJgwMekUjgFrNuTGbVlo7JRQoGFQiYK8Dc7lUY2LUV9yTNzX3uWmuNQdzqc0KAs3md1KsajzmkT-lDiHjecAf0N4ZkWag0joeNeOFr6EgEs2u0C1hTJ-1FBMm8LKx-524myLW_g/s320/AEMD%20Logo.jpg" width="320" /></a></div><br /><p></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">December 4, 2023 - Investorideas.com (</span><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">https://www.investorideas.com</span></a></span><u><span lang="EN-US" style="color: blue; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">) </span></u><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">a global investor news source covering biotech and medical technology stocks
releases a research/media alert for investors following the sector, featuring
medical therapeutic company, Aethlon Medical, Inc. (</span><span lang="EN-US"><a href="https://finance.yahoo.com/quote/AEMD?p=AEMD&.tsrc=fin-srch"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">NASDAQ:AEMD</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">). Zacks
small-cap research </span><span lang="EN-US"><a href="https://finance.yahoo.com/news/aemd-expect-focus-oncology-studies-160600342.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">issued</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> a summary of
the report, ’Expect Focus on Oncology Studies; Cost Containment Efforts,’ on
November 16<sup>th</sup>. <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Link to news/report <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"><a href="https://finance.yahoo.com/news/aemd-expect-focus-oncology-studies-160600342.html"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">https://finance.yahoo.com/news/aemd-expect-focus-oncology-studies-160600342.html</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Read the full research report <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US"><a href="https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_11162023_AEMD_Marin.pdf"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">https://s27.q4cdn.com/906368049/files/News/2023/Zacks_SCR_Research_11162023_AEMD_Marin.pdf</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNoSpacing"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Read this news, featuring AEMD in full at </span></b><span lang="EN-US"><a href="https://www.investorideas.com/news/2023/biotech/12041Aethlon-Medical-AEMD-Oncology-Studies.asp">https://www.investorideas.com/news/2023/biotech/12041Aethlon-Medical-AEMD-Oncology-Studies.asp</a></span><span lang="EN-US" style="font-family: "Arial","sans-serif"; mso-bidi-font-family: "Times New Roman"; mso-bidi-theme-font: minor-bidi;"><o:p></o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Excerpt: <o:p></o:p></span></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">By M. Marin<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Expect no disruption from management change; increased emphasis on
studying Hemopurifier® in oncology likely…<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO.
We expect no disruption as a result of the management change – Mr. Frakes has
been with Aethlon since 2008 & knows the company well, in our view.
Moreover, including Aethlon, he has had 27 years of CFO level financial
responsibility with publicly traded companies. We anticipate increased emphasis
on studying the Hemopurifier® in the oncology area, as well as potential cost
containment measures when possible, are likely.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Mr. Frakes, who was also appointed as a member of the company's board,
will continue his responsibilities as CFO. In addition, Guy Cipriani has been
named as the company's Chief Operating Officer. He had been Aethlon’s Chief
Business Officer prior to assuming the COO role. Mr. Cipriani has resigned from
the Aethlon board. We do not anticipate major changes as a result of this
management shift, although we believe the company is likely to emphasize its
clinical efforts in the field of oncology.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">… and potential cost containment measures when possible…<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Mr. Frakes has been with Aethlon since January 2008 and therefore knows
the company well, in our view. Moreover, including his role at Aethlon, he has
had 27 years of CFO level financial responsibility with publicly traded
companies, as noted. We do not anticipate a major shift in strategy as a result
of this management change, as noted, other than likely increased emphasis on
studying the Hemopurifier® in the oncology area and potential cost containment
efforts when possible.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Expect cash balance, lowering costs where possible, plus accessing ATM
funding will enable company to continue moving Hemopurifier forward towards
potential regulatory approval, commercialization<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">We believe lowering costs where possible, plus accessing funding, will enable
the company to continue moving the Hemopurifier forward in clinical studies
towards potential regulatory approval and commercialization. Under James
Frakes’ leadership as CFO, the company put in place an ATM (At The Market
offering) to enhance its financial flexibility. AEMD believes its cash balance
is sufficient to fund operations for at least a year. We believe lowering costs
where possible, plus accessing ATM funding, will enable the company to continue
moving the Hemopurifier forward in clinical studies towards potential
regulatory approval and commercialization. If Aethlon can demonstrate the
Hemopurifier’s ability to improve outcomes of cancer patients suffering from a
variety of different cancer types, we would anticipate strong commercial prospects
for the device.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">… majority of patients treated with checkpoint inhibitors do not
respond; studying whether Hemopurifier with checkpoint inhibitors can improve
overall patient outcomes<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">The company recently received clearance from the Drug Controller General
of India (DCGI), which is India’s central drug authority, to conduct a phase 1
safety, feasibility and dose-finding trial of the Hemopurifier® in patients
with solid tumors who have stable or progressive disease during anti-PD-1
monotherapy treatment such as Keytruda® or Opdivo®. PD-1, or Programmed Cell
Death Protein 1, is a protein found on the cell surface that plays a role in
inhibiting immune responses. Treatment such as Keytruda®, a type of
immunotherapy, helps to block the PD-1 pathway to prevent cancer cells from
hiding and, in turn, help the immune system work. While Keytruda® and other
anti-PD-1 monotherapy treatments represent a substantial advance in cancer
treatment, with certain tumor types it does not work on the majority of cancer patients.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Checkpoint inhibitors such as Keytruda have been used to treat 25+
different types of cancer. By launching a basket oncology trial to study the
impact of the Hemopurifier on a variety of cancerous tumors, AEMD believes it
can generate data to support the Hemopurifier’s ability to improve outcomes,
when combined with checkpoint inhibitor treatment, in multiple tumor types
where cancer associated extracellular vesicles may promote immune suppression
and resistance to anti-PD-1 antibodies. Given the Hemopurifier’s demonstrated
ability to remove exosomes, management believes the device can be used to
affect improved outcomes in a number of cancers.<o:p></o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></i></p>
<p class="MsoNormal"><i style="mso-bidi-font-style: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Moreover, by focusing on multiple cancers, the company has also expanded
the opportunities for patient enrollment, as well as for building a database to
support regulatory approval. By including both Keytruda and Opdivo can also
facilitate patient enrollments.<o:p></o:p></span></i></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">About Aethlon Medical, Inc. (NASDAQ:AEMD)<o:p></o:p></span></b></p>
<p class="MsoNormal"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Aethlon Medical is a medical therapeutic company
focused on developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening viral infections
and for use in organ transplantation. In human studies, the Hemopurifier has
demonstrated the removal of life-threatening viruses and harmful exosomes from
blood utilizing its proprietary lectin-based technology. This action has
potential applications in cancer, where exosomes may promote immune suppression
and metastasis, and in life-threatening infectious diseases. The Hemopurifier
is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device
indicated for the treatment of individuals with advanced or metastatic cancer
who are either unresponsive to or intolerant of standard of care therapy, and with
cancer types in which exosomes have been shown to participate in the
development or severity of the disease. The Hemopurifier also holds an FDA
Breakthrough Device designation and an open Investigational Device Exemption
(IDE) application related to the treatment of life-threatening viruses that are
not addressed with approved therapies.<o:p></o:p></span></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><o:p> </o:p></span></b></p>
<p class="MsoNormal" style="background: white; line-height: 140%;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">About
Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: 140%;"><span lang="EN-US" style="background: #EEEEEE; color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Investorideas.com is a platform for
investing ideas. </span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">We publish
breaking stock news, stock research, guest posts and create original top rated
investing podcasts, plus sector tag articles featuring up and coming companies
and industry leaders.<span style="mso-spacerun: yes;"> </span>Investor Idea’s
original branded content includes the</span><span lang="EN-US"><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Crypto Corner Podcast</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;"> ,</span><span lang="EN-US"><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Play by Play Sports Podcast</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;"> ,</span><span lang="EN-US"><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Cannabis News and Stocks on the Move Podcast</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;"> ,</span><span lang="EN-US"><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"><span style="mso-spacerun: yes;"> </span></span></a><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Cleantech and Climate Change Podcast</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">,</span><span lang="EN-US"><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"><span style="mso-spacerun: yes;"> </span></span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Exploring Mining Podcast</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;"> ,</span><span lang="EN-US"><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Betting on Gaming Stocks Podcast</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;"> and the</span><span lang="EN-US"><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">AI Eye Podcast</span></a></span><span lang="EN-US" style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">.<span style="mso-spacerun: yes;">
</span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">We also create
free investor stock directories for AI and tech, biotech, cannabis, cleantech,
crypto, defense, gaming, health and wellness, mining, oil and gas, sports and
water.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 140%;"><span lang="EN-US" style="background: #EEEEEE; color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;">Public companies within the sectors we
cover can use our news publishing and content creation </span><span lang="EN-US"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="background: #EEEEEE; color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;">services</span></a></span><span lang="EN-US" style="background: #EEEEEE; color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 140%; mso-bidi-font-family: Arial;"> to help tell
their story to interested investors.<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p> </o:p></span></b></p>
<p class="MsoNormal"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Disclaimer/Disclosure:</span></b><span lang="EN-US"><a href="https://www.investorideas.com/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">Investorideas.com</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> is a digital publisher of third party sourced news, articles and equity
research as well as creates original content, including video, interviews and
articles. Original content created by investorideas is protected by copyright
laws other than syndication rights. Our site does not make recommendations for
purchases or sale of stocks, services or products. Nothing on our sites should
be construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. Disclosure: Aethlon Medical, Inc. (NASDAQ:AEMD) is a paid
featured stock on Investorideas.com More disclaimer info:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/News/Clientspecifics.asp"><span style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">https://www.investorideas.com/About/News/Clientspecifics.asp</span></a></span><span class="MsoHyperlink"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> </span></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"><span style="mso-spacerun: yes;"> </span></span><span lang="EN-US"><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;">https://www.investorideas.com/About/Disclaimer.asp</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-bidi-font-family: Arial;"> <o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">Learn more about publishing your news release and our other news
services on the Investorideas.com newswire</span><span lang="EN-US"><a href="https://www.investorideas.com/News-Upload/"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://www.investorideas.com/News-Upload/</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"> Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy:</span><span lang="EN-US"><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://www.investorideas.com/About/Private_Policy.asp</span></a></span><u><span lang="EN-US" style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%;"><u><span lang="EN-US" style="color: #23527c; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p><span style="text-decoration: none;"> </span></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">Follow us on Twitter</span><span lang="EN-US"><a href="https://twitter.com/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://twitter.com/Investorideas"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://twitter.com/Investorideas</span></a></span><u><span lang="EN-US" style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">Follow us on Facebook</span><span lang="EN-US"><a href="https://www.facebook.com/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.facebook.com/Investorideas"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://www.facebook.com/Investorideas</span></a></span><u><span lang="EN-US" style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">Follow us on YouTube</span><span lang="EN-US"><a href="https://www.youtube.com/c/Investorideas"><span style="color: windowtext; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial; text-decoration: none; text-underline: none;"> </span></a><a href="https://www.youtube.com/c/Investorideas"><span style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">https://www.youtube.com/c/Investorideas</span></a></span><u><span lang="EN-US" style="color: #1155cc; font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p></o:p></span></u></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><b style="mso-bidi-font-weight: normal;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">Contact Investorideas.com<o:p></o:p></span></b></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;">800-665-0411<o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>
<div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgxepp9KV-torjEycObdtmfN-yp0zsvzSM1flHwTgG7qRBHFkhZt_auU_wCnwIBc-Ud7pyKh7hQ4eBCQ_eRr0_3rpsnjDDx76B-E_0MuU19DFdeqTvJ7WpiJ0PVUSvNlhpIgad6HCCOQKA_vwCFqVQFANNazauZMJShjVsvn9Cx_mp1Ev8QwcMwBJM2zjq2/s100/BIS.gif" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="100" data-original-width="100" height="100" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgxepp9KV-torjEycObdtmfN-yp0zsvzSM1flHwTgG7qRBHFkhZt_auU_wCnwIBc-Ud7pyKh7hQ4eBCQ_eRr0_3rpsnjDDx76B-E_0MuU19DFdeqTvJ7WpiJ0PVUSvNlhpIgad6HCCOQKA_vwCFqVQFANNazauZMJShjVsvn9Cx_mp1Ev8QwcMwBJM2zjq2/s1600/BIS.gif" width="100" /></a></div><br /><p class="MsoNormal" style="background: white;"><br /></p>
<p class="MsoNormal" style="background: white; margin-bottom: 7.5pt; margin-left: 0cm; margin-right: 0cm; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Biotech
Industry Stocks- investing ideas in biotechnology stocks, medical technology
and life sciences<o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US" style="color: #333333; font-family: "Verdana","sans-serif"; font-size: 10.0pt;">Like Biotech Stocks? View our </span><span lang="EN-US"><a href="https://www.investorideas.com/BIS/stock_list.asp"><span style="background: #F0AD4E; border: solid #EEA236 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-border-alt: solid #EEA236 .75pt; padding: 5.0pt;">Biotech
Stocks Directory</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="background: white; margin-top: 15.0pt; mso-outline-level: 3;"><span lang="EN-US"><a href="https://visitor.r20.constantcontact.com/manage/optin?v=001sG2XUya07KoaQtQwEHk8BhMX76bZ3I7Gh6Cc9G6VJZlEwQlzYCYTiI7k6Y2OzN9GD8tkimXwEYJ3dfFMIYkbPiWTQFDNThCvnsXE8A79w7B1OTG_i2a9BBiC3RGY9hfBXd5390yBHHyRm_WZbAziKnUFELcezWy5GE5LJc9GidOSO5UryfWQ3A%3D%3D"><span style="background: #5BC0DE; border: solid #46B8DA 1.0pt; font-family: "Verdana","sans-serif"; font-size: 10.0pt; mso-border-alt: solid #46B8DA .75pt; padding: 5.0pt;">Get News
Alerts on Biotech Stocks</span></a></span><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt;"><o:p></o:p></span></p>
<p class="MsoNormal" style="line-height: 120%;"><span lang="EN-US" style="font-family: "Verdana","sans-serif"; font-size: 10.0pt; line-height: 120%; mso-bidi-font-family: Arial;"><o:p> </o:p></span></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-16140108077647994972023-11-10T07:38:00.002-08:002023-11-10T07:38:09.648-08:00 New #InvestorIdeas (CSE: $AUEX.C) (CSE: $KOG.C) (CSE: $REDC.C) (NYSE: $TMO) (CSE: $METX.C) (CSE: $XTCY.C) (CSE: $ICS.C)<p> <b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #InvestorIdeas (CSE: $AUEX.C) (CSE: $KOG.C) (CSE: $REDC.C) (NYSE: $TMO) (CSE: $METX.C) (CSE: $XTCY.C) (CSE: $ICS.C)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #Stocks to watch in #Mining, #Biotech, #Cannabis and #Cybersecurity</span></i></b><b><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"><o:p></o:p></span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhY0tBVRomdGcLTX7Pwvij26S7e3XcGFP0leMR_TMR5Oe80LpdtfQsl0lHycgOTNsxd0cEY1NIfs0Efn1CV8mUHcrb1QfT70QsSBIUKPkHYwEF_XXHhlF1w4ry1EiL0yjFTtl8mLtBYdIJw2NOtMy8F0lS0NHUtO78QhMApaL2cDHsw9ZPHNGrdoPv9Uno/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhY0tBVRomdGcLTX7Pwvij26S7e3XcGFP0leMR_TMR5Oe80LpdtfQsl0lHycgOTNsxd0cEY1NIfs0Efn1CV8mUHcrb1QfT70QsSBIUKPkHYwEF_XXHhlF1w4ry1EiL0yjFTtl8mLtBYdIJw2NOtMy8F0lS0NHUtO78QhMApaL2cDHsw9ZPHNGrdoPv9Uno/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Arial, "sans-serif";"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">November 10, 2023 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Mining, Biotech, Cannabis and Cybersecurity. Today’s stocks have been added to our lists of free stock directories in each sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at </span></b><a href="https://www.investorideas.com/news/2023/main/11101Stocks.asp">https://www.investorideas.com/news/2023/main/11101Stocks.asp</a><o:p></o:p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest mining companies are all CSE-listed and operations are involved in gold and copper resources.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The latest biotech companies include a cross-over into nanotech and </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">immune-oncology therapeutics.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest cannabis company is a prospect generator in hemp and CBD-related, psilocybin and functional mushrooms, while the latest cybersecurity company is a managed security service provider (MSSP).<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/Gold_Stocks/Stocks_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Mining Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal" style="background: white;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Advanced Gold Exploration Inc.(</span><a href="https://issuers.thecse.com/en/listings/mining/advance-united-holdings-inc"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE:AUEX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) - formerly Advance United Holdings Inc. - is an exploration stage mineral resources company whose principal business activities include acquiring, exploring and evaluating strategic mineral properties.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.kogoldnz.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">KO Gold</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://issuers.thecse.com/en/listings/mining/ko-gold-inc"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE:KOG</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a Canadian private exploration company focused on exploring the world-class Otago Gold District on the South Island of New Zealand.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.redcanyonresources.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Red Canyon Resources Ltd</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://issuers.thecse.com/en/listings/mining/red-canyon-resources-ltd"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE:REDC</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a mineral resource company principally engaged in the acquisition and exploration of mineral resource properties. Its objective is to locate and develop copper and associated precious metals, focusing initially on the exploration and development of its principal project, the Peak Property, located in British Columbia, Canada. The Company also holds a secondary property, the Scraper Springs Property.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New stocks added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.thermofisher.com/ca/en/home.html"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Thermo Fisher Scientific Inc.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/TMO?p=TMO&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE:TMO</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.metherapeutics.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">ME Therapeutics Holdings Inc.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://issuers.thecse.com/en/listings/diversified-industries/me-therapeutics-holdings-inc"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE: METX)</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is an early stage Vancouver based biotechnology company involved in the discovery and development of novel immuno oncology therapeutics targeting immune suppression in cancer. Our main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-tumour immunity.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to </span></b><a href="https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cannabis Directory</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal" style="background: white;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Xtacy Therapeutics Corp (</span><a href="https://thecse.com/en/listings/diversified-industries/global-wellness-strategies-inc"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE:XTCY</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) Formerly Global Wellness Strategies Inc.- is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The present focus of the company is in hemp and CBD-related, psilocybin and functional mushrooms, and health-care related industries.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to </span></b><a href="https://www.investorideas.com/Companies/HomelandDefense/Stock_List.asp#CyberSecurity"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cybersecurity Directory</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal" style="background: white;"><a href="https://www.integrated-cyber.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Integrated Cyber Solutions Inc.</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://issuers.thecse.com/en/listings/technology/integrated-cyber-solutions-inc"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">CSE:ICS</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a managed security service provider (MSSP) that humanizes cybersecurity managed services to the Small-to-Medium Business (SMB) and Small-to-Medium Enterprise (SME) sectors. They integrate capabilities from third-party cybersecurity providers, allowing companies to continuously adapt their services to evolving technologies and providers – ensuring customers have access to the latest cybersecurity solutions. Apart from providing essential cybersecurity services, Integrated Cyber's managed services and IC360 technology platform consolidate vast amounts of information to generate actionable intelligence from the numerous software point solutions within their customer's environments. The results enable simple, understandable, and actionable insights to help customers comprehend and better secure their organization. Integrated Cyber greatly emphasizes the human aspect of cybersecurity management, simplifying complex concepts, and highlighting the crucial role that employee behavior plays in a company's cyber defenses.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the</span><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Crypto Corner Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Play by Play Sports Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cannabis News and Stocks on the Move Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cleantech and Climate Change Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">,</span><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Exploring Mining Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Betting on Gaming Stocks Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and the</span><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">AI Eye Podcast</span></a><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">. </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Public companies within the sectors we cover use our news and content </span><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">services</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> to tell their story to interested investors. Paid for content is disclosed. <o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and tickertagstocknews.com<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span class="MsoHyperlink"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;"></span></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></b></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com to be added to our stock directories or learn more about us<o:p></o:p></span></b></p><p class="MsoNormal"><a href="mailto:dvanzant@investorideas.com"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Dawn Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and </span><a href="mailto:cvanzant@investorideas.com"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Cali Van Zant</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"></span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411</span></b> </p><p class="MsoNormal"><o:p> </o:p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjTFPT5Eh8DJI_Gmqbsyqj13kChW-17i67oRvHypf1crkvUftZtk_W7VjP4UF5LOkY9D5c45Q2vAuY8xOSc9yTrYpLexSUn2C0ZzKYj9L3iKeZXpGQujh3BEu7IeAaf37TUbPdHnyXV4m6uJfBqlGFNnCGcws4DKqjmYhMQ-Kmv90TADBPEpAf1-KQ5qO4/s343/social-media%20ICONS.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="102" data-original-width="343" height="95" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjTFPT5Eh8DJI_Gmqbsyqj13kChW-17i67oRvHypf1crkvUftZtk_W7VjP4UF5LOkY9D5c45Q2vAuY8xOSc9yTrYpLexSUn2C0ZzKYj9L3iKeZXpGQujh3BEu7IeAaf37TUbPdHnyXV4m6uJfBqlGFNnCGcws4DKqjmYhMQ-Kmv90TADBPEpAf1-KQ5qO4/s320/social-media%20ICONS.png" width="320" /></a></div><div><br /></div>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-20558902497394810772023-08-04T07:52:00.003-07:002023-08-04T07:52:28.170-07:00 New #InvestingIdeas (TSX: $QIPT.TO) (NYSE: $EVH) (NASDAQ: $DH) (NASDAQ: $NXGN) (Nasdaq: $BOF) (NYSE: $CAVA)<p> <b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #InvestingIdeas</span></b><b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> (TSX: $QIPT.TO) (NYSE: $EVH) (NASDAQ: $DH) (NASDAQ: $NXGN) (Nasdaq: $BOF) (NYSE: $CAVA)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #LifeSciences and #Food&Beverage #</span></i></b><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">InvestorIdeas<o:p></o:p></span></i></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhpnbtnk5xfGhWuRzk4e5J5jO9YYMAFniwxUE4Z0A-NrfIXriOSc5WtAel4UDV_brheHTK28P6s2UreRTlOkSULTx0PaBHUYjd9z2lss1Sdp5KIzT-rFmf2BNrCaII1A9ddx52ubbJFDsxYad55E3DRP4qkjLg3HtJ5o963Jqq0fKm38weqv5dPRWbcEvg/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhpnbtnk5xfGhWuRzk4e5J5jO9YYMAFniwxUE4Z0A-NrfIXriOSc5WtAel4UDV_brheHTK28P6s2UreRTlOkSULTx0PaBHUYjd9z2lss1Sdp5KIzT-rFmf2BNrCaII1A9ddx52ubbJFDsxYad55E3DRP4qkjLg3HtJ5o963Jqq0fKm38weqv5dPRWbcEvg/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Arial, "sans-serif";"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Vancouver, Kelowna, Delta, BC – August 4, 2023 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Life Sciences and Food & Beverage. Today’s stocks have been added to our lists of free stock directories in each sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at </span><a href="https://www.investorideas.com/news/2023/main/08041Stocks.asp">https://www.investorideas.com/news/2023/main/08041Stocks.asp</a><o:p></o:p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest life sciences companies are involved in non-medicinal healthcare technologies.</span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The latest food and beverage companies are involved in plant-based foods and Mediterranean restaurants, respectively.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://quipthomemedical.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Quipt Home Medical Corp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://ca.finance.yahoo.com/quote/QIPT?p=QIPT&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">TSX:QIPT</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.evolenthealth.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Evolent Health</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/EVH?p=EVH&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NYSE: EVH</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable. Evolent serves a national base of leading payers and providers and is consistently recognized as a top place to work in health care nationally.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.definitivehc.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Definitive Healthcare</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/DH?p=DH&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: DH</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://www.nextgen.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NextGen Healthcare, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/NXGN?p=NXGN&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: NXGN</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral, and oral health providers in their journey toward whole-person health and value-based care. Our highly integrated, intelligent, and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/Beverage_Stocks/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Food and Beverage Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://branchoutfood.com/"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">BranchOut Food Inc</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">. (</span><a href="https://finance.yahoo.com/quote/BOF?p=BOF&.tsrc=fin-srch"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">Nasdaq:BOF</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">) is an international food-tech company delivering truly great natural snacks and real superfood ingredients enabled by their licensed dehydration technology. The Company is a leading provider of high-quality dehydrated fruit and vegetable-based products and its commitment to quality and innovation sets it apart as a trusted brand and private label supplier.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://cava.com/"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">CAVA GROUP, INC</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">. (</span><a href="https://finance.yahoo.com/quote/CAVA?p=CAVA&.tsrc=fin-srch"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">NYSE:CAVA</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">) is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. Rooted in our rich Mediterranean heritage, we bring a timeless approach to modern wellness through our authentic cuisine and vibrant brand experience. Guided by our mission, we believe food is a unifier for a more diverse and inclusive world for our guests, team members, and our grower and rancher partners, where all are welcome at our table. We believe that consumers should not have to choose between taste and health – our innovative cuisine appeals to a wide variety of preferences, satisfying the modern consumer’s desires for flavorful, craveable, and nutritious food without compromise.<o:p></o:p></span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com is a platform for investing ideas. We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the</span><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/crypto-corner/"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Crypto Corner Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Sports/PlayByPlay.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Play by Play Sports Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Potcasts.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cannabis News and Stocks on the Move Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Cleantech-ClimateChange.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Cleantech and Climate Change Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">,</span><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Exploring-Mining.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Exploring Mining Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> ,</span><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-Gaming.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">Betting on Gaming Stocks Podcast</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and the</span><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt; text-decoration-line: none;"> </span></a><a href="https://www.investorideas.com/Audio/Podcasts-AI-Eye.asp"><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">AI Eye Podcast</span></a><span style="color: #1155cc; font-family: Verdana, "sans-serif"; font-size: 10pt;">. </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors.<o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Public companies within the sectors we cover use our news and content </span><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">services</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> to tell their story to interested investors. Paid for content is disclosed. <o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and tickertagstocknews.com<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></b></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411</span> </p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8JDieFMy3p3bVfRrPpwVM1megmh9T6A_eApXOrzdNs13GQGaGvOkY16-nBfS3PY9GvH-lwy1ffFvCYbKHxTAp9o7W4No4EHQKl70jRyRW2NpsWyeJoK3sM1U0tzQkLOcE-dvib5mHBt-QK6vEKNlZnAagfR79MC3C83wig54iluzFVCQwBsyu2UKMK24/s274/social-media%20ICONS.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="60" data-original-width="274" height="60" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh8JDieFMy3p3bVfRrPpwVM1megmh9T6A_eApXOrzdNs13GQGaGvOkY16-nBfS3PY9GvH-lwy1ffFvCYbKHxTAp9o7W4No4EHQKl70jRyRW2NpsWyeJoK3sM1U0tzQkLOcE-dvib5mHBt-QK6vEKNlZnAagfR79MC3C83wig54iluzFVCQwBsyu2UKMK24/s1600/social-media%20ICONS.jpg" width="274" /></a></div><div><br /></div>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0tag:blogger.com,1999:blog-917437462516219002.post-61425652553179848812023-07-07T07:46:00.003-07:002023-07-07T07:46:38.717-07:00 New #InvestingIdeas in #Biotech (NASDAQ: $AGLE) (NASDAQ: $MRTX) (Nasdaq: $SXTP) (NYSE American: $AZTR) (NASDAQ: $KPRX) (NASDAQ: $RSLS) (OTCQB: $GENFF)<p> <b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">New #InvestingIdeas</span></b><span style="text-align: center;"> </span><b style="text-align: center;"><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;">in #Biotech (NASDAQ: $AGLE) (NASDAQ: $MRTX) (Nasdaq: $SXTP) (NYSE American: $AZTR) (NASDAQ: $KPRX) (NASDAQ: $RSLS) (OTCQB: $GENFF)</span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></b></p><p align="center" class="MsoNormal" style="text-align: center;"><b><i><span style="font-family: Verdana, "sans-serif"; font-size: 12pt;"> </span></i></b></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj5-v7LHpwrNZRLtAn3VH6t8eYQCWUuP3GQHvv0UYaVtmt7FLy8MDixwi3pcGMkHVb19D2T6pZgP9ez01eXYofRlxYV_v_qXWKIMjT23wQgkWOSKDckOkMqla7PfFp0_9mxT8WLDx7iWSOT_qJA6dMfMhv-K7z-GJzICDwCvn9Bgka5fxRFAy1tFwQCB88/s1024/II%20newsletter.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="576" data-original-width="1024" height="180" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEj5-v7LHpwrNZRLtAn3VH6t8eYQCWUuP3GQHvv0UYaVtmt7FLy8MDixwi3pcGMkHVb19D2T6pZgP9ez01eXYofRlxYV_v_qXWKIMjT23wQgkWOSKDckOkMqla7PfFp0_9mxT8WLDx7iWSOT_qJA6dMfMhv-K7z-GJzICDwCvn9Bgka5fxRFAy1tFwQCB88/s320/II%20newsletter.jpg" width="320" /></a></div><br /><p align="center" class="MsoNormal" style="text-align: center;"><br /></p><p class="MsoNormal"><span style="font-family: Arial, "sans-serif";"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Vancouver, Kelowna, Delta, BC - July 7, 2023 – (Investorideas.com Newswire) </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">, a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech. Today’s stocks have been added to our lists of free stock directories in each sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Read this in full at </span></b><a href="https://www.investorideas.com/news/2023/main/07071Stocks.asp">https://www.investorideas.com/news/2023/main/07071Stocks.asp</a><o:p></o:p></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The newest biotech companies are involved in treatments for rare metabolic disease, cancer treatments, tropical disease treatment and the treatment of </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">ophthalmic diseases, as along with life sciences companies focused on weight loss and longevity.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">New Stocks Added to the </span></b><a href="https://www.investorideas.com/BIS/Stock_List.asp"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Biotech Directories</span></b></a><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">:<o:p></o:p></span></b></p><p class="MsoNoSpacing"><a href="https://www.aeglea.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Aeglea BioTherapeutics, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/AGLE?p=AGLE&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: AGLE</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. Aeglea has investigated pegtarviliase in a Phase 1/2 clinical trial for the treatment of Classical Homocystinuria. Aeglea's other clinical program, pegzilarginase, achieved the primary endpoint of arginine reduction in the PEACE Phase 3 clinical trial. The Marketing Authorization Application for pegzilarginase is currently under review with the European Medicines Agency. Aeglea has also developed a pipeline of engineered human enzymes that have been explored in preclinical testing, the most advanced of which is for the potential treatment of Cystinuria. In June 2023, Aeglea completed the acquisition of Spyre Therapeutics and shifted its disease focus to inflammatory bowel disease (IBD). Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. Spun out of Paragon Therapeutics in 2023, Spyre was founded by Fairmount and is based in Waltham, MA.<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNoSpacing"><a href="https://www.mirati.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Mirati Therapeutics, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/MRTX?p=MRTX&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: MRTX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="vertical-align: middle;"><a href="https://60degreespharma.com/"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">60 DEGREES PHARMACEUTICALS, INC</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">. (</span><a href="https://finance.yahoo.com/quote/SXTP?p=SXTP&.tsrc=fin-srch"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">Nasdaq:SXTP</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">) founded in 2010, focuses on discovering, developing and distributing new medicines for the treatment and prevention of tropical diseases, including malaria and dengue. 60P’s mission is supported through in-kind funding from the United States Department of Defense. The Company also collaborates with prominent research organizations in the U.S., Australia and Singapore. In addition, 60P has been funded by Knight Therapeutics Inc. (TSX: GUD), a Canadian specialty pharmaceutical company that obtained FDA approval for Impavido, a product for leishmaniasis, a tropical disease, and monetized a PRV. 60P is headquartered in Washington D.C., with a majority-owned subsidiary in Australia.<o:p></o:p></span></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><a href="https://azitrainc.com/"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">Azitra Inc</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;"> (</span><a href="https://finance.yahoo.com/quote/AZTR?p=AZTR&.tsrc=fin-srch"><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">NYSE American:AZTR</span></a><span style="border: 1pt none windowtext; font-family: Verdana, "sans-serif"; font-size: 10pt; padding: 0cm;">) is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts and helps screen the Company's library of strains for drug like molecules. The Company's initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal therapeutic candidate species for engineering of dermatologic therapies.<o:p></o:p></span></p><p class="MsoNormal" style="background: white;"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal" style="background: white;"><a href="https://kiorapharma.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Kiora Pharmaceuticals, Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/KPRX?p=KPRX&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: KPRX</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">)</span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">is a clinical-stage biotechnology company developing and commercializing products for the treatment of ophthalmic diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-101 is being developed for the treatment of the Ocular Presentation of Rheumatoid Arthritis (OPRA). It is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with what Kiora believes is best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with commercially available DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing.<br /><br /><b><o:p></o:p></b></span></p><p class="MsoNormal" style="background: white;"><a href="https://www.reshapelifesciences.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">ReShape Lifesciences Inc</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">. (</span><a href="https://finance.yahoo.com/quote/RSLS?p=RSLS&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">NASDAQ: RSLS</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) is America’s premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss.<br /><br /><o:p></o:p></span></p><p class="MsoNoSpacing"><a href="https://genflowbio.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Genflow Biosciences PLC</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> (</span><a href="https://finance.yahoo.com/quote/GENFF?p=GENFF&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">OTCQB: GENFF</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">; </span><a href="https://finance.yahoo.com/quote/GENF.L?p=GENF.L&.tsrc=fin-srch"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">LSE: GENF</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">) mission is to increase the understanding of factors that control and impact healthspan and lifespan. They research, develop, and commercialize therapeutic solutions to extend health span, enabling longer and healthier lives. Genflow is dedicated to developing and commercializing novel therapeutics for aging in both humans and dogs. The first 2 development programs target nonalcoholic steatohepatitis (NASH) and Werner Syndrome (a disease of accelerated aging). By addressing aging, Genflow aims to decrease healthcare costs and alleviate the emotional and societal burden associated with an aging population.<br /><br /></span><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">About Investorideas.com - Big Investing Ideas<o:p></o:p></span></b></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">We publish breaking stock news, stock research, guest posts and create original top rated investing podcasts, plus sector tag articles featuring up and coming companies and industry leaders. Investor Idea’s original branded content includes the Crypto Corner Podcast , Play by Play Sports Podcast , Cannabis News and Stocks on the Move Podcast , Cleantech and Climate Change Podcast, Exploring Mining Podcast , Betting on Gaming Stocks Podcast and the AI Eye Podcast. We also create free investor stock directories for AI and tech, biotech, cannabis, cleantech, crypto, defense, gaming, health and wellness, mining, oil and gas, sports and water. <o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Public companies within the sectors we cover use our news and content </span><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">services</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> to tell their story to interested investors. Paid for content is disclosed. <o:p></o:p></span></p><p class="MsoNormal"><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></span></p><p class="MsoNoSpacing"><strong><span style="color: #333333; font-family: Verdana, "sans-serif"; font-size: 10pt;">Disclaimer/Disclosure:</span></strong><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span><a href="https://www.investorideas.com/"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Investorideas.com</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: </span><a href="https://www.investorideas.com/About/Disclaimer.asp"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Disclaimer.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> Learn more about publishing your news release and our other news services on the Investorideas.com newswire </span><a href="https://www.investorideas.com/News-Upload/"><span style="color: #337ab7; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/News-Upload/</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> and tickertagstocknews.com<o:p></o:p></span></p><p class="MsoNoSpacing"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: </span><a href="https://www.investorideas.com/About/Private_Policy.asp"><span style="color: #23527c; font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/About/Private_Policy.asp</span></a><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Investors/Services.asp"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Investors/Services.asp</span></a><span class="MsoHyperlink"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Learn more about advertising and guest posts<o:p></o:p></span></b></p><p class="MsoNormal"><a href="https://www.investorideas.com/Advertise/"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.investorideas.com/Advertise/</span></b></a><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Twitter </span><a href="https://twitter.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://twitter.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on Facebook </span><a href="https://www.facebook.com/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.facebook.com/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Follow us on YouTube </span><a href="https://www.youtube.com/c/Investorideas"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;">https://www.youtube.com/c/Investorideas</span></a><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"><o:p></o:p></span></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></b></p><p class="MsoNormal"><b><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">Contact Investorideas.com<o:p></o:p></span></b></p><p class="MsoNormal"><span lang="EN-US" style="font-family: Verdana, "sans-serif"; font-size: 10pt;">800 665 0411<o:p></o:p></span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><p class="MsoNormal"><span style="font-family: Verdana, "sans-serif"; font-size: 10pt;"> </span></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQqOdoO_Vqfiepd58m46yfF315rUw6jghl3H-ZkPwkL2iPVJomQQq_Qz0TK2w_znJchqLOcu48XmUg6evpV7CWcocaxqIFT_A1vYtE0tqyjol2jLTpnz_BqXA-me2Uknfx87718b6n1BpSm2OMPMLxEzuFFx913YXdS1ioBZ1QMmLp2yW1OOLBbzGNHfA/s274/social-media%20ICONS.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="60" data-original-width="274" height="60" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiQqOdoO_Vqfiepd58m46yfF315rUw6jghl3H-ZkPwkL2iPVJomQQq_Qz0TK2w_znJchqLOcu48XmUg6evpV7CWcocaxqIFT_A1vYtE0tqyjol2jLTpnz_BqXA-me2Uknfx87718b6n1BpSm2OMPMLxEzuFFx913YXdS1ioBZ1QMmLp2yW1OOLBbzGNHfA/s1600/social-media%20ICONS.jpg" width="274" /></a></div><br /><p></p><br /><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p><p class="MsoNormal"><o:p> </o:p></p>Investor Ideashttp://www.blogger.com/profile/01149911451424553904noreply@blogger.com0